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Staphylococcus aureus is asymptomatically carried in approximately 30% of the population, 
which is a risk for subsequent infections. S. aureus produces a vast array of virulence 
factors, leading to varied infections. In this project, a functional genomics approach was used 
to try and gain further insights into how this pathogen regulates its virulence. First, a result 
from a Genome Wide Association Study (GWAS) investigating the link between genotypic 
variation and variation in toxin production showed a link between mupirocin resistance and 
toxin production. Second, a group of clinical Methicillin-Resistant S. aureus (MRSA) isolates of 
the ST239 lineage were screened for variation in lipase activity, and a GWAS was carried out 
using this data.   
 
Mupirocin is an antibiotic which targets isoleucyl-tRNA synthetase, which binds isoleucine to 
its tRNA to form isoleucyl-tRNA. The mutation associated with toxin production in the GWAS 
was shown to increase the presence of free isoleucine in mupirocin resistant S. aureus cells, 
suggesting that there was less isoleucyl-tRNA. This would be expected to affect proteins which 
are high in isoleucine, of which AgrC is one; this is part of the accessory gene regulator (agr) 
system, which controls virulence. Initially, AgrC is translated slower in mupirocin resistant 
strains, however there is no difference in overall agr activity at later time points. It was also 
found that competitive fitness of mupirocin resistant strains lacking the agr system is lower, 
therefore lowering toxin production seems to alleviate the fitness cost of this mutation.  
 
The GWAS carried out on lipase production resulted in a list of genes, three of which were 
taken for further investigation - these were SAUSA300_1966, murA and atpH. 
SAUSA300_1966 is a putative phage-antirepressor protein, which may also repress lipase or 
interact with a lipase repressor.  murA is part of peptidoglycan biosynthesis, and atpH is an 
ATP synthase subunit.  
 
These studies demonstrate that a GWAS approach can be used to study the virulence of S. 







Antibiotic resistance, Staphylococcus aureus carriage and infections 
Antibiotic resistance in Staphylococcus aureus 
Complicating the treatment of infections, S. aureus has become resistant to multiple 
antibiotics, with Methicillin-Resistant S. aureus (MRSA) being the most notable example1,2. 
This problem is exacerbated by inappropriate antibiotic use, ease and decreasing cost of 
international travel and the use of antibiotics as growth promoters for livestock. Antibiotic 
resistance can be conferred by various mechanisms, including mutation of the target so that 
the antibiotic no longer affects its action, the acquisition of resistance genes on plasmids or 
mobile genetic elements (MGEs) and by the use of efflux pumps to force the antibiotic out of 
the cell.  
 
Carriage of S. aureus the risk of subsequent infection and atopic dermatitis 
- Risk of infections due to S. aureus carriage 
Staphylococcus aureus is a Gram-positive opportunistic pathogen most commonly found on 
the anterior nares of humans3. It can be asymptomatically carried, but also cause infections4. 
Carriage of S. aureus has been known to be a risk factor for S. aureus infections since 19315, 
and is thought to be the first step in the infection process6. People who are carriers have a 
higher rate of S. aureus infections than non-carriers, due mostly to their own strains7, and 
breakdown of the epithelial barrier predisposes to intravascular/systemic infections8. 
Consequently, there does not seem to be a genetic difference between carriage isolates and 
those which cause infections, and there has been a case where the carriage isolate has gone 
on to cause bacteraemia with only a small number of mutations9.  Temporary eradication of 






- Types of carriers 
There are three different carriage states; persistent, intermittent and non-carriage11,12. 
Depending on the method used, the percentage of the population falling into each of the 
carriage types varies, but generally around 20% are persistent nasal carriers, around 30% are 
intermittent carriers and around 50% are non-carriers5. Persistent carriers are colonised by 
one strain, while intermittent carriers may carry different strains at different times13–15. In one 
study, where a group of volunteers were inoculated with a S. aureus mixture, it was found 
that persistent carriers selectively re-acquire their strain while non-carriers quickly eliminate 
the mixture, suggesting involvement of host factors11. This is supported by the observation 
that there is variation in carriage rates between ethnicity16, gender16 and co-morbidities, etc. 
Factors which are associated with an increase in carriage rate include diabetes17, IV drug use18, 
and immune deficiency18 – this includes Acquired Immune Deficiency Syndrome (AIDS), and 
quantitative or qualitative leukocyte deficiency. Another factor which seems to differentiate 
between persistent carriers and intermittent carriers is the load; persistent carriers have a 
higher S. aureus load compared to intermittent carriers19.  
 
- How does S. aureus colonise the host? 
To successfully colonise the host, S. aureus needs to adhere to the epithelial cells in the nose. 
These are fully keratinised and the layers in the nose formed by these epithelial cells include 
several glands (apocrine sweat glands, sebaceous glands) and hair follicles5. The top-most 
layer is made up of keratinocytes, which are cornified – the cytoplasmic membrane is replaced 
by a cornified envelope – and these cells are eventually desquamated from the epithelium20. 
Loricrin accounts for the majority of the cornified envelope protein, making up around 85%, 
which cross-links with other proteins including keratins (cytokeratin 10, involucrin, filaggrin) 
and small proline-rich proteins, and these create a waterproof layer on the cornified 
envelope20. Keratinocytes have been shown to be important sites for S. aureus binding, and 
several S. aureus adhesins are able to bind to the cornified envelope; they include iron-
regulated surface determinant A (IsdA) and clumping factor B (ClfB)21–23. Studies have shown 
ClfB to be the major adhesion in S. aureus attachment to the cornified envelope, interacting 
with cytokeratin 10 and loricrin21. The expression of these cornified envelope proteins is linked 
to the tissue repair process, and controlled by cytokines including ilterleukin-6 (IL-6) and IL-
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2224; IL-6 production is triggered by the interaction between keratinocytes and S. aureus, and 
when heat-killed and sonicated S. aureus cells interact with these cells IL-6 production leads 
to a reduction in loricrin, cytokeratin 10 and filaggrin25. IL-22 meditates keratinocyte 
differentiation, and this leads to a decreased expression of the above cornified envelope 
proteins26. Therefore, a reduction in IL-6 and IL-22 is required in order for the cornifies 
envelope proteins to be expressed, which then allows for adhesion of S. aureus to establish 
colonisation24,27.  
 
In order to establish carriage, S. aureus must interact with the host immune system in such a 
way that it is not cleared. Nasal secretion, or mucous, contains antimicrobial factors, including 
IgA, IgG, lysozyme, lactoferrin and antimicrobial peptides5. Some antimicrobial peptides have 
been shown to be inactive towards S. aureus, or require the presence of other peptides to 
have activity towards S. aureus5,28,29. S. aureus commonly colonises sites in the nares where 
there are reduced nasal cilia and where there is less mucous16. It has been noted that S. aureus 
carriers have higher concentrations of α-defensins Human Neutrophil Peptide (HNP) 1, HNP2 
and HNP3, and human β-defensin 2 (HBD2), which suggests that neutrophil- and epithelial-
mediated inflammation is active30. Knowing that lipoteichoic acid stimulates neutrophil 
chemotaxis31, the indication is that S. aureus colonisation causes an immune reaction, 
however, the HNP1, -2, -3 and HBD2 do not kill S. aureus in vitro. Therefore whatever immune 
response is mediated by the carriers is not effective at eradicating S. aureus16. Putting these 
together, the innate immune response against S. aureus in the nares is not efficient, but may 
play a role in ensuring that the carriage strain does not cause in an invasive infection5.  
 
- Does carriage of S. aureus influence immunity? 
Differences in adaptive immunity between carriers and non-carriers have also been noted; 
carriers have been found to have a higher titre of IgG in their serum compared to non-
carriers12,32, and persistent carriers have a higher concentration of IgA specific for 
staphylococcal proteins33. Despite this, antibody responses between individuals (carriers and 
non-carriers) display significant variation24. This antibody response may provide some 
protection against S. aureus infections in carriers34, whose antibodies are able to neutralise 
superantigens produced by their carriage strain35. Carriers also display a higher IgG titre after 
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infection with their carriage strain – these show similar binding pattern before and after 
infection36. While this may suggest that carriers may be “pre-immunised” with their carriage 
strain36, when human volunteers were colonised short-term with S. aureus there was no 
evidence of an antibody response37. This shows that while carriage does cause a change in the 
humoral immune response, this may not be protective and also this may not influence 
carriage; maternal IgG does not seem to protect infants from S. aureus carriage38.  
 
Cellular adaptive immunity has been shown to be required for S. aureus clearance from the 
nose, with the Th17 cytokines IL-17 and IL-22 being shown to promote clearance in several 
studies in animals24,27. IL-22 was also shown to induce the innate immune response by up-
regulating the expression of antimicrobial peptides, as well as controlling the expression of 
loricrin and cytokeratin 10 as mentioned previously27. Interestingly, in humans those who had 
been able to clear S. aureus showed an elevated IFN-γ response, indicative of a Th1 response, 
therefore a Th1 response may be crucial in humans for driving S. aureus clearance39.  
 
- Influence of the microbiome on S. aureus carriage 
As there are other bacteria colonising humans, studies have investigated how this affects S. 
aureus colonisation; these bacteria include Corynebacterium species, Propionibacterium 
species, coagulase-negative Staphylococci (CoNS, mainly S. epidermidis), and Streptococcus 
pneunomiae. There seems to be an inverse correlation between carriage of S. aureus and 
other commensal bacteria, as demonstrated by several studies40–42. Perhaps this is due to the 
fact that these bacteria need to compete to colonise the niche; the increase in the use of 
streptococcal vaccines, which prevents S. pneumoniae carriage, has led to increased S. aureus 
carriage in the vaccinated population43. Another study has found that H2O2 produced by S. 
pneumoniae has the ability to induce lysogenic phages in S. aureus, a mechanism by which S. 
pneumoniae eliminates S. aureus from the niche44. One study by Ramsey et al. found that in 
the presence of Corynebacterium striatum, S. aureus gene expression was altered; virulence 
genes were down-regulated while genes involved in colonisation were up-regulated45. This 
included a strong repression of the accessory gene regulator (agr) response45 – the system will 
be explored further on. This led to increased adherence to epithelial cells and a decrease in 
haemolysin production45, which is indicative of a shift towards commensalism. During in vivo 
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co-infection with C. striatum, S. aureus had lower fitness compared to a mono-infection, which 
supports the above finding45.  
 
- Carriage of S. aureus and atopic dermatitis 
Atopic dermatitis is a chronic inflammatory skin disease found in people whose skin barrier is 
disrupted46. It is characterised by a polarised T-helper 2 (Th2) inflammation47, typically 
characterised by eczematous lesions, itching and increased susceptibility to bacterial skin 
infections, particularly by S. aureus47. Patients with atopic dermatitis have been known to be 
carriers of S. aureus, notably in the eczematous lesions, where it is present in up to 100% of 
patients and has a higher CFU count compared to non-lesional skin48; this perhaps explains 
the high incidences of S. aureus skin infections seen in patients with atopic dermatitis.  
High levels of S. aureus colonisation and the subsequent reduction in skin microbiome 
diversity have been linked to atopic dermatitis flares49. However, it has been noted that 
treating the inflammation by the use of agents such as corticosteroids or calcineurin inhibitors 
reduce the amount of S. aureus on the atopic dermatitis lesions; therefore, it seems that 
inflammation itself is driving the proliferation of S. aureus in these lesions48,50. The 
inflammation leads to damage of the skin, thus exposing extracellular matrix proteins, giving 
a surface on which S. aureus can attach, and this is exacerbated by scratching of the skin48,51,52. 
This causes further damage and also promotes the release of cytokines, which upregulates the 
expression of extracellular matrix proteins52. This increased S. aureus adhesion did not occur 
in IL-4 knock-out mice and incubating the skin with IL-4 lead to increased S. aureus adhesion, 
therefore it is likely that a Th2 response drives the production of extracellular matrix proteins 
(particularly fibronectin) to promote increased adhesion48. Another study showed evidence of 
biofilms on the skin of patients with atopic dermatitis, and also that the protease staphopain 
B was present; staphopain B was shown to degrade the antimicrobial peptide LL-37 into 
shorter fragments, perhaps protecting the S. aureus from its action46.  
 
As S. aureus colonisation is linked to atopic dermatitis flares, studies have investigated the 
effects of decolonisation on disease severity. The use of antibiotics long-term is a concern for 
inducing resistance, as well as having a harmful effect on the other bacteria which form the 
skin microbiome47 – these bacteria may in fact prevent aberrant S. aureus growth, so removal 
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of these bacteria may in fact exacerbate the situation. Therefore, recently a study began 
looking at the efficacy of a bacteriophage endolysin for the treatment of atopic dermatitis; 
Staphefekt SA.100 is a chimeric endolysin engineered to lyse staphylococcal cell membrane53. 
If this proves safe and efficacious, then it would not only provide an alternative treatment for 
atopic dermatitis but possibly S. aureus SSTIs.  
 
Resistance to β-lactam antibiotics; the Rise and Fall of MRSA Clones 
S. aureus was generally susceptible to most antibiotics, however the introduction of these 
agents into clinical use has fuelled the rise of resistance in S. aureus. The development of 
resistance to penicillin and methicillin in S. aureus can be seen in “waves”; the initial rise of 
penicillin-resistant strains after the introduction of penicillin into the clinic, then the second 
wave of Methicillin-Resistant S. aureus emerging in the 1960s after its introduction into the 
clinic2. These “archaic MRSA” strains were prevalent in European hospitals (Healthcare-
Associated MRSA (HA-MRSA)), however they did not spread into the community and were 
seen sporadically in the US2,54,55. By the 1980s, these archaic MRSA clones were replaced by 
their descendants or other MRSA lineages which were more successful56. This third wave then 
spread to the US and the rest of the world by the mid 1980’s, but this third-wave MRSA 
pandemic was still confined to hospitals and other healthcare institutions2.  
 
To treat this rising MRSA pandemic, the use of vancomycin increased as this was one of the 
only antibiotics which was still effective against MRSA2. However, this emergence of 
Vancomycin-Intermediate S. aureus (VISA, Minimum Inhibitory Concentration (MIC) 8 - 
16μg/ml) and Vancomycin-Resistant S. aureus (VRSA, MIC ≥128μg/ml)57,58. Around the same 
time, the fourth wave began when MRSA started to spread in the community (Community-
Associated MRSA (CA-MRSA)). This was first noticed in Western Australia in the 1990s, and 
between 1997 and 1999 there were cases of MRSA seen in children with no healthcare contact 
in the US2,59,60. Both these incidences were caused by MRSA strains which were unrelated to 
the HA-MRSA circulating around the time, therefore it would seem that methicillin resistance 
had jumped into Methicillin-Susceptible S. aureus (MSSA) strains which were circulating in the 




In the US, the CA-MRSA wave is in fact mediated by two different lineages; the early cases, 
such as those mentioned above, were caused by the USA400 lineage, and the emergence of 
USA300 in between 1999-2001 effectively replaced the USA400 lineage2. These CA-MRSA 
strains are noted for the increased virulence, and it has been noted that they produce many 
virulence factors at a high level. PVL is thought to be one of the contributing factors behind 
the increased virulence. At sub-lytic concentrations, PVL is thought to “prime” neutrophils by 
partially activating them, and this leads to the release of pro-inflammatory mediators such as 
leukotriene B4 and IL-861. Another non-lytic activity of PVL is the induction of reactive oxygen 
species production from neutrophils when stimulated by N-formyl-methionly-leucyl-
phenylalanine (fMLP). The USA300 clone is now the most common cause of SSTIs in the US, 
and the CA-MRSA clones have now started to be seen in the healthcare system62,63. 
 
Methicillin resistance is conferred by the mecA gene carried on Staphylococcal cassette 
chromosome mec (SCCmec), a mobile genetic element1,2. mecA encodes an alternative PBP2, 
PBP2a, which is not susceptible to β-lactam antibiotics. To date, 8 allotypes of SCCmec have 
been identified, designated SCCmec I – VIII. SCCmec II is larger, and associated with HA-MRSA 
strains. Due to its size, resistance to other antibiotics can be carried alongside the mecA gene 
in SCCmecII. CA-MRSA frequently carry the smaller SCCmec IV, and are generally susceptible 
to non-β-lactam antibiotics, however, resistance to other classes of antibiotics in CA-MRSA is 
also increasing2,64. A study in our lab has found that the expression of mecA resulted in a 
reduction in the expression of cytotoxins by preventing AIP from being detected by the agr 
system, which subsequently lead to reduced virulence in a mouse sepsis model65. The study 
also showed that while MecA expression from SCCmec II was higher than the expression from 
SCCmec IV, therefore the presence of SCCmec IV may allow for the maintenance of high 
virulence, which correlates with the increased virulence seen in CA-MRSA strains which 
frequently carry SCCmec IV. This could represent adaptations to the two environments, where 
high MecA expression leading to increased resistance to β-lactams is beneficial in the hospital 
environment, but this consequently drives down the expression of virulence factors which 





- Does MRSA carriage differ from MSSA carriage? 
One study looked at the carriage rates for MRSA and methicillin-sensitive S. aureus (MSSA) in 
a Taiwanese high school – the study found that of the 323 S. aureus strains isolated in the 
study (which represented 26.2% of nasal screening swabs), 278 were MSSA and 45 were 
MRSA66. This represents a carriage rate of 22.6% for MSSA and 3.7% for MRSA. A review of 31 
studies showed that healthcare workers had an MRSA carriage rate of 1.8%, with nurses 
having the highest carriage rate (6.9%)67. Another review of 33 studies found that people with 
livestock contact had a higher rate of MRSA carriage (14.2%) compared to the general 
population, which ranged from 0.8 - 1.3%68. A further review showed that contact with 
healthcare or nursing homes and coming into contact with healthcare associated pathogens 
such as Clostridium difficile also increased the likelihood of MRSA carriage at time of hospital 
admission69. The same review also showed that congestive heart failure, diabetes, pulmonary 
disease, immunosuppression and renal failure were also associated with an increased 
likelihood of MRSA carriage at time of hospital admission. These studies show that MRSA 
carriage rate is lower than MSSA carriage rates, but that certain people are more likely to carry 
MRSA, such as farmers and patients with certain co-morbidities. 
 
Reducing the risk of carriage; decolonisation and the role of resistance in decolonisation 
failure 
To reduce the risk posed by the carriage of S. aureus, particularly Methicillin-Resistant S. 
aureus (MRSA), decolonisation strategies are in place to eradicate the colonising strain. These  
regimes typically involve the use of topical agents such as chlorhexidine and mupirocin.  
 
- Chlorhexidine 
Chlorhexidine is an antiseptic typically in the form of chlorhexidine gluconate. It is a water 
soluble cationic biguanide which binds to and disrupts the cell wall, altering the osmotic 
balance70. Chlorhexidine, which has a positive charge, is thought to be attracted to the 
negatively charged bacterial cell wall, where it then binds to the phospholipids in the 
cytoplasmic membrane71. This then increases the permeability of the cytoplasmic membrane, 




Tolerance to this antiseptic in S. aureus is by the utilisation of efflux pumps coded by the 
plasmid bourn qacA/B as well as smr72–74. In one study, it was found that the presence of the 
qac genes was associated with ciprofloxacin and erythromycin resistance74, and other studies 
have shown links between these genes and resistance to other antibiotics. The presence of 
qac genes and increased tolerance to chlorhexidine also has implications for decolonisation, 
with studies showing that tolerance to chlorhexidine leads to decolonisation failure74.  
 
- Mupirocin 
Mupirocin is a polyketide antibiotic produced by Pseudomonas fluorescens, and targets 
isoleucyl-tRNA synthetase (IleRS); it inhibits IleRS by binding to the active site where isoleucine 
binds as well as binding to the ATP-binding pocket75. Resistance to mupirocin exists at two 
levels, low-level (Minimum Inhibitory Concentration (MIC) 8 - 256μg/ml) and high-level (MIC 
≥512μg/ml). Low-level mupirocin resistance is mediated through single nucleotide 
polymorphisms (SNPs) in the chromosomal ileS gene75, which will be discussed in more detail 
in chapters 3 and 4, and high-level mupirocin resistance is mediated through the acquisition 
of an alternative IleRS carried on a plasmid, mupA75,76 or mupB77. Resistance to mupirocin at 
both levels has been associated with decolonisation failure, particularly high-level 
resistance10.  
 
The presence of mupA was discovered when a study showed that strains which were highly 
resistant to mupirocin showed two distinct activity peaks on a radiometric IleRS activity 
assay78. Initially, the highly resistant strains were grown with mupirocin, but then they were 
sub-cultured into medium without mupirocin prior to the extraction of IleRS at late log-phase, 
where the highly resistant strains showed two IleRS activity peaks. This would indicate that 
the mupA IleRS is active alongside the chromosomal IleRS during the log-phase. The mupA 
gene is carried on various plasmids in different strains, and in one instance it was shown that 
one such plasmid carrying mupA had conjugated from Staphylococcus epidermidis within a 
carrier79. These plasmids can also carry genes conferring resistance to other antibiotics, such 
as tetracycline resistance seen in mupA containing plasmids studied by Needham et al80.  
However, the correlation between the mupA gene and high-level mupirocin resistance is not 
straightforward; several incidences of mupA being present on the chromosome have been 
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reported, with the first being reported by Ramsey et al. in 199681. In this study, the strain 
displayed low-level mupirocin resistance as opposed to the expected high-level resistance. 
This was also observed in a study by Fujimura et al., in which they studied an MRSA strain from 
Japan with low-level mupirocin resistance82. However, in the study by Udo et al. showed that 
the presence of mupA on the chromosome also lead to high-level mupirocin resistance83. Also, 
in a study by Driscoll et al. it was found that loss of high-level mupirocin resistance was seen 
in mupA positive isolates, where a single deletion caused a frame-shift which rendered the 
protein inactive84. The authors observed that high-level mupirocin resistance was frequently 
re-established, with the mutated allele reverting back to wild-type. Therefore, if a low-level 
mupirocin resistant strain is mupA positive, there is a possibility that this strain may become 
highly resistant – this has implications for decolonisation, as higher resistance to mupirocin 
would lead to a less effective clearance of MRSA.  
 
The second alternative IleRS, mupB, was found by Seah et al., where they investigated a case 
of an MRSA strain showing high-level mupirocin resistance in the absence of mupA77. The 
authors found that the mupB gene has only 45.5% DNA sequence identity with the 
chromosomal ileS gene, and has more similarity with the mupA gene, with 65.5% DNA 
sequence being identical. At the protein level, the MupB protein has 25.4% identity with IleRS 
and 58.1% identity with MupA, but despite this low homology the MupB protein contains 
conserved motifs found in class I tRNA synthetases.  
 
- Is resistance to these agents linked with decolonisation failure? 
Due to the fact that mupirocin is typically used as an ointment (Bactroban® (GlaxoSmithKline) 
is 20mg/g85), the application site has a high concentration of the antibiotic86. Therefore, low-
level mupirocin resistance would not be expected to impede MRSA decolonisation. Indeed, 
several studies have questioned the clinical relevance of low-level mupirocin resistance86–88. 
Even so, a trend towards decolonisation failure were seen in multiple studies - for example, 
five studies looking at MRSA decolonisation showed that 24% (total 84) of patients with high-
level mupirocin resistant MRSA achieved decolonisation, 29% (totla 103) of patients with low-
level mupR MRSA achieved decolonisation compared to 62% (total 627) of patients with 
mupirocin susceptible MRSA89. Therefore, mupirocin resistance at low and high levels can lead 
12 
 
to failure90, and if resistance to the two commonly used agents are linked, then this would 
make decolonisation failure more likely. Indeed, one study found that the combination of low-
level mupirocin resistance alongside resistance to chlorhexidine was associated with MRSA 
decolonisation failure91. This in turn impacts on infection rates, with one study showing that 
patients who were successfully decolonised (104/268) of MRSA had no subsequent infection, 
while in 4.3% of those whose decolonisation failed  (7/164) there was subsequent MRSA 
infection92. 
 
Vancomycin resistance  
As mentioned above, the increase in the use of vancomycin to treat MRSA infections has led 
to a rise in VISA and VRSA. S. aureus modifies its cell wall to become resistant to vancomycin; 
one mechanism is thought to be by the modification of peptidoglycan biosynthesis, whereby 
VISA strains synthesise more peptidoglycan but with less cross-linking, leaving more D-Ala-D-
Ala terminal peptide, the target for vancomycin, exposed1,93. This results in a thicker cell wall 
with irregular shape, and the increase in exposed D-Ala-D-Ala residues can then bind more 
vancomycin and trap it without affecting cell wall biosynthesis. The reduced cross-linking is 
thought to be the result of a reduction in L-glutamine residues, leading to reduced amidation 
of the L-glutamate in the pentapeptide bridge. VRSA is thought to be the result of S. aureus 
acquiring the vanA gene, probably from Enterococcus faecalis1,94. The terminal peptide is 
modified to D-Ala-D-Lac when exposed to low concentrations of vancomycin, and this makes 
the terminal peptide less susceptible to binding by vancomycin, therefore cell wall 
biosynthesis is not affected.  
 
Resistance to fluoroquinolones 
Fluoroquinolones were introduced in the 1980s, and S. aureus quickly acquired resistance to 
this class of antibiotics1. Fluoroquinolones target topoisomerase IV (which breaks 
concatenated DNA) or DNA gyrase (which relaxes supercoiled DNA), and mutations in these 
genes and the induction of an efflux pump have been associated with resistance to these 
antibiotics. The mutations can arise spontaneously, and exposure to fluoroquinolones at sub-
therapeutic concentrations may induce these mutations in a sub-population of colonising S. 
aureus.95 The presence of these resistant sub-populations and limited concentrations of 
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fluoroquinolones at the site of infection may lead to more resistance mutations accumulate, 
thus driving increased resistance.  
 
Types of infections caused by S. aureus 
Despite the fact that there is a lot of research carried out, infections caused by staphylococci 
are still a significant problem7. These infections range from skin and soft tissue infections to 
endocarditis, bacteraemia, bone and joint infections, and pneumonia6. S. aureus is also 
capable of colonising prosthetic devices, such as endovascular catheters96–98, subsequently 
leading to infections. Here, I will explore a few of these infections in more detail.  
 
- Skin and Soft Tissue Infections 
Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) strains are a 
major cause of skin and soft tissue infections (SSTIs)64, but incidences of S. aureus SSTIs have 
been reported prior to the expansion of CA-MRSA clones99. Cutaneous abscesses are generally 
regarded as the hallmark of S. aureus SSTIs, however other manifestations have been seen99–
105. In children, impetigo is generally caused by S. aureus, where it presents as bullous/papular 
legions which progress to crusted legions99,106. Usually, these infections are not accompanied 
by systemic symptoms. Other forms of SSTI include cellulitis, necrotising fasciitis, pyomyositis 
and surgical site infections99. A severe surgical site infection is mediastititis, a complication 
arising from median sternotomy, a cardiac surgical procedure99,107.  
 
A feature of S. aureus SSTIs, particularly furunculosis, or abscesses in the hair follicle, is 
recurrence, where patients have three or more incidences of furunculosis within a year108. 
Colonisation is thought to be a factor in the development of these recurrent furunculosis 
attacks, and as such decolonisation can be beneficial in preventing these recurrent attacks108. 
However, S. aureus can also survive on household surfaces109, thus may re-colonise carriers 
who had been decolonised. As with other SSTIs, furunculosis is associated mainly with CA-
MRSA strains, or strains carrying the Panton Valentine Leukocidin (PVL) 108,110. Innate and T-
cell mediated immune responses play an important role in protection from SSTIs22, however 
it is possible that any antibody response mediated against S. aureus is not protective, due to 
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the immune evasion strategies utilised by S. aureus, such as Protein A111, which will be 
discussed further on.  
 
- S. aureus bacteraemia 
In S. aureus bacteraemia, common origins of infection include vascular catheters (particularly 
those which are already infected), SSTIs, lung infections, bone and joint infections and 
infective endocarditis99. However, in ~25% of cases, however, there is no clear focus of 
infection99. While S. aureus infections can be an origin for subsequent bacteraemia, 
bacteraemia can also lead to S. aureus infections at secondary sites; this includes infective 
endocarditis, septic arthritis and osteomyelitis112. Further complicating this, S. aureus 
bacteraemia can result in sepsis, further complicating these infections112,113. Knowing that 
epidemiology of S. aureus bacteraemia is linked to other forms of S. aureus infection, changes 
in this epidemiology will likely result in a change in the epidemiology of S. aureus 
bacteraemia99. For example, improvements in the management of intravascular catheters 
have resulted in a reduction in catheter related infections, therefore this contributes to 
reduction in S. aureus bacteraemia originating from infected intravascular catheters114.  
 
One group who are at particular risk of bacteraemia are patients undergoing haemodialysis, 
and S. aureus is an established organism causing these catheter related bloodstream 
infections in these patients99,115. Most commonly, these bacteraemia are secondary to 
infection or inflammation around the catheter116. As a preventative measure, studies have 
investigated the efficacy of using antibiotics at the catheter exit site and found that use of 
agents such as mupirocin and polysporin were effective at reducing the incidences of catheter 
related bacteraemia116. However, with the prolonged use of antibiotics comes the risk of 
bacteria developing resistance to the agent used. Studies have also shown that, in the short 
term, coating the catheter with antibiotics or antiseptics was effective at reducing the 







- Infective endocarditis 
S. aureus is the most common cause of infective endocarditis, with a study reporting that the 
proportion of infective endocarditis caused by S. aureus to be 32% in 2009, an increase from 
24% in 1998119. Damage to the cardiac endothelium gives a niche for bacteria to colonise, and 
this can be caused by direct trauma or inflammation99,120. This exposes the subendothelium, 
and leads to production of thrombotic vegetations formed by the deposition of fibrin and 
platelets onto extracellular matrix proteins and tissue factors99,120. Cell wall associated factors 
on S. aureus allows the bacteria to attach to these vegetations, thus setting a focus of infection 
for infective endocarditis99,121. S. aureus is also the most common cause of prosthetic heart 
valve infections, shown to account for 23 – 33% of cases in these patients122,123. These 
infections are related to healthcare-associates bacteraemia, which is frequently caused by S. 
aureus; once the bacteria have gained access to the bloodstream, then it is possible for the 
prosthetic valve to be seeded with the bacteria, leading to infection124. A patient is most likely 
to develop prosthetic valve related infective endocarditis during the first year after the valve 
is implanted, likely due to ongoing contact with the healthcare system and incomplete 
endothelialisation of the new valve123.  
 
Pathogenicity of S. aureus – virulence factors 
S. aureus has various factors for virulence, and these can be categorised into those involved 
in attachment, immune evasion and toxins (adhesion, evasion and toxicity)6. Depending on 
the function of the virulence factor, they can be expressed on the cell surface or secreted out 
of the cell98. Certain virulence factors have more than one role in causing disease, and multiple 
virulence factors can have the same role in virulence.  
 
Adhesins 
- Microbial Surface Components Recognising Adhesive Matrix Molecules 
The majority of molecules involved in attachment are known as “Microbial Surface 
Components Recognising Adhesive Matrix Molecules” (MSRAMMs) and is essential for the 
attachment of S. aureus to host cells to initiate carriage or infection51. These MSCRAMMs bind 
to host proteins such as collagen, fibrinogen, and fibronectin, and have been shown to play 
an important role in invasive infections such as endovascular infections and septic 
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arthritis125,126, as well as enabling S. aureus to adhere to the host proteins coating prosthetic 
devices127,128. Adhesion is the initial step in the formation of biofilms, where S. aureus produce 
an extracellular matrix and protect itself from the host defences and antibiotics129; this will be 
explored later on. This allows S. aureus to persist, making these kind of infections extremely 
difficult to treat.  
 
MSCRAMMs are typically covalently anchored to the cell wall peptidoglycan, and contain a 
Sec-dependent secretory signal at the N-terminus and an LPXTG sortase cleavage site, 
hydrophobic domain and a positively-charged region at the C-terminus51,130. The hydrophobic 
domain and the positively-charged region maintains the protein in the cell membrane during 
secretion, and this allows the sortase to act on the protein21. MSCRAMMs are distinguished 
from other cell wall anchored proteins by the presence of IgG-folded domains, where at least 
two are present adjacent to each other, and this is where the ligand binding occurs21.  
 
Clumping Factors 
Clumping factors A and B (ClfA, ClfB) are a prime example of an S. aureus MSCRAMM (fig. 1.1); 
these bind fibrinogen using dock, lock and latch and form clumps21,131,132. ClfA is expressed 
throughout S. aureus growth, while ClfB is only expressed in aerobically growing cells during 
early exponential phase132,133. It has been shown that ClfA and CLfB bind to different regions 
of fibrinogen, therefore the synergistic action of the two may promote stronger adhesion. The 
N-terminal A region of Clfs contain three N domains (N1, N2 and N3), with N2 and N3 having 
the characteristic IgG-folded domains21. The R region, which connects the A region with the 
wall-spanning region (W), in Clfs is formed of serine-aspartate repeats21.  
 
Fig. 1.1: a diagram showing the domains in clumping factors. Taken from Foster et al., Nat Rev 




Fibronectin Binding Proteins 
Fibronectin binding proteins (FnBPs) are another member of MSCRAMMs (fig. 1.2). Two 
closely linked FnBPs are found in S. aureus, FnBPA and FnBPB134, and they mediate attachment 
to immobilised fibronectin and plays a role in S. aureus adhesion to plasma clots and host 
conditioned implants – i.e. biomaterial which has resided in the host for a prolonged period, 
and thus coated with host extracellular matrix97,135,136. Like the Clfs, FnBPs have three N 
domains in their A region, but also contain Fibronectin-binding repeats in the R region21. As 
well as being a linker of A and wall-spanning regions, the R region of FnBPs forms the primary 
binding sites for fibronectin, however this domain seems to lack a secondary structure51,137.  
 
 
Fig. 1.2: a diagram showing the domains in fibronectin binding proteins. Taken from Foster et al., Nat 
Rev Microbiol 201321.  
 
Collagen binding protein 
The collagen adhesin (Cna) is an MSCRAMM which binds to collagen, and is necessary for S. 
aureus to adhere to and cause cartilage infection (fig. 1.3). This MSCRAMM is not as frequently 
expressed as the other MSCRAMMs51,138,139, and it would be assumed that this adhesin would 
be important in bone and joint infections; however, there is contradictory evidence for this, 
with one study suggesting that nearly all S. aureus isolates from these infections express Cna, 
but another study found no difference in the frequency of Cna expressing strains51,138,139. The 
A region of this protein is also divided into three domains, but unlike the other MSCRAMMs, 
the IgG-folded domains which bind to collagen is the N1 and N2 rather than the N2 and N3 
used in Clfs and FnBPs21. The link between the A and W region comprises of a repeated B 
domains, and the linker between the B domains and the W domain is not flexible, 





Fig. 1.3: a diagram showing the domains in the collagen adhesion protein Can. Taken from Foster et 
al., Nat Rev Microbiol 201321.  
 
- Other adhesins 
The NEAT motif family proteins include the iron-regulated surface proteins IsdA, IsdB and IsdH 
(fig. 1.4)21. These proteins contain at least one Near Iron Transporter (NEAT) motif, and these 
bind to haem which is then transported into the bacterial cell to release iron. This is an 
effective mechanism by which S. aureus acquires iron in an iron-limited environment, such as 
the bloodstream. IsdA has also been shown to enhance S. aureus attachment to squamous 
cells. Another group are the G5-E repeat family, which includes S. aureus surface protein G 
(SasG)21. These contain multiple G5-domains, which contain 5 conserved glycines and fold into 
a β-triple helix-β -like conformation. The G5 domains are separated by a 50-amino acid E 
regions. While SasG has no know ligand, it has been shown to be involved in adhesion to 
desquamated epithelial cells.  
 
 
Fig. 1.4: a diagram showing the domains in a NEAT motif family protein and G5-E repeat family 
proteins. Taken from Foster et al., Nat Rev Microbiol 201321.  
 
Immune Evasion 
There are various mechanisms used by S. aureus to evade the immune system; S. aureus is 
capable of lysing immune cells by producing toxins (which will be explored further on), 
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inactivating complement, preventing the recruitment (chemotaxis) of neutrophils, resistance 
to phagocytosis and preventing the action of antimicrobial peptides140. S. aureus also 
produces factors including Protein A and capsule, as well as other cell wall-anchored proteins 
mentioned above to evade the immune system140, and biofilm formation provides protection 
by the formation of an extracellular matrix129.  
 
- Complement, complement evasion and chemotaxis inhibition 
The complement pathways are a part of the immune response in the host, and can be 
activated by the innate and adaptive immune response141. The main function of the pathway 
is the formation of the C3 convertase, leading to C3a, C3b, C5a and C5b formation. C3a is also 
known as anaphylatoxin and along with C3b, which coats, or opsonises, the target cell, causes 
the recruitment of immune cells as well as inducing a pro-inflammatory response. These C3b 
incorporates into the C3 convertase, leading to an increase in C3 convertases. This leads to 
the formation of the membrane attack complex (MAC) (fig. 1.5); C5b binds to C6 and C7, then 
deposits into the cell membrane. This leads to C8 binding to the C5b-C6-C7 complex, which 
then causes the recruitment and binding of C9 to form the lytic MAC.  
 
 
Fig. 1.5: a schematic showing the pathway leading to cell lysis by the complement pathways.  
 
The classical pathway and the lectin pathway are related, producing the same “classical C3 
convertase”, C4b2b, but is activated by separate pathways (fig. 1.6)141. C1q is part of the C1 
complex, and is the molecule in the classical pathway that recognises and binds to antibody 
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complexes, which activates the proteases C1r and C1s. This activated C1 complex then cleaves 
C4 into C4a and C4b, and exposes a thioester within C4b and thus C4b deposits on the target 
cell. The active C1 also cleaves C2, which is bound to C4b, into C2a and C2b, and this then 
becomes the C4b2b C3 convertase. In the lectin pathway, mannose binding lectin (MBL) and 
ficolin, which recognises carbohydrates, recruits MBL associated serine proteases (MASPs), 
which shares function with C1r and C1s. MASP-2 is the only MASP which cleaves C4 and C2, 
which gives rise to the classical C3 convertase.  
 
 
Fig. 1.6: a schematic of the classical and lectin complement pathways, leading to the formation of the 
classical C3 convertase.  
 
The alternative pathway leads to the formation of the “alternative C3 convertase”, C3bBb (fig. 
1.7); this pathway is triggered by hydrolysed C3, C3H20140. The hydrolysis creates new binding 
sites in C3, which is usually not active. The binding of factor B, a protease, to C3H2O leads to its 
cleavage by factor D to form a solvent-based alternative C3 convertase (C3H2OBb). This solvent-
based alternative C3 convertase then cleaves C3 into C3a and C3b, and C3b then binds to the 
target cell membrane. The bound C3b then forms the alternative C3 convertase “C3bBb” by 





Fig. 1.7: a schematic of the alternative complement pathway, leading to the formation of the 
alternative C3 convertase by the action of a solvent-based alternative C3 convertase.  
 
To counteract the effect of complement, S. aureus produces Staphylococcus complement 
inhibitor (SCIN) which inhibits the activity of the C3 convertase by stabilising the convertase142. 
The C3 convertases can dissociate which leaves C4B and C3b bound on the surface, and these 
act as co-factors for further C3 convertase formation141. This then amplifies the complement 
response, but SCIN inhibits this process and thus prevents the activation of complement142. 
Extracellular fibrinogen binding protein (Efb) was shown to interact with C3, therefore 
preventing C3 from attaching to the cell surface143. Staphylokinase binds to and activates 
plasmin, which then degrades IgG and C3b bound on the cell surface144.  
 
As mentioned above, C3a and C5a recruit immune cells by activating specific transmembrane 
receptors, and formyl peptides produced by bacteria also acts in the same way140. S. aureus 
produces chemotaxis inhibitory protein of staphylococci (CHIPS), which prevents chemotaxis 
by binding to C5a receptor and formyl peptide receptor145. Another protein produced by S. 
aureus, extracellular adherence protein (Eap)/MHC II analogue protein (Map), binds to ICAM-
1 on endothelial cells, which then prevents LFA-1 from binding to ICAM-1146. This then means 
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that leukocytes cannot bind to endothelial cells, therefore cannot reach the site of infection 
by extravasation140.  
 
- Preventing phagocytosis: Protein A, ClfA and capsule formation 
Protein A is a 45kDa protein found on the cell surface which is also secreted, and is expressed 
in most clinical S. aureus strains147,148. This protein contains 4-5 immunoglobulin binding 
domains, which bind to the Fc region of IgG and thus prevents the antibody binding to, or 
opsonising, its target antigen140,148. Antibody binding not only activates the classical 
complement pathway, but marks the antigen for phagocytosis, therefore a reduction in 
antibody opsonisation would lead to reduced phagocytosis140. Protein A also binds to the Fab 
region of VH3 idiotype immunoglobulins through a superantigen domain which interacts with 
CDR2148,149; this is capable of inducing B cell affinity maturation, however a study found that 
the response was limited and biased towards a VH3 antibodies. Therefore Protein A prevents 
the development of an antibody response to other S. aureus antigens148. 
 
The binding of fibrinogen by ClfA, which is expressed throughout S. aureus growth, can lead 
to the bacteria gaining a fibrinogen coat, and this may in turn protect the bacteria by 
preventing access to ligands which opsonising proteins would otherwise bind to; this has been 
shown to lead to reduced phagocytosis by murine macrophages140,150. Other fibrinogen 
binding proteins may also play this role, such as ClfB, which is more prevalent than ClfA during 
exponential growth140.  
 
Another mechanism used by S. aureus to prevent phagocytosis is the production of the 
polysaccharide capsule; most strains either express serotype 5, serotype 8 or serotype 336 
capsules151. The capsule covers the surface of S. aureus cells, and serotypes 5 and 8 have been 
associated with increased virulence152–154. The capsule is thought to prevent opsonisation, and 
while complement can bind to the bacteria under the capsule, this is thought to be 
inaccessible to the complement receptors on neutrophils140. Capsule is however susceptible 
to antibody binding, and it has been found that high levels of anti-capsule antibodies gives 
protection from S. aureus infection by enabling the bacteria to be opsonised and then 
phagocytosed155.   
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- Resisting antimicrobial peptides and survival in neutrophils 
S. aureus naturally modifies its cell wall; Dlt includes D-alanine in ribitol teichoic acid and 
lipoteichoic acid, and MprF adds L-lysine to phosphatidylglycerol on the outer part of the 
cytoplasmic membrane156,157. These modification changes the charge of the cell, and makes it 
less susceptible to cationic defensins, which are secreted in the phagosome formed in 
neutrophils, and phospholipase D2 and lactoferrin140. Staphylokinase, mentioned above, has 
an additional role of binding to defensins, providing protection from this antimicrobial 
peptide158. Aurelolysin is an extracellular metalloprotease, and this is thought to cleave and 
inactivate cathelicidin LL-37, a defensin peptide159.  
 
To survive in neutrophils, S. aureus has developed the ability to interfere with endosome 
fusion and release of antimicrobial substances160. These are mediated through the production 
of factors regulated by SarA140,161. Staphyloxanthin, the yellow/orange carotenoid pigment 
which gives S. aureus colonies its distinctive colour, has been shown to bind oxygen free 
radicals which are produced during the oxidative burst during phagocytosis162,163. Other 
factors such as two superoxide dismutases and three methionine sulphoxide reductases and 
Mn2+ uptake has also been shown to remove oxygen free radicals164–166. Superoxide 
dismutases are enzymes which catalyse oxygen free radicals, and Mn2+ acts as a non-
enzymatic superoxide dismutase140,164,165. Methionine sulphoxide reductases reduces the 
sulphur in methionine, which can become oxidised by oxygen free radicals and damage 
proteins167.  
 
- Biofilm formation 
Another way which S. aureus evades the immune system is by forming a biofilm; an aggregate 
of bacterial cells encased in an extracellular matrix composed of polysaccharides, proteins and 
DNA (fig. 1.8)129. The process starts by the adhesion of S. aureus cells to a surface, where the 
cells then multiply. As this happens, an extracellular matrix is produced which encases the 
cells. Before the biofilm matures, there is an “exodus” where some cells are released from the 
biofilm. Those that have not dispersed then form a mature biofilm with secondary structures. 





Fig. 1.8: The stages of biofilm formation in S. aureus, taken from Moormeier et al., Mol Microbiol 
2017129. Biofilm formation begins when cells attach to a surface (A), where they then multiply (B). 
There is an exodus of cells (C) prior to the maturation of the biofilm (D). Finally, cells from the biofilm 
disperse (E).  
 
During the attachment phase, where S. aureus attaches to host-derived extracellular matrix 
proteins, cell wall-anchored proteins play a key role; the MSCRAMMs enables the S. aureus to 
bind to host tissue but implanted materials which have been coated with host extracellular 
matrix, such as intravascular catheters. When it comes to abiotic surfaces, it is believed that 
adhesion is mediated by electrostatic and hydrophobic interactions and negatively charged 
teichoic acid rather than the adhesins mentioned above129,168,169. The autolysin AtlA also aids 
the attachment of cells to hydrophilic and hydrophobic polystyrene, and further evidence for 
this and cell wall-anchored protein independent attachment comes from a study using 
Nebraska transposon (Tn) mutants170 with a Tn insertions in some of the cell wall-anchred 
proteins. These included agrA (part of the virulence regulating agr system), atlA and sortase 
A and B; only the agrA and atlA mutants had an effect on biofim formation in vitro, suggesting 
that cell wall-anchored proteins are not required129.  
 
Before the development of a mature biofilm, the adherent S. aureus cells multiply, and this 
occurs in the presence of sufficient nutrients129. In the absence of the extracellular matrix the 
newly formed cells can become detached from the attached cells, particularly if there are 
shear forces (i.e. in flowing fluid)129. Therefore, intercellular adhesion is important to ensure 
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that these new cells are not removed from the attached cells; cell wall-anchored proteins such 
as FnBPs, ClfB and SdrC are thought to have a dual role, in mediating intracellular attachment 
as well as attachment to biological matrix171. However, the role of other cell wall-anchored 
proteins in the accumulation stage are unclear, as some studies have suggested that they are 
involved while others have not seen a difference172. Other proteins seem to be involved in 
aiding the accumulation of cells during S. aureus biofilm formation, as protease treatment of 
multiplication-stage biofilms lead to abrogation of biofilm formation172. 
 
A study by Foulston et al. showed that enolase and GAPDH attached to the cell surface as the 
pH of the early biofilm decreased173. These proteins were not known to affect biofilm 
development, and lack an export signal meaning that there must be another mechanism by 
which they are released – the authors proposed that they are released by “regulated 
autolysis”, in a similar mechanism by which extracellular DNA (eDNA) is released173,174. A study 
proposed that enolase and GAPDH bind to eDNA in low pH conditions, thus providing an 
extracellular matrix during early biofilm development175. Other studies suggest that phenol 
soluble modulins (PSMs), β-haemolysin, immunodominant antigen B (IsaB) also binds to eDNA 
and stabilises the early extracellular matrix176–178. Therefore, the combination of cytoplasmic 
proteins and eDNA may play a role in stabilising the early biofilm129. S. aureus is also capable 
of producing polysaccharide intercellular adhesin (PIA) through the ica genes, which forms a 
adhesive polysaccharide layer between the S. aureus cells, which then forms a part of the 
growing biofim matrix179.  
 
Prior to the maturation of the biofilm, there is a release of cells from the biofilm, and this 
forms the “exodus” phase of biofilm development129. This happens at the same time as the 
microcolony formation and causes the biofilm structure to be re-arranged129. This is distinct 
from the “dispersal” stage, and is triggered by the degradation of eDNA by nuclease rather 
than an agr response129. During this phase, only a small number of the biofilm population 
expresses the nuclease (nuc), which is regulated by the S. aureus exotoxin expression (sae) 
system172. Coagulase (coa) is another factor under sae control, and in the presence of host 
matrix proteins it is known to facilitate biofilm formation180. Notably, it is during this phase of 
biofilm formation that the biofilm integrity shifts from dependent on proteins during the 
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attachment phase to relying on both proteins and DNA172. The specific role of this “exodus” 
phase plays in biofilm maturation is unclear, however nuc mutants do not display 
microcolonies when they form biofilms, thus it is possible that the exodus of cells lead to re-
structuring of the biofilm172.  
 
The formation of secondary structures, or microcolonies, increases the surface area of the 
biofilm and thus makes nutrient acquisition and waste removal more efficient129. Also, these 
microcolonies makes it easier for cells to disperse from the biofilm. This formation of 
microcolonies occurs during the maturation phase of biofilm formation. One possibility was 
that the biofilm was degraded by the release of PSMs, which are short peptide toxins and will 
be explored later on181, forming channels, however time-lapse microscopy showed that these 
microcolonies form from cells which remain during the exodus, which forms the basal 
layer129,182. Studies observed two distinct types of microcolonies, a rapidly growing 
microcolonies expressing lrgA constitutively with delayed cidABC expression, and slow 
growing microcolonies constitutively expressing cidABC with no lrgA expression183. lrgA and 
cidABC operons are associated with cell-death, and the delayed cidABC expression seen in the 
fast growing microcolonies is thought to be induced by increasing hypoxia in these 
microcolonies183. A study revealed that lrgAB mutants had increased eDNA and adherence in 
the biofilm, suggesting that it functions as an inhibitor for cid-mediated cell lysis184. This would 
suggest that the slower growing microcolonies, which expresses cidABC without lrgA, would 
have a higher rate of cell death and thus increased eDNA.  
 
Seemingly, during biofilm maturation S. aureus cells undergo metabolic diversification, and 
these two microcolonies displayed different dispersal rates, where “streaking” from a biofilm 
is seen in some but not all microcolonies129,183. Another advantage of having metabolically 
distinct populations could be advantageous for survival129 – if one mode of metabolism leads 
to inability to survive in the environmental stresses, then there are cells displaying another 
mode of metabolism which may be better adapted for survival.  
 
The final stage of biofilm formation is the dispersal of cells, and this is mediated by the agr 
system185. The agr system is a quorum sensing system which controls virulence in S. aureus, 
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and will be discussed further on186. agr deficient strains were shown to develop a stronger 
biofilm compared to wild-type strains187. Under low flow rate, AIP, the signal of the agr 
system, accumulates in the microcolonies and this seems to lead to biofilm dispersal188,189. 
One factor under control of the agr system are the PSMs. These toxins are expressed when 
AgrA, the response regulator of the agr system, binds to the psm operon promoters, and in 
the absence of these genes the biofilm formed was thicker compared to strains which 
harboured these genes181,182. PSMs are surfactant-like, and this is thought to disrupt the 
interaction of the biofilm matrix129. Alternatively, the PSMs could form insoluble aggregates 
promoted by eDNA, and this is thought to abrogate biofilm dispersal178. Therefore, the form 
that the PSMs take may play a role in biofilm integrity by maintenance of biofilm structure129.   
 
Toxins  
S. aureus toxins can be grouped by their mechanism of action190. Cytotoxins such as α-toxin 
(also α-haemolysin) cause damage to cells by forming pores in the cell membrane, which in 
turn causes pro-inflammatory activity from the host. Other toxins include surfactant-like 
toxins and superantigens, which bind directly to the Major Histocompatibility Complex II (MHC 
II) proteins on T-cells, causing rapid proliferation of T-cells as well as a cytokine storm.  
 
Toxins have a role in virulence by releasing nutrients and allowing the bacteria to invade 
further into the host or transmit to a new host191. Traditionally, it has been thought that high 
toxicity correlates with higher virulence, therefore leading to more severe disease – however, 
S. aureus switches off toxin production in vitro, as toxin production required a lot of energy. 
However, a study from our lab looking at a collection of USA300 MRSA isolates, from either 
carriage, SSTI or bacteraemia, and S. aureus isolates carried by a single patient, found that 
while high toxin production facilitates transmission of S. aureus, it was the strains which 
produced low levels of toxins which was correlated with disease severity (i.e. bacteraemia)191. 
These low-toxic isolates were shown to have better fitness in serum, thus have increased 
chances of establishing an infection in the bloodstream. Therefore, it seems that there is a 
trade-off between the ability to transmit between hosts (high toxicity) and maintaining fitness 




It may be assumed that the action of these pore-forming haemolytic toxins on leukocytes may 
also aid in S. aureus colonisation, however these could also cause damage to the surrounding 
tissue and thus would induce an inflammatory response192. This would be counterproductive 
to long-term colonisation, however studies have found an inverse link between toxicity and 
degree of infection191,193. Therefore, it should be considered that S. aureus toxins may in fact 
be manipulating the immune system so that it can co-exist with the immune cells192. As Phenol 
Soluble Modulins (PSMs), which will be discussed in more detail later, do not act via a receptor, 
it could potentially target any cell, including other bacteria194. This could enable S. aureus to 
dominate its niche by inhibiting the growth of other bacteria, thus enabling S. aureus to access 
the nutrients found in the host.  
 
- Cytolytic toxins 
Haemolytic toxins are released as monomers, which oligomerise on the target cell membrane 
and cause the target cell to lyse190. Most of these toxins target immune cells, and the lysis of 
these cells are thought to have two affects. By killing the immune cells, S. aureus is able to 
evade phagocytosis as well as damaging the surrounding tissue by the pro-inflammatory 
response which occurs when the cytosolic components from the killed cells are released into 
the surrounding tissue195. Evidence has emerged to show that leukocidins may also interact 
with pro-inflammatory receptors, or have a “sub-lytic effect” as well195.  
 
α-haemolysin 
The most well studied haemolytic toxin is α-haemolysin, or α-toxin, noted for its ability to lyse 
erythrocytes. It is released as a 33.2kDa monomer, which is water soluble and binds to target 
cells (erythrocytes. platelets, monocytes, lymphocytes, endothelial cells) and forms a 
heptameric barrel196. The ability of α-haemolysin to lyse erythrocytes means that S. aureus 
strains producing this toxin display β-haemolysis, where a clear zone of inhibition is visible on 
blood agar197. The process beings when the α-haemolysin monomer binds to the target cell 
membrane, which is able to interact with the lipid bilayer; at low concentrations, this is 
mediated by the ADAM10 receptor, a disintegrin and metalloproteinase198. The monomers 
diffuse in the membrane, which results in oligomerisation, then the formation of the 
heptameric barrel, which ultimately leads to the formation of a pore of around 1-2nm190. 
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Formation of the pore leads to the lysis of the target cell through the efflux of small molecules 
and K+ ions, and the influx of other small molecules, Na+ and Ca2+ ions190. This disrupts the 
osmotic balance across the membrane, leading to rupture of the target cell. 
 
The heptameric α-haemolysin is shaped like a mushroom of 100Å in height and up to 100Å in 
diameter, and the pore is a solvent-filled channel running through the middle (fig. 1.9)196. It 
was concluded from various studies that N-terminus of α-haemolysin has a role in opening the 
pore of the oligomeric toxin. The oligomeric structure of α-haemolysin can be subdivided into 
the cap, stem and rim domains; the cap domain, which along with parts of the rim domain 
protrudes from the target cell membrane, is composed of seven β-sandwiches. The stem 
domain forms the transmembrane component of the toxin, and a cleft is formed between the 
top of the stem domain and the rim domain; this cleft is rich in basic and aromatic amino acids, 
therefore could interact with the phospholipid head of the membrane.  
 
 
Fig. 1.9: the structure of heptameric α-toxin. Taken from Song et al., Science 1996196.  
 
Bi-component toxins 
Some haemolysins are made of two distinct subunits, thus they are called “bi-component 
toxins”, and this class of toxins includes γ-toxin (γ-haemolysin, HlgA, HlgB, HlgC), the 
leukocidins (LukED, LukGH (LukAB) and Panton-Valentine Leukocidin (PVL, LukSF-PV))195. 
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These toxins are composed of an S subunit (HlgA/HlgC, LukE, LukH (LukB) and LukS-PV) and an 
F subunit (HlgB, LukD, LukG (LukA), and LukF-PV), and are structurally similar to α-
haemolysin195. They are β-barrel pore forming toxins formed by the octamerization of four 
alternating S and F units (four of each). The subunits of these toxins are coded together on the 
genome with the exception of γ-toxin, which is organised as three open reading frames. These 
leukocidins also act via a receptor, including CCR5 (LukDE), C5aR and C5L2 (PVL), and CD11b 
(LukAB (LukGH)). The S subunit binds to the target receptor on the cell, which causes a 
conformational change thus allowing the F subunit to dimerise with the S subunit. The dimers 
then oligomerise to form the pre-pore, then the β-barrel transmembrane channel is inserted 
into the membrane to form the pore.  
 
γ-haemolysin exists in two forms, HlgAB (classical γ-haemolysin) and HlgCB; HlgAB is mostly 
active against erythrocytes, while HlgCB is mainly active against leukocytes199. 89-100% of 
carriage strains have the genes encoding for γ-haemolysin, however studies have not been 
able to discover a link between γ-haemolysin and a particular infection200,201. However, the 
presence of HlgAB seems to promote survival of S. aureus in blood, most likely related to Fe2+ 
release from erythrocytes and macrophage evasion199.  
 
LukED has shown lytic activity against erythrocytes and leukocytes, however this is at a 
reduced level compared to γ-haemolysin199. As LukED also has affinity for a wide range of cells 
and host species, there has been animal studies carried out using this toxin; in a rabbit skin 
infection model, it was found that injection of LukED resulted in dermonecrosis, therefore it 
elicits a pro-inflammatory response in vivo195. It has also been shown that the presence of 
LukED is required for virulence in systemic infections in mice202. It is thought that LukED may 
play a role in impetigo, antibiotic associated diarrhoea, furuncles and invasive bacteraemia, 
as S. aureus isolated from these infections were found to contain the lukED genes more 
frequently195. However, since these studies it was found that lukED is present in a higher 
proportion of S. aureus, therefore the correlation between this toxin and the above infections 




LukGH, also called LukAB, was shown to be important in enabling S. aureus to survive in 
polymorphonuclear leukocytes; wild-type strains survived better than the lukGH/lukAB 
deletion mutant195. This was due to the damage caused to the polymorphonuclear leukocytes, 
as well as enabling S. aureus to escape from the phagosome; when bacteria are phagocytosed, 
they are restricted to the phagosome, however it seems that this toxin enables the S. aureus 
to escape from the phagosome and thus survive phagocytosis.  
 
PVL is a phage-encoded bi-component leukocidin, and is frequently seen in CA-MRSA strains; 
these strains mainly affect people without risk factors for S. aureus infections and frequently 
causes SSTIs4,199. In contrast, the prevalence of PLV in carriage isolates is less than 3%200. It is 
thought that PVL+ve S. aureus strains have increased virulence, however this cannot be 
attributed to PVL alone199.  These CA-MRSA clones are seen across the world, however it is 
thought that multiple S. aureus strains carrying a PVL phage and SCCmec VI (which causes 
methicillin resistance) expanded rather than a single PVL +ve MRSA strain199. In SSTIs caused 
by PVL+ve S. aureus strains, it has been demonstrated that PVL is expressed in the abscess, 
therefore PVL may be a contributing factor in the development of abscesses199. One study 
showed that PVL+ve S. aureus strains contributed to an increased ulceration and haemorrhage 
during pneumonia, likely caused by excessive inflammation triggered by the lysis of imunne 
cells by PVL203. However meta-analysis of epidemiological studies have not shown an 
association between PVL and increased virulence in S. aureus pneumonia204.  
 
β-haemolysin 
β-haemolysin is a non-pore forming toxin, instead it is a sphingomyelinase C which hydrolyses 
the membrane lipid sphingomyelin into ceramide and phosphorylcholine and is thought to 
require Mg2+ ions as a co-factor190,205. While the precise mechanism of how β-haemolysin 
causes cell death is unknown, it could be due to the toxin causing changes in membrane 
fluidity of target cells, or by the formation of large ceramide-rich signalling platforms205. In the 
presence of DNA, β-haemolysin has been shown to covalently link with itself to form oligomers 
which then facilitates biofilm formation177 - the initiation of a biofilm involves the attachment 
of S. aureus to a surface, and during this stage β-haemolysin produces an insoluble 
nucleoprotein matrix which becomes part of the biofilm matrix. This was also shown to 
32 
 
happen in vivo, where vegetation formed during endocarditis were found to be smaller when 
the infecting strain did not express β-haemolysin177.  
 
- Phenol Soluble Modulins 
As the above toxins act through a receptor, they specifically target certain cells. S. aureus also 
produces toxins which do not act via a receptor, which are the surfactant-like PSMs192. These 
toxins are short, amphipathic peptides and are also produced by other staphylococci. They are 
grouped according to their size; the αPSMs (PSMα-1-4 and δ-toxin) are approximately 20-25 
amino acids, βPMSs (PSMβ1 and 2) are approximately 44 amino acids181. They are encoded at 
different locations in the genome, and encode seven PSMs; the αPSMs genes are found in the 
psmα operon, as are the βPSMs (psmβ operon), and the δ-toxin is encoded within RNA III, the 
regulatory RNA effector of the agr response181.  
 
The charge of the PSM peptides seem to correlate with their cytolytic activity, with the αPSM 
displaying the highest cytolytic activity, δ-toxin displaying moderate levels and βPSMs are not 
cytolytic181. Studies such as the one by Periasamy et al. have shown that PSMs are involved in 
biofilm formation, particularly in forming secondary structures by forming the channels and 
microcolonies, and they are also important for biofilm dispersion as mentioned above182. 
αPSMs have been linked to increased virulence seen in CA-MRSA, while other PSMs have not 
been as clearly linked206. αPMSs have also been shown to prevent the inactivation of the 
antibiotic daptomycin in a study by Pader et al.207. Daptomycin binds to the most abundant 
phospholipid in S. aureus membrane, phosphatidylglycerol, and the study found that the 
release of phospholipids (mainly phosphatidylglocerol) bind to daptomycin which then 
renders the antibiotic inactive. However, it was only S. aureus strains lacking a functional agr 
system which inactivated daptomycin even though both this mutant and the wild-type strains 
used released phospholipids. The authors therefore looked for factors which are controlled by 
the agr system which could interfere with phospholipid-daptomycin binding and found that 
αPSM mutants were able to inactivate daptomycin. Therefore, αPSMs (particularly PSMα1) 
binds to phospholipids which means that they cannot bind to and inactivate daptomycin. 
Another study showed that PSMs are capable of regulating the expression of genes including 




Superantigens, also known as pyrogenic toxin superantigens, include Toxic Shock Syndrome 
Toxin-1 (TSST-1) and staphylococcal enterotoxins SEA, SEB, SECn, SED, SEE and SEH190. Three 
functions seen in all these toxins are pyrogenicity (cause fever), and superantigenicity, and 
they have also been shown to increase the lethality of endotoxin in rabbit models190. These 
superantiens give rise to different toxin mediated infections, which will be explored below.  
Toxic shock syndrome is an example of a superantigen mediated infection, and has been linked 
to the use of tampons during menstruation190. It is an acute systemic illness which can become 
fatal, characterised by high fever, rash, desquamation of the skin, low blood pressure and also 
involves other organs209,210. Early studies of patients with menstruation-associated toxic shock 
syndrome showed that they were not bacteraemic, therefore the syndrome was likely caused 
by factors produced by the bacteria190. TSST-1 was the first virulence factor to be associated 
with toxic shock syndrome, and is unique in its ability to cross mucosal barriers190. TSST-1 is 
the only toxin known to cause menstruation-associated toxic shock syndrome, while SEB and 
SEC have been seen to cause non-menstruation-associated toxic shock syndrome190,211,212.  
 
A property unique to enterotoxins, the other family of superantigens, is their ability to induce 
vomiting, hence it is a key factor in S. aureus food poisoning190. S. aureus food poisoning 
causes inflammation along the gastrointestinal tract, with the most severe lesions occurring 
in the stomach and the top of the small intestine190,213. When enterotoxin producing S. aureus 
strains colonise food, they can form toxins within the food, and ingestion of contaminated 
food results in vomiting and possibly diarrhoea, typically resolving in around 24-48 hours190. 
The incidences of S. aureus food poisoning is unclear, and as there are many enterotoxins 
involved prior infection may not result in protection from subsequent infections190. Although 
the mechanism of how enterotoxins induce vomiting has yet to be established, one proposed 
mechanism is that it is a response to inflammation caused by the enterotoxin190.  
 
Exoenzymes  
S. aureus produces various enzymes, including nucleases, lipases and proteases214. These 
enzymes degrade host tissue, allowing the bacteria to invade deeper tissue, or degrade 
antimicrobial compounds produced by the host, such as antimicrobial peptides and fatty acids. 
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Aureolysin, a protease produced by S. aureus, inactivates PSMs, which then has an effect in 
the pathogenesis of osteomyelitis215. Aureolysin is also responsible for the activation of 
another S. aureus protease, SspA, and these along with staphopain A and B disrupts 
complement216. The pathogenesis of Staphylococcal Scalded Skin Syndrome is mediated by 
the cleavage of desmosomal cadherins by S. aureus exfoliative toxin, which is a serine 
protease217. Nuclease has a role in degrading neutrophil extracellular traps (NETs); these are 
DNA-based structures, with proteases antimicrobial peptides and histones bound to them, 
and these trap microbes218. The action of nuclease degrades these nets, thereby allowing the 
bacteria to escape from these NETs. Other enzymes, such as β-lactamases, actively degrade 
antibiotics to allow the bacteria to resist the action of the antibiotic, β -lactams in this case98.  
 
- Lipases 
Lipases are enzymes which hydrolyse the ester bond in lipids, and S. aureus utilises lipases for 
lipid metabolism, and also as virulence factors219. Fatty acids are produced on human skin, 
and these can be harmful to S. aureus220. Lipases therefore break these down, so that these 
fatty acids are essentially disarmed. Lipases are also thought to be involved in the invasion of 
S. aureus into deeper tissue; this is supported by research which showed that S. aureus strains 
isolated from deep infections produce more lipase, and that lipase knock-out S. aureus lead 
to reduced bacterial load in a mouse model221. Also, lipases can be used as biotechnology 
catalysts, in industries such as food and pharmaceutical industries222. Chapter 5 looks at 
finding new genetic loci which regulate lipase activity in S. aureus, therefore more is discussed 
there.  
 
Regulation of virulence factors 
Virulence factors such as toxins are energetically costly to produce, therefore their expression 
is highly regulated223,224. These factors are generally either produced at low cell density 
(exponential phase) or high cell density (stationary phase); Protein A is an example of a protein 
expressed in the exponential phase, while toxins and enzymes are expressed during the 





- Accessory Gene Regulator 
One well studied regulator is the accessory gene regulator (agr) quorum sensing system (fig. 
1.10)186,223,225. S. aureus strains with the agr system produces AgrD, which is processed by AgrB 
and a part of AgrD is exported through AgrB - this becomes the signal of this quorum sensing 
system, known as auto-inducing peptide (AIP)225. At high cell density, the bacterial cells 
recognise AIP through AgrC, a membrane-bound histidine kinase. AgrC then phosphorylates 
AgrA, the response regulator, and this causes transcription from the P2 and P3 agr promoters; 
P2 promoter transcript, RNA II, yields more Agr proteins (AgrD, AgrB, AgrC, AgrA) while the P3 
transcript is a regulatory RNA, RNA III, the primary regulatory element of the agr system225. 
RNA III is thought to primarily act on transcription of the virulence factors, while acting on 
translation in some cases225.  
 
Fig. 1.10: a schematic demonstrating the auto-activating cascade of the agr system. Taken from 
Thoendel et al., Chem Rev 2011225.  
 
The agr locus may also be activated by the RNA III activating protein (RAP), by the RAP-TRAP 
two component system223. RAP is a secreted protein which is secreted throughout S. aureus 
growth, and it is proposed that it may phosphorylate TRAP that may lead to transcription from 
the P2 and P3 agr promoters. It is thought that AIP inhibits TRAP phosphorylation, thus it 




The effect of agr on the genes it regulates vary depending on the kind of proteins which are 
encoded by the gene; for example, proteins promoting adherence to the host such as 
coagulase and fibronectin binding protein, are downregulated by agr activity while toxins and 
exoenzymes are upregulated by agr activity223. The upregulation of toxins by the agr system 
is thought to be the inhibition of repressor of toxins (Rot) by RNA III; Rot is a transcriptional 
regulator belonging to the SarA family, and downregulates the expression of toxins and 
exoenzymes while upregulating the expression of MSCRAMMs and Protein A. two loop-loop 
interactions between RNA III and rot mRNA prevents the translation of Rot, therefore 
changing the gene expression pattern.  
 
The role of the agr system in pathogenicity has been established in animal models in studies 
such as the one by Abdelnour et al.226. However, clinical strains often have mutations in the 
agr locus, meaning that the activity is reduced, and there have been instances of clinical 
isolates which are agr negative227. However, for the USA300 lineage of CA-MRSA studies has 
found that agr activity is necessary for the development of SSTIs in a mouse model; one study 
found that mice infected with LAC, a USA300 strain, developed larger abscesses and showed 
necrosis in the epidermis and the dermis compared to an agr knock-out mutant or strain 252, 
a hospital-acquired MRSA strain228. The use of agr knock-out mutants and heat-killed bacteria 
in this study demonstrated that the development of larger abscesses with necrosis was due 
to toxins produced by LAC rather than an immune response, however comparison between 
LAC and 252 showed no difference in agr activity. Rather, it was found that there was a 
difference in the expression of PSMs, lipases and proteases seen between LAC and 252, which 
seemingly resulted in the larger necrotic abscesses.  
 
Animal models have also shown that the agr system is required for the development of 
infective endocarditis, with mutants leading to vegetations with fewer bacteria compared to 
the wild-type229. It is interesting then, to note that S. aureus strains with an agr defect are 
frequently isolated from bacteraemia. Typically, mutations which inactivate the agr system 
occur mainly in agrC and agrA, and this has been shown to mainly occur prior to the onset of 
bacteraemia230. Therefore, it is plausible that selection for agr defective strains involve factors 
outside the bloodstream, such as those present in wounds or colonised intravascular 
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catheters. Interestingly, nasal colonisation does not seem to be a factor for the development 
of agr defective mutants, as majority of these S. aureus strains have a functional agr system231. 
However, this changes when the patients go into hospitals or are given antibiotics such as 
fluoroquinolones and β-lactams, therefore healthcare contacts seems to be a risk factor for 
the selection of agr defective S. aureus strains231. Studies have shown that agr system is not 
expressed in blood, even if there is a functional agr system in the strain, and this does not 
seem to be due to low density, as studies using higher densities have reported reduced RNA 
III expression in blood232,233. Apolipoprotein B is produced by the host in the serum, and this 
protein and other serum lipoproteins captures AIP as well as PSMs and thus disabling the 
activity of the agr system232,234. S. aureus can counteract this by aggregating, thus producing 
a higher local concentration of AIP, or by mutating agrC so that it is constitutively 
expressed235,236. Some cytotoxins such as α-haemolysin, γ-haemolysin and leukocidins are 
expressed in blood in an agr independent manner, and this seems to enable S. aureus to 
survive in the blood230.  
 
- Staphylococcal Accessory Regulator A 
Another regulator of staphylococcal virulence is the staphylococcal accessory regulator A 
(sarA), which also controls virulence in a growth phase dependent manner161,223. This is 
regulated by σA -specific promoters, sarP1 and sarP2, as well as the sarP3 promoter, which 
has similarity to σB-dependent promoters. By being activated by different σ factors, the sarA 
operon is active during all growth phases; sarP1 and sarP2 during exponential growth and 
sarP3 during late exponential to stationary phase. As σB has a role in responding to stress, the 
sarP3 promoter is also activated during environmental stress.  
 
The multiple regulatory mechanisms of sarA leads to peak expression during late exponential 
growth, although there is a possibility that the SarA protein may be under post-translational 
regulation as its levels remain relatively constant even when the sarA mRNA levels differ223. 
SarA is a DNA binding protein which binds to conserved AT-rich recognition sites, or Sar boxes, 
within the promoter of the target genes; one such binding occurs at the P2 and P3 agr 
promoters, thus altering the level of agr activity. Other genes regulated directly by SarA 
include Protein A, FnBPs, Cna, α-, δ- and γ-haemolysins. SarA binds as a homodimer, and its 
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binding reduces the number of base-pairs per turn of the DNA helix, which changes the 
spacing between the -35 and -10 regions within the promoter so that it either becomes 
optimal or becomes repressed. The pattern of regulation differs slightly between sarA and 
agr, as can be seen in table 1.1.  
 
Gene +/- regulated by agr? +/- regulated by sarA? 
cap8 (capsule) + + 
spa (Protein A) - - 
fnbA, fnbB (fibronectin binding proteins) - + 
hla (α-haemolysin) + + 
hld (δ-haemolysin) + + 
hlgA, hlgCB (γ-haemolysin) + + 
luk-PV (PVL) + + 
lukED (leukocidin) + + 
tst (TSST-1) + + 
seb (enterotoxin B) + + 
sspA (V8 serine protease) + - 
Table 1.1: a table showing examples of genes which are either up-regulated (+) or down-regulated (-) 
by the accessory gene regulator (agr) or the staphylococcal accessory regulator A (sarA) regulatory 
systems. While the majority of these genes are regulated by the two systems in the same manner, 
there are some which are regulated differently. Based on tables from Bronner et al., FEMS Microbiol 
Rev 2004223  
 
- Staphylococcal Exoprotein Expression 
The staphylococcal exoprotein expression (sae) locus is another two-component regulatory 
system, like the agr system, and regulates expression of virulence genes mainly at a 
transcriptional level223. SaeS has high similarity with other sensor histidine kinases, and 
contains two transmembrane domains at the N-terminus and a histidine residue at the C-
terminus which is auto-phosphorylated. SaeR is the response regulator which has similarities 
with other known regulatory proteins, and has a conserved aspartate residue which can be 
phosphorylated. The sae locus has been shown to be important in the expression of α- and β-
haemolysin as well as Coa, but this is thought to be independent of the agr or sarA regulation. 
A study found that the level of hla (α-haemolysin) transcript was reduced in sae mutants both 
in vivo and in vitro, and that hla transcription was activated independently of agr or sarA in a 
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guinea pig infection model237. Another study found that the deletion of saeS lead to a loss of 
TSST-1 expression from a menstruation-associated TSS-causing strain, therefore the sae locus 
may play a role in the expression of this superantigen toxin238.  
 
Genome Wide Association Studies 
Genome Wide Association Studies look for a link between genetic polymorphisms and a 
particular phenotype in a population - in bacteria this involves identifying SNPs and insertions 
and deletions (indels) within a population, then analysing to see if any of these genetic 
polymorphisms are statistically associated with a change in phenotype, such as toxicity239. The 
first GWAS were carried out for human diseases, such as Age-related Macular Degeneration, 
and the development of cheap whole genome sequencing technologies and the subsequent 
increase in the availability of bacterial genome sequences have facilitated the development of 
bacterial GWAS.  
 
Success of bacterial GWAS requires a phenotype that can be tested, such as toxin production, 
a collection of sequenced strains, a statistical approach and then power calculations so that 
sufficient number of strains can be chosen239. Success of GWAS also depends on how the 
genetic polymorphisms are distributed in the population - the mixing of alleles within a 
population enables the identification of causal and passive loci. Causal loci are those which 
cause the effect, such as a change in toxin production, and passive loci are those that do not 
actually cause the effect despite being identified in the GWAS. Due to the fact that bacteria 
reproduce asexually, this leads to what is called a strong Linkage Disequilibrium (LD); LD is 
defined as “non-random association of alleles at two or more loci”240, and in the absence of 
recombination or mutations a block of DNA will remain the same when passed onto the next 
generation. Genome variation does occur in bacteria, although not at each generation as is 
the case in humans; mechanisms include horizontal gene transfer, non-homologous 
recombination, homologous recombination and recurrent mutations. These distinct 
mechanisms lead to different branches of phylogeny containing similar genetic loci. Also, 
population structure is another important aspect which needs to be considered when 
designing GWAS. Due to these differences between human and bacterial genomes, 
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parameters in the tools developed for human GWAS needs to be adapted before carrying out 
bacterial GWAS.   
 
Aims 
The aim of this PhD was to see if functional genomics can be used to find novel ways in which 
virulence is regulated in S. aureus. Previous research in our lab has used GWAS to identify 
genetic loci which are associated with a change in toxicity in ST239 and USA300 MRSA strains, 
and this revealed that a SNP in the ileS gene was associated with a change in toxicity of these 
strains; this SNP is the most frequently seen SNP in isolates displaying low-level mupirocin 
resistance. The first part of the research focuses on how mupirocin resistance links to changes 
in toxicity. In the second part of the research, I applied GWAS to find out which genetic loci 
are associated with a change in lipase production of ST239 MRSA strains, as there is not much 






















- Materials and Methods 
 
Laboratory Methods 
Bacterial strains and growth conditions 
Staphylococcus aureus strains were grown in Tryptic Soy Broth (TSB)/Agar (TSA) unless 
otherwise stated. E. coli strains were grown in Luria-Bertani (LB) medium. All were grown at 
37°C, with shaking if using liquid medium. 
 
To determine the mupirocin Minimum Inhibitory Concentration (MIC) of selected USA300 
strains, 100µl of overnight cultures of these strains were plated onto agar plates containing 
the following concentrations of mupirocin; 0µg/ml, 32µg/ml, 64µg/ml, 96µg/ml and 125µg/ml 
and allowed to grow overnight at 37°C.  
 
THP-1 cell growth conditions 
THP-1 cells were grown in RPMI 1640 supplemented with foetal bovine serum (10%), L-
glutamine (2mM), penicillin (100 units/ml) and streptomycin (100µg/ml). The flasks were 
incubated at 37°C with 5% CO2, with sub-culturing every 2-3 days. 
 
Polymerase Chain Reaction  
DNA was extracted using High Pure PCR Template Preparation Kit (Roche); 5µl lysostaphin 
(5mg/ml)was added instead of lysozyme, and incubated for 30 mins. PCR was set up using 
GoTaq (Promega) OneTaq (NEB), DreamTaq (Thermo) or Phusin (Thermo) for cloning, and was 
set up according to the manufacturer’s guidelines. The primers used are listed below (table 
2.1).  
 
The products were run on a 1% agarose gel in Tris-acetate-EDTA (TAE) buffer, at 85V for 35 






- table 2.1a: PCR primers 
 
 
- table 2.1B: cloning primers (for lipase project) 
name purpose sequence Tm (°C) restriction site 
SAUSA300_1966 cloing fwd cloning of SAUSA300_1966 TTT GAATTC CTCCTTTTAAGATGTTTG 57.4 EcoRI 
SAUSA300_1966 cloing rev  AAA GGTACC AAAGGAGCATAAAC  57.1 KpnI 
murA cloning fwd cloning of murA TTT GAGCTC AAAACAAGATAAATCTATACA 58.6 SacI/BanII 
murA cloning rev  AAA GGTACC AAGTAATGGACAAAGG 59.7 KpnI 
atpH cloning fwd cloning of atpH 
TTT GAATTC 
TCACTCCTCTTTATAATTAATTAA 58.3 EcoRI 




name purpose sequence Tm (°C) 
ileS control checks for the mupR SNP status CTTATAAATTCTTACTTTCTCATGGTTTT 56.8 
ileS S2 (mupirocin sensitive) TAAATTCTTACTTTCTCATGGTTTTGG 57.4 
ileS R4 (the mupR SNP) TAAATTCTTACTTTCTCATGGTTTCT 55.3 
ileS rev. 2  GATTGGTGCTAACAACTTCGTCATA 59.7 
gyrB for qPCR control primers (gryB gene) CCAGGTAAATTAGCCGATTGC 57.9 
gyrB rev  AAATCGCCTGCGTTCTAGAG 57.3 
agrC RT fwd agrC real-time PCR (qPCR) GCAGATTATTCTATACTGTGCTAAC 58.1 
agrC RT rev  ACTACAAAAAAGCTAGGGAATATTACAAA 58.2 
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Creating and screening mupirocin resistant mutants 
As ileS is an essential gene, it cannot be knocked-out. Therefore, we have created a selection 
based method where an overnight culture of the mupirocin sensitive strain was plated onto 
agar with 4µg/ml mupirocin. This was incubated for 42- 48h to allow colonies to grow. Few of 
these colonies were streaked out onto fresh agar with mupirocin (4µg/ml), and after these 
had grown fully (approx. 42h) a colony was inoculated into broth and grown overnight. This 
overnight culture was then mixed with glycerol and stocked in -80°C, or used to extract DNA 
(as above). 
 
Once DNA was extracted, an allele specific PCR241 was performed to determine what 
nucleotide is present at 1,762 of the ileS gene; G results in V588, which is mupirocin sensitive, 
and T results in F588, which confers resistance to mupirocin. The ileS control, ileS R4 and ileS 
S2 primers were paired with ileS reverse 2 primer, thus each colony was screened with three 
different primers; control to check for the presence of ileS, R4 to see if it is T at 1,762 and S2 
to see if it is G at 1,762. The reactions were set up as recommended for GoTaq (Promega), and 
the cycling conditions were as recommended by the manufacturer; 50.5°C was used as the 
annealing temperature, and the extension time was 1 min. The products were visualised as 
above. 
 
Genome sequencing using Illumina MiSeq was carried out by Prof. Sheppard and colleagues 
for the SH1000 mupirocin resistant mutants (MY40, SH1000:2, SH1000:3, SH1000:4, 
SH1000:5, SH1000:6), to check that this mutation in ileS had occurred, and also to ensure there 
were no other mutations in the genome which could account for a change in toxicity. 
 
Toxicity assay 
Strains were grown in a glass tube for 18h, and the supernatant was harvested by centrifuging 
up to 1ml of the above culture at maximum speed for 10 mins in a microcentrifuge. 
Meanwhile, the THP-1 cells were harvested by centrifuging at 1,200 rpm for 10 mins, then re-
suspending in sterile phosphate buffered saline (PBS) to get a dilution of approx. 1*106 
cells/ml. 20µl of the bacterial supernatant was mixed with 20µl of THP-1 cells, and incubated 
for 12 mins at 37°C. 260µl of Guava ViaCount (Milipore) was then added to the sample, and 
44 
 
incubated at room temperature for 5 mins before analysing the viability count on the Guava 
flow cytometer (Milipore).  
 
Growth curves 
Mupirocin sensitive and mupirocin resistant strains were grown overnight, then diluted 1/500 
in fresh broth before pipetting 200µl into a 90-well plate; the outer wells were filled with 
water. The lid of the plate was wiped with Triton X-100 before placing in a plate reader at 
37°C, and OD600 readings were taken every 5 mins for 16h, with shaking in between each 
reading.  
 
Analysing isoleucine content of mupirocin sensitive and mupirocin resistant cells 
Cultures of SH1000 and MY40 were grown for 18h (5ml). The cultures were then washed 3 
times with 1ml sterile PBS, centrifuging at 14,000rpm for 10 mins after each wash. The pellet 
was then re-suspended in 500µl sterile PBS, and 200µg/ml lysostaphin, 10µg/ml RNase A and 
20µg/ml DNase I was added. This was then incubated at 37°C for 1h, and sonicated briefly on 
ice. The samples were then centrifuged at 14,000rpm for 10 mins, and 500µl of the resulting 
supernatant was applied to a Vivaspin 500 (3,000 MWCO) protein concentrator (GE 
Healthcare). This was then centrifuged at 15,000g for 30 mins.  
 
The samples were analysed using Liquid Chromatography-tandem mass spectrometry (LC-
MS/MS), similar to the protocol by Sowell et al.242. Five DL-isoleucine standards were made in 
0.1% formic acid for quantification, and these were run before and after the samples through 
the system using a C18 column and positive ion mode MS/MS.  
 
Making an agr knock-out strain  
To eliminate the differential agr activity between strains, an agr knock-out of SH1000 was 
used (MY18). MY18 was created by phage transduction as follows; initially a ϕ11-ROJ48 lysate 
was created; ROJ48 was cultured overnight in LK (1% tryptone, 0.5% yeast extract, 1.6% KCl), 
and 200µl of ROJ48 overnight was mixed with 3ml LK and 3ml phage buffer (10mM MgSO4, 
4mM CaCl2, 50mM Tris-HCl (pH 7.8), 100mM NaCl and 0.1% gelatine powder in 
molecular/MiliQ water) with up to 500µl ϕ11. This was placed on a shelf in a 30°C shaking 
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incubator until the media became clear. This 1st round lysates were then filter sterilised, and 
a second round of lysis was carried out with this first round lysate.  
 
After these two lysis steps, the ϕ11-ROJ48 2nd round lysate was used to attempt a transduction 
into SH1000. Briefly, 1.8ml LK, 10µl 1M CaCl2, 200µl of SH1000 overnight culture in LK and 
various volumes of the ϕ11-ROJ48 2nd round lysate (up to 500µl) was mixed together, then 
incubated at 37°C with shaking for 45 mins. 1ml ice cold 20mM trisodium citrate was added 
to the transduction mix, and incubated on ice for 5 mins. This was centrifuged to pellet the 
bacteria, which were then re-suspended with 1ml ice cold 20mM trisodium citrate. This was 
incubated on ice for 2.5h, and plated onto TSA plates with 20mM trisodium citrate, 
erythromycin and lincomycin (25µg/ml) which was incubated overnight at 37°C. One of the 
resulting colonies, SH1000 Δagr::P3-lux, was named MY18. 
 
Transformation of pAgrC(his)A, a plasmid containing his-tagged AgcC and AgrA 
pAgrC(his)A, a plasmid containing his-tagged AgrC and AgrA (AgrC(his)A), allows a strain 
harbouring it to respond to extracellular AIP without being able to produce AIP. This plasmid 
was extracted from E. coli TOP10 grown in broth with 100µg/ml ampicillin. This plasmid was 
extracted using a plasmid extraction kit (Thermo) following the manufacturer’s protocol, and 
then electroporated into RN4220; briefly, RN4220 was grown overnight in Brain Heart Infusion 
(BHI) medium, and diluted 1:500 into 10ml fresh BHI. This was then incubated at 37°C with 
shaking until OD600 0.4 - 0.6. The culture was then cooled, before centrifuging at 5,000rpm for 
10 mins at 4°C. The media was discarded, and the pellet was re-suspended with 5ml ice cold 
500mM sucrose. This was then re-centrifuged, supernatant discarded then 5ml ice cold 
500mM sucrose added to the pellet. This above process was repeated for a total of 3 sucrose 
washes, and centrifuged as above.  
 
After discarding the supernatant for the third time, 500µl ice cold 500mM sucrose was added 
to the pellet and re-suspended. This was left on ice for 30 mins, before centrifuging and re-
suspending in 100µl ice cold 500mM sucrose. The cells were pipetted into an electroporation 
cuvette, and 5-10µl of the plasmid pAgrC(his)A was added on top. This was then 
electroporated using the StA setting on the MicroPulser (Bio-Rad), and then recovered in 
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750µl BHI at 37°C for 1h. 200µl of the transformant was plated onto agar plates with 
chloramphenicol, and incubated overnight at 37°C.  
A mupirocin resistant variant of MY18, MY41, was created using the method described 
previously. pAgrC(his)A from RN4220 was electroporated into MY18 and MY41 as above, 
yielding MY42 and MY43. The resulting colonies were re-streaked onto fresh TSB-
chloramphenicol plates, with mupirocin for colonies from MY41.  
 
Protein extraction 
-α-toxin and secreted Protein A 15ml of an 18h culture of SH1000 and MY40 were pelleted by 
centrifugation at 5,000rpm for 10 mins. The supernatant proteins were concentrated by 
precipitation using trichloroacetic acid (TCA). Briefly, 10ml of the supernatant was mixed with 
2.5ml TCA and incubated on ice for 1h. This was centrifuged at 14,000 rpm for 20 mi.s at 4°C, 
and the pellet was washed 3 times with 300µl ice cold acetone. After the washes, the pellet 
was re-suspended in 80µl 8M urea and 0.5µl 1M NaOH.  
 
-Cellular Protein A 15ml of an 18h culture of SH1000 and MY40 were pelleted by centrifugation 
as above and washed three times with phosphate buffered saline (PBS) (Difco). The pellet was 
re-suspended in 1ml PBS and lysostaphin (200µg/ml), DNase I (20µg/ml) and RNase A 
(10µg/ml) was added to the cells, and incubated at 37°C for 1h. The samples were then 
sonicated briefly on ice, and 700µl of lysate was mixed with 700µl PBS with 0.2% Triton X-100.  
 
-AgrC(his) Overnight cultures of MY42 and MY43 was diluted 1:500 into 120ml broth with 
chloramphenicol, and grown for 2h at 37°C with shaking. 100nM AIP-1 was added to the 
culture to induce the expression of AgrC(his). This was allowed to grow for 1-3h, and 30ml 
samples were taken every hour from 1h after induction. Samples were centrifuged as before, 
media discarded and the pellet re-suspended in 100-250µl sterile PBS (100µl for 1h samples, 
150µl for 2h samples, 200µl for 3h samples and 250µl for 4h samples). Lysostaphin, DNase I 
and RNase A was added to the cells as above, and incubated at 37°C for 1h. The samples were 




-Phenol Soluble Modulins (PSMs) An overnight culture of SH1000 and MY40 was diluted 
1:1000 into 50ml fresh media, and grown for 18h. The cultures were centrifuged at 18,000 
rpm for 10 mins, and 35ml of the supernatant was mixed with 10ml butanol. The samples 
were incubated at 37°C shaking for 3h, and were then centrifuged at 3,000 rpm for 3 mins and 
1ml of the upper organic layer was taken off. The samples were then freeze-dried overnight 
and then re-suspended in 160µl 8M urea.  
 
SDS-PAGE and Western blotting 
Concentration of the protein samples were measured using Bradford reagent, and the 
samples were made equal concentration. The samples were mixed with the same volume of 
Morris SDS-PAGE sample buffer, then incubated at 95°C for 5 mins (Protein A, PSM) or 60°C 
for 2 mins (membrane, AgrC(his)) before loading into 12% SDS-PAGE gels (unless otherwise 
stated). 5µl pre-stained protein ladder was added to a free well, and the gel was run at 120V 
for 1.5h, unless otherwise stated. Once run, the gels were washed in deionised water for 15 
mins on an orbital shaker before staining with GelCode Blue Safe protein strain (Thermo) for 
15 mins, again on the shaker. The gels were de-stained in deionised water overnight. 
 
AgrC(his) Western blotting was carried out using HisProbe HPR Conjugate (Thermo). 15µl of 
the stained sample was loaded into the gels, and the gel was run at 200V for 1h. The proteins 
from the gel were transferred onto nitrocellulose membrane by wet transfer and blocked in 
50ml 5% skimmed milk for 1h on a shaking platform or 4°C overnight. It was then washed 4 
times with 15ml TBS-T (25mM Tris-HCl, 150mM NaCl (pH7.2), 0.05% Tween 20) on a shaking 
platform for 10 mins. The membrane was then incubated with 10ml of HisProbe working 
solution (2.5ml 10mM Tris-HCl and 150mM NaCl (pH7.4), 7.5ml TBS-T, 5µl HisProbe (4mg/ml), 
0.25g BSA) for 1h on a shaking platform. The above wash process was then repeated twice, 
and the membrane was then placed onto 4ml SuperSignal West Pico Chemiluminescent 
Substrate (Thermo) working solution for 5 mins before visualising using an imaging system. 
Densitometry to determine the strength of the signal was carried out using ImageJ.  
 
Protein A Western blotting was carried out using goat polyclonal anti-Protein A HRP conjugate 
(Abcam). 15µl of the stained sample was loaded into the gel. The proteins were transferred 
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and blocked as above. The membrane was washed 5 times in PBS, and incubated with the 
antibody-HRP conjugate (1:5000 in PBS) for 1h. The membrane was washed 5 times with PBS 
and developed and was visualised as above. 
 
α-toxin Western blotting was carried out using anti-Staphylococcal a-toxin antibody (rabbit- 
whole anti-serum) and Protein G horseradish peroxidase (HRP) Conjugate (Invitrogen). The 
proteins were transferred as above and blocked overnight at 4°C. The membrane was washed 
5x in PBS, the antibody was diluted 1:3000 in PBS and added to the membrane. This was 
incubated for 2h on a shaking platform. The membrane was washed 5x in PBS, the Protein G-
HRP Conjugate was diluted 1:1000 and was added to the membrane and incubated for 1h on 
a shaking platform. This was visualised using Opti-4CN substrate kit according to the 
manufacturer’s protocol (BioRad). 
 
RNA extraction 
As the protein samples from 1h after AIP-1 induction consistently showed differences, this 
time point was chosen to see if there is a difference in transcription of agrC. Overnight cultures 
of MY42 and MY43 was diluted 1:500 into 3ml fresh broth with chloramphenicol. This was 
grown for 2h, and induced with 100nM AIP-1 for 1h. 2ml of these cultures were mixed with 
4ml RNA Protect Bacteria (Qiagen), and the RNeasy Mini Kit (Qiagen) was used to extract RNA 
following the manufacturer’s protocol. Lysostaphin (200µg/ml) was added to Tris-EDTA buffer 
(Ambion), and this was added to the sample after the RNA Protect step before continuing with 
the protocol. when the RNA was extracted, Turbo DNA-free kit (Thermo) was used to remove 
genomic DNA from the RNA samples; 3µl Turbo DNase was added to the sample and incubated 
for 1.5h at 37°C, the a further 4µl Turbo DNase was added and incubated for 1.5h. 35µl DNase 




RNA concentration of the samples were measured using Qubit RNA Broad Range kit (Thermo) 
and normalised before using QuantiTect Reverse Transcription Kit (Qiagen) to convert the RNA 
samples into cDNA according to the manufacturer’s protocol. After adding the reverse 
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transcriptase, the samples were incubated at 42°C for 20 mins before raising the temperature 
to inactivate the reverse transcriptase.   
 
Real-time PCR 
Primers for gyrB, a housekeeping gene, was used alongside those for agrC to standardise 
transcript levels. ssoAdvanced SYBR Green Supermix (Bio-Rad) was used, using a standard 
curve of known genomic DNA concentrations for each primer set. 5µl of samples, standards 
and water were pipetted into the wells of a 96-well PCR plate. The supermix was added to 
water and primers according to the manufacturer’s protocol, and 15µl of this mix was pipetted 
over the DNA samples. This was then placed into a qPCR machine, and run using the 
manufacturer’s recommendation. The quantity of agrC cDNA was divided by the quantity of 
gyrB cDNA to get a ratio of agrC transcription levels.  
 
Competition assay 
Two pairs of strains, SH1000 and MY40, and MY18 and MY41, were co-cultured to detect 
fitness costs associated with mupirocin resistance. The strains were cultured individually 
overnight, then diluted 1,000,000x. 25µl of the mupS strain and 25µl of the mupR strain were 
pipetted into 5ml fresh broth, and grown at 37°C with shaking for 24h. The mixed culture was 
diluted 10,000,000x, and the lowest two dilutions were plated onto TSA and TSA with 4µg/ml 
mupirocin and incubated at 37°C. The resulting colonies were counted, and the number of 
colonies from the mupirocin plate was subtracted from the count from TSA. The Malthusian 
parameter was calculated using the following formula:  
 
Ln (final density (colony forming units (CFU)/ml) / starting density (CFU/ml)) 
 
The Malthusian parameters of the mupS and mupR strains were compared using a t-test.  
 
Lipase assay 
Strains were grown and supernatants harvested in the same was as for toxicity assays. The 
substrates, para-nitrophenol butyrate (pNPB) and para-nitrophenol palmitate (pNPP) (Sigma), 
were made to 8mM concentration in isopropanol, and mixed with a buffer (50mM Tris-HCl 
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(pH 8.0), 1mg/ml gum Arabic, 0.005% Triton-X100) in a 1:9 ratio to create the assay mixes. A 
standard curve using para-nitrophenol (pNP) (Sigma) was created using the assay mixes, and 
200µl of each dilution was pipetted into individual wells of a 96-well plate (Costar). 180µl of 
the assay mixes was pipetted into the remaining wells of a 96-well plate, and 20µl of the 
harvested bacterial supernatant was mixed into the wells in duplicates. The plate was placed 
in a FLUOstar Omega microplate reader (BMG Labtech) at 37°C, and a reading at 410nm was 
taken every 5 mins for 1h. The absorbance readings were converted to µM pNP released/min. 
using the standard curve.   
 
Cloning 
Once genes of interest were found by GWAS and verified by screening Tn knock-out 
mutants170, they were cloned into the plasmid pRMC2243 and transformed into the relevant 
Tn mutants. pRMC2 was extracted from E. coli DH5α using a plasmid extraction kit (Thermo). 
Genomic DNA from JE2, the strain which the Tn mutants are derived from, was extracted using 
the method stated previously. PCR was carried out using Phusion DNA polymerase with the 
HF buffer (Thermo) as recommended by the manufacturer. The cycle conditions used were 
also as recommended by the manufacturer; the annealing temperature was set to 5°C lower 
than the lower Tm for the primer pair, and the extension times were 30 sec.s for USA300_1966 
and atpH, and 1 min. for murA.  
 
The products were run on a 1% agarose gel as above, and if correct size were purified using a 
PCR purification kit (Thermo). The PRC product, which will be the insert, and pRMC2 were 
digested with the relevant restriction enzymes; 25.6µl of DNA was mixed with 3µl CutSmart 
buffer and 0.7µl of each restriction enzyme (all New England BioLabs), and was incubated in a 
37°C water bath for 1.5h. The DNA was then run on a 1% agarose gel as above, and the correct 
bands were excised from the gel. The DNA was extracted from the gel slices using a gel 
extraction kit (Thermo). Alternatively, the digested products were purified using a PCR 
purification kit. 
 
The double digested DNA was then quantified, and mixed in a 1:3 plasmid to insert ratio into 
a 20µl ligation reaction containing up to 100ng plasmid, 2µl Ligase Buffer and 1µl T4 DNA 
51 
 
Ligase (both NEB). This was incubated at 22°C for 1h, or the ligase volume was reduced to 
0.5µl and incubated at 16°C overnight. Alternatively, molar ratios of 1:2, 1:3, 1:5 and 1:7 were 
calculated using NEBio Ligation Calculator (NEB), and a 10µl ligation reactions were set up, 
using 25ng plasmid, 1µl T4 ligase buffer and 0.5µl T4 ligase and incubated as above. As 
controls, double digested plasmid without the insert was also ligated. Further controls include 
1A: single cut vector; ligated, 1B: single cut vector; un-ligated, 2A: single cut vector (other 
enzyme); ligated, 2B: single cut vector (other enzyme); un-ligated, 3A: double digest; ligated, 
3B; double digest; in-ligated, 4; vector and insert; ligated. 
 
The ligated plasmid and the no insert control were transformed into CaCl2 competent DH5α 
cells; at this stage, uncut vector was used as a transformation control. To make these 
competent cells, an overnight culture was diluted 1/250 into 50ml broth and grown until OD600 
0.5 – 0.8. The culture was then placed on ice for 30 mins, and pelleted by centrifuging at full 
speed for 10 mins at 4°C. The pellet was washed with ice-cold sterile water, and pelleted again 
as above. The supernatant was discarded, and the pellet was re-suspended in 15ml of ice-cold 
0.1M CaCl2. This was incubated on ice for 1 - 2h, and pelleted again as above. The pellet was 
then re-suspended in 500µl of ice-cold 0.1M CaCl2 with 15% glycerol, and 50µl were aliquoted 
into sterile Eppendorf tubes. These were then stored at -80°C.  
 
The aliquot of CaCl2 competent cells was thawed on ice, and was mixed with 5µl DNA (ligated 
plasmid, etc.) and incubated on ice for 30 mins. The cells were then heat shocked for 2 mins 
in a 42°C water bath. This was incubated on ice for 5 mins, and then 750µl of media was added. 
The cells were then incubated at 37°C to recover, and 100µl was plated out onto selective agar 
plates. The remaining cells were pelleted and most of the media was discarded. The cells were 
re-suspended in the remaining 100µl media, and plated out onto selective agar plates. These 
were then incubated at 37°C overnight. 
 
If the transformation was inefficient, then electroporation was used with a similar protocol to 
above; using sterile dH2O instead of 500mM sucrose. EcI setting on the MicroPulser was used 
here. The resulting colonies, if any, were streaked onto fresh agar plates. These were then 
grown in broth with ampicillin, and the plasmid was extracted as above. A small volume of the 
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plasmid was digested as above, as well as with only one restriction enzyme (1.4µl) – this gives 
a total of three reactions, with a double digest and two single digests. The digests were then 
run on an agarose gel as above, and if the correct insert was present the plasmid was 
electroporated into RN4220 as described above. The plasmid was then extracted from the 
resulting colony, remembering to add lysostaphin and incubating for 30 mins at 37°C, and 
checked by digesting as above (with the single digests). If correct, this plasmid was then 
electroporated into the correct Tn mutant. For these complemented mutants with the ligated 
plasmid, anhydrous tetracycline (50-400ng/ml) is required to try induce the expression of the 



































#Assisted by Dr Sion Bayliss. 
 
#Variables: 
my$output = "Genes and Locus Tags ST239.txt"; #Output file. To be used in next script. 
my$file = "S. aureus TW20 (ST239) full sequence.gb"; #The GenBank file. 
my$line = ''; #Each element of the file. 
my$locus_tag = ''; #Stores the locus tag. 
my$genes = 0; #Count of the number of genes. 
my$protein = ''; #Translated gene. 
my$check = 0; #keep on reading file. 
 
#Create the output file. 
open OUTPUT, ">$output" or die "$output could not be created.\n"; 
 
#Open the GenBank file. 
open FILE, $file or die "$file did not open.\n"; 
 
#Loop through the file, and print locus tags (with a >) and protein sequence into the output 
file. 
while (<FILE>){ 
$line = $_; 
if ($line =~ /\/locus_tag\=\"(\S+)\"/){ 
$locus_tag = $1; #$1 captures what's in the first bracket. 
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} elsif ($line =~ /\/translation=\"(\S+)\"/){ 
print OUTPUT ">$locus_tag\n"; 
print OUTPUT "$1\n"; 
$genes ++; 
} elsif ($line =~ /translation=\"(\S+)/){ #beginning of protein 
$protein = $1; 
$check = 1; 
} elsif ($check == 1 and $line =~ /(.+)"/){ #end of protein 
$protein .= $1; 
$check = 0; 
$protein =~ s/\s//g; 
print OUTPUT ">$locus_tag\n"; 
print OUTPUT "$protein\n"; 
$genes ++; 
} elsif ($check == 1 and $line=~/\s+(\S+)/){ #in-between 




#Print the number of CDSs found in the file. 
say  "$genes CDSs found.\n"; 
 


















#Variables for section 1: 
my$file = 'Genes and Locus Tags ST239.txt'; #File from the previous program. 
my$gene = ''; #the locus tag 
my@sequence = (); #The protein sequence. 
my$iso = 0; #Ile count for the gene. 
my$isoleucine = 0; #Count of total Ile in the gene. 
my$total = 0; #Count of total amino acids, including Ile. 
my$gene_length = 0; #Lengths of each gene. 
my@gene_list = (); #All the locus tags. 
my@iso_summary = (); #All the Ile counts. 
my@gene_lengths = (); #All gene lengths. 
 
#Open the file with the locus tags and genes. 
open INPUT, "$file" or die "$file could not be opened\n"; 
 
#Loop through the file, taking out the protein sequence to count the number of Ile. 
while (<INPUT>){ 
if (/^>(\S+)/){ 
$gene = $1; 
} elsif (/(.+)/){ 
@sequence = split (//, $1); 
$iso = 0; #Re-set count. 
$gene_length = 0; #Re-set count. 
foreach (@sequence) { 
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} elsif ($_ =~ /[ABCDEFGHKLMNPQRSTVWXYZ]/){ 
++ $total; 
++ $gene_length; 
} else { 
die "Incorrect character $_"; 
} 
} 
push (@gene_list, $gene); #Names of genes (Locus Tags). 
 push (@iso_summary, $iso); #Ile counts of the gene. 




#Print how many Iles there are and the total amino acids. 
say "Out of $total amino acids, there are $isoleucine isoleucines.\n"; 
 
#Close the INPUT file. 
close INPUT; 
 
#Section 2 written with Dr Sion Bayliss 
#Variables for section 2: 
my$output2 = "Simulated Ile Distribution ST239.txt"; #Output - the distribution of the 
simulated Ile counts. 
my$output3 = "Random Ile 1M reps ST239.txt"; #Output - the data. 
my@distribution = (); #Simulated Ile counts. 
my$replicates = 1000000; #The number of times the simulation will be run. 
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my$simulated_isoleucine = 0; #Count of Ile in simulation. 
my$number = 0; #Random number. 
my$diff = ''; #Difference between observed and mean Ile. 
my$low = ''; #Simulated Ile counts lower than actual. 
my$high = ''; #Simulated Ile counts higher than actual. 
my@max_min = (); #Sorted simulated Ile counts. 
my$min = ''; #The lowest simulated count. 
my$max = ''; #The highest simulated count. 
 
#Create the two new output files. 
open OUTPUT2, ">$output2" or die "$output2 could not be created.\n"; 
open OUTPUT3, ">$output3" or die "$output3 could not be created.\n"; 
 
#Print a header in OUTPUT3. 
print OUTPUT3 "Gene Name\tGene Length\tObserved Ile\tMean Simulted Ile\tDiff in 
Means\tMin. Simulated\tMax Simulated\tp-value\n"; 
 
#Simulating the Ile distribution. 
for my$k(0..scalar (@gene_lengths)-1){ #Look at every gene in the genome. 
@distribution = (); #Clear the array. 
for (my$j = 0; $j < $replicates; $j ++){ #Repeat $replicates number of times; 
$simulated_isoleucine = 0; 
for (my$i = 0; $i < $gene_lengths[$k]-1; $i ++){ #for each amino acid of the 
gene except the first, 
#Generate random number between 1 and total amino acids-no. of genes (to get rid of first 
Met). 
$number = int(rand(($total-2779)))+1; 
#If that number is below threshold (Ile in the genome), add to Ile count. 






push (@distribution, $simulated_isoleucine); 
} 
 
print OUTPUT2 "$gene_list[$k]\t"; 
print OUTPUT2 join "\t", @distribution, "\n"; 
 
my$m = 0; #Re-set the count. 
foreach (@distribution){ 
$m = $m + $_; 
} 
 
$m = $m / scalar(@distribution); #mean 
$diff = $m - $iso_summary[$k]; #Difference in means. 
 
#separate simulated Ile counts into those lower than actual and those higher than actual. 
$low = scalar (grep {$distribution[$_] <= $iso_summary[$k]} 0..$#distribution); 
$high = scalar (grep {$distribution[$_] >= $iso_summary[$k]} 0..$#distribution); 
 
#calculating the P, = n (no. as extreme/more extreme than actual) / m (replicates). 
my$p1 = ''; 
if ($diff > 0){ 
$p1 = $low / $replicates; 
} else { 
$p1 = $high / $replicates; 
} 
 
#Sort the simulated Ile counts, to get the min. and max. 
@max_min = sort {$a <=> $b} @distribution; 
$min = $max_min[0]; 




#P where the actual is more extreme than all replicates. 
if ($iso_summary[$k] < $min or $iso_summary[$k] > $max){ 
$p1 = 1/$replicates; 
} 
 




























- Verifying the Association Between Mupirocin 
Resistance and Toxicity in Staphylococcus aureus 
 
Introduction  
The increased risk of infections caused by carriage of MRSA has led to screening and 
decolonisation to reduce this risk in hospitalised patients, especially those about to have 
surgery. Most of these regimes include using the antibiotic mupirocin to decolonise the nose. 
Mupirocin is a polyketide antibiotic made by Pseudomonas fluorescens as a mixture consisting 
mainly of pseudomonic acid A (figure 3.1), and is used in ointment form to treat skin infections 
or to decolonise MRSA carriers75. Mupirocin acts by inhibiting the activity of isoleucyl-tRNA 
synthetase (IleRS), which charges tRNA with isoleucine (Ile), by mimicking isoleucyl-adenylate 
and binding to both the Ile site and the ATP-binding pocket; the 14-methyl terminus of the 
monic acid moiety imitates the side chain of Ile, and the pyran ring around C1-C3 binds to the 
ATP-binding site.  
 
Figure 3.1: structure of mupirocin (pseudomonic acids), taken from Thomas et al., Nat Rev Microbiol 
201075. The variation in the R groups of the pyran ring gives rise to different pseudominic acids, i.e. 




The inhibition of IleRS by mupirocin reduces the pool of isoleucyl-tRNA, signalling Ile starvation 
and thus triggering the stringent response. This is a conserved process which alters gene 
expression in bacteria to allow it to cope under stress244. In S. aureus, amino acid starvation 
leads to the production of ppGppp and pppGpp ( (p)ppGpp), known as “alarmones” via the 
synthase activity of the bifunctional RSH (rel/SpoT homologue) enzyme245. This then leads to 
the re-programming of gene expression so that the available energy is focused into the 
necessary cellular processes, such as the synthesis of amino acid precursors. The end result of 
mupirocin inhibiting IleRS is that cell division does not occur, arising from the inability to 
synthesise new proteins due to a lack of charged isoleucyl-tRNA244.  
 
The use of mupirocin has led to resistance in S. aureus, which occurs at low-level (Minimum 
Inhibitory Concentration (MIC) 8-256µg/ml) and high-level (MIC ≥ 512µg/ml))75. Low-level 
resistance is conferred by Single Nucleotide Polymorphisms (SNPs) in the target gene, ileS, 
while high-level resistance is through the acquisition of an alternative IleRS, mupA or mupB77. 
Mutation of IleRS leads to changes in the structure around the Rossman fold of the protein, 
or the “synthetic site”, where tRNA charging occurs, and this leads to mupirocin not being able 
to bind efficiently while allowing the enzyme to remain active. In S. aureus, there are three 
mutations in ileS which are commonly found; V588F, V631F and G593V75. 
 
The alternative IleRS is typically found on a plasmid, and is not inhibited by mupirocin, thus 
conferring high-level mupirocin resistance75. However, there have been reports of low-level 
mupirocin resistant strains carrying the mupA gene; in these cases, it seems that the mupA 
gene had become inserted into the chromosome, thus the strain is positive for mupA without 
having high-level mupirocin resistance81,82. This has implications in diagnosis, as these strains 
could potentially become highly resistant to mupirocin. Another report also found S. aureus 
strains carrying the mupA gene on the chromosome, however these strains retained the high-
level mupirocin resistance mediated by mupA83. The other alternative IleRS is mupB, and is 
also found on a plasmid77. Despite having relatively low homology to ileS and mupA, the 




Genome Wide Association Studies (GWAS) compare genetic variations against a phenotype to 
see which genetic polymorphisms are statistically associated with the phenotype239. One of 
the mutations conferring low-level resistance to mupirocin was found to be associated with 
toxicity in two distinct lineages of MRSA – USA300 and ST239 – through GWAS246. This 
particular association was shown to be an epistastic association, meaning that this single 
nucleotide polymorphism (SNP), a change from G to T at position 1,762 in the ileS gene 
(G1762T SNP in ileS), leading to the amino acid change V588F, interacts with multiple other 
SNPs at other loci in the genome to confer this effect rather than on its own (Fig. 3.2). The 
SNPs which were found to be in epistasis with the G1762T SNP in ileS in the USA300 and ST239 
strains were different, so the only SNP in common was the one in the ileS gene. In this chapter, 
we sought to verify this association and to see if there is also an association between high-




Fig. 3.2: heatmaps showing illustrating the epistatic interactions between the mupR SNP in ileS and 
other SNPs in USA300 and ST239 strain collections – the ST239 heatmap from Laabei et al, Genome 
Research 2014246. The axes represent the position in the genome, where 0 is the origin of replication. 
The circles represent instances where the presence of the two SNPs at these particular locations in the 
genome were associated with a change in toxicity. Larger, redder circles are where the interactions 
were more significant. The red arrows indicate the position of the G1762T SNP in ileS within the whole 
genome, and the circles represents the location of the second SNPs in the genome, and the presence 




Using genome sequencing data to find plasmids carried by the USA300 strains 
Genome sequence readily reveals SNPs, as they reveal the positions where the nucleotide 
varies in different strains. However, detecting plasmids by sequencing is not as straight 
forward. In the USA300 lineage, pUSA03 is the plasmid which carries the mupA gene, so to 
find out which strains in our USA300 collection carry this plasmid collaborators at the Sanger 
Institute mapped the sequencing reads of our USA300 collection to known plasmids of the 
USA300 lineage (fig. 3.3)247. The data included the mapping to FPR3757 genome248, which is 
the USA300 reference genome, so that we can have confidence that these strains are indeed 
USA300 and that the mapping is good, therefore the sequencing yielded good read coverage. 
Here, by using the mapping data provided by the Sanger collaborators, I was able to see if any 
of the sequencing reads matched known plasmids; for example, 8728_5#44 has a peak under 
“p18805-P03£, therefore I concluded that this strain carries the plasmid “p18805-P03”. In this 
manner, I was able to separate our USA300 strains into those with and without each of these 















Fig. 3.3: genome sequencing reads from our USA300 collection were mapped to known USA300 
plasmid sequences to provide a visual map, as shown in the above example, by collaborators at the 
Sanger Institute. This includes the USA300 genome on the right. Peaks represents areas where the 
sequencing reads matched to the sequence, therefore the presence of strong peaks under the 
plasmids shows that the strain carries this plasmid. By using this data, I was able to identify which 
USA300 strains carried plasmids.  
 
G1762T Single Nucleotide Polymorphism in the ileS gene and the mupA gene results in 
mupirocin resistance 
We next sought to verify that the G1762T in ileS, leading to V588F in IleRS, and the presence 
of mupA does result in resistance to mupirocin. The SNP will be referred to as “mupR SNP” 
from here on as none of the other low-level resistance conferring SNPs were present in this 
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collection of strains. To achieve this, we carried out minimum inhibitory concentration (MIC) 
assays on 14 USA300 strains; four are known to carry the mupR SNP and/or the plasmid 
carrying mupA, pUSA03, 10 being mupirocin sensitive. The mupR SNP was determined from 
the genome sequence of the strains, while the presence of mupA was determined by PCR, and 
confirmed by mapping sequencing reads to mupA as described above. The strains behaved as 
expected; the two strains with the mupR SNP only have low-level mupirocin resistance (mupR) 
(MIC between 64-96µg/ml), the strains with mupA have high-level mupR (MIC >128µg/ml) 
while the 10 strains without either are mupirocin sensitive (mupS) (table 3.1).  
 
Strain MIC mupR SNP? mupA? PCR? 
7790_7#77 >128μg/ml Yes Yes Yes 
7790_7#82 >128μg/ml Yes Yes Yes 
7738_3#61 64-96 μg/ml Yes No n/d 
7738_3#69 32-64 μg/ml Yes No n/d 
7748_4#35 <1μg/ml No No n/d 
7748_4#36 <1μg/ml No No n/d 
7748_4#37 <1μg/ml No No n/d 
7748_4#43 <1μg/ml No No n/d 
7790_7#43 <1μg/ml No No n/d 
7790_7#44 <1μg/ml No No n/d 
8728_5#44 <1μg/ml No No n/d 
8728_5#45 <1μg/ml No No n/d 
7790_7#48 <1μg/ml No No n/d 
7738_4#23 <1μg/ml No No n/d 
Table 3.1: selected USA300 strains and their mupirocin Minimum Inhibitory Concentrations (MICs). 
The four mupirocin resistant isolates carried the mupR SNP, but two also carried the mupA gene. This 
is reflected in the MICs, where the strains with mupA have a higher MIC compared to those without 
this gene, and those without the mupR SNP were fully susceptible to mupirocin. This shows that the 
mupR SNP and mupA gene does confer low-level and high-level mupirocin resistance respectively 
 
Does low-level mupirocin resistance affect toxicity of ST239/USA300 clinical isolates? 
Having confirmed that the mupR SNP does confer low-level mupirocin resistance in the ST239 
background we wanted to see if there were any differences in toxicity between mupS and 
mupR strains in our ST239 and USA300 clinical strains. Using toxicity data collected by a 
colleague (Dr Maisem Laabei) in the lab previously, we sought to see if there was a difference 
between mupS and low-level mupR strains of these MRSA isolates191,246. Dr Laabei used the 
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supernatant of ST239 strains to see how much lipid vesicles were lysed; these vesicles were 
designed to be sensitive to δ-toxin, Phenol Soluble Modulin (PSM)-α1, PSM-α2 and PMS-α3, 
and higher release fluorescence correlates with higher degradation of the vesicles. USA300 
strains are a group of strains known to produce Panton-Valentine Leukocidin (PVL), so to test 
the toxicity of these strains Dr Laabei used THP-1 monocyte cells, which also have 
susceptibility to PVL. Then, I grouped the isolates into those with and without the mupR SNP 
and looking at the toxicity of those strains there was no difference in toxicity between mupS 
and mupR strains in either collection (p=0.4 for both USA300 and ST239 strains) (fig. 3.4). This 
is however expected, as the GWAS association was predicted to be due to epistasic 
interactions, therefore only apparent when present with specific combinations of SNPs in 
other genes.  
 
Fig. 3.4: Toxicity of USA300 and ST239 strains, using data collected by Dr Maisem Laabei. For both 
these groups of MRSA strains, mupirocin resistant strains show a difference in toxicity compared to 
mupirocin sensitive strains. However, these changes in toxicity are not significant (p=0.4 for USA300 
both ST239, Kurskal-Wallis test), which was expected as this association was found to be an epistasis, 
therefore the presence of other SNPs at other loci are required. The box represents the lower and 
upper quartiles, with the line showing the median value. The whiskers show the lower and upper 






High-level mupirocin resistance does not affect toxicity of USA300 isolates. 
We next sought to investigate if this change in toxicity is also associated with high-level mupR; 
high-level mupR is conferred by the acquisition of the plasmid bourn mupA gene, also known 
as the alternative IleRS. Using mapped genome sequences from our Sanger Institute 
collaborators, we were able to identify which strains in our USA300 collection carried 
plasmids, as mentioned above. I then used this data to separate our USA300 strains into those 
with and without each plasmid, and the toxicity data collected by Dr Laabei was used to see if 
there was a difference between strains harbouring pUSA03 and those which do not. There 
was no difference in toxicity between strains with and without pUSA03 (p=0.4) (fig. 3.5, 
“pUSA03”). This was also true of other plasmids, so the carriage of the four known USA300 
plasmids does not affect the toxicity of USA300 strains (fig. 3.5). As low-level mupR did reveal 
an association with toxicity in the GWAS studies, we chose to investigate this further.  
 
 
Fig. 3.5: Toxicity of USA300 strains with (+)/without (-) various plasmids. pUSA03 is the plasmid which 
contains mupA, the alternative IleRS, and there is no difference in toxicity between strains without and 
with this plasmid (p=0.4, Kruskal-Wallis test). Looking at the presence or absence of other known 
USA300 plasmids within the collection also show no differences in toxicity (p>0.05, Kruskal-Wallis 
(pUSA01)/t-test (others)). Therefore, the carriage of these four plasmids is not linked to a change in 
toxicity, even in the case of the mupA containing pUSA03. The box represents the lower and upper 
quartiles, with the line showing the median value. The whiskers show the lower and upper extremes, 






Isolating and verifying mupirocin resistant SH1000 strains using a PCR based screen 
Next, we sought to see if it was possible to select for this mutation in the ileS gene by growing 
strains in the presence of mupirocin. As ileS is an essential gene, it cannot be knocked out, 
therefore selecting for this mutation using mupirocin is the practical way of mutating this 
gene. Firstly, overnight cultures of mupS USA300 strains were grown without mupirocin, and 
then 100µl of this culture was plated onto agar plates with 4µg/ml mupirocin. After 
approximately 48h, we observed individual mupR colonies growing on some of these plates. 
To quickly analyse if these colonies had the desired mutation, we designed a PCR based 
screen; by designing primers in such a way that the T1762 would have one mismatch while 
the G1762 would have two mismatches, it was possible to differentiate the mupR SNP (fig. 3.6 
A)241. The one mismatch does not affect the PCR, while two mismatches does, therefore no 
product is seen if the template DNA has G1762 while a product is seen if the template is T1762 
(fig. 3.6 B, “Sens.” (G) and “Res.” (T)). This PCR based screen showed that this mutation had 
indeed occurred in these colonies (fig. 3.6).   
 
To ensure that the change in toxicity is only related to the mupR SNP, we applied the same 
selection method on the lab S. aureus strain SH1000 and obtained mupR colonies; having 
isogenic mupS and mupR strains ensures that there are no other variations in the genome, 
particularly at the loci identified as being in epistasis with the mupR SNP by the GWAS. The 
colonies were analysed using the PCR based screen, and their genomes were sequenced by 
collaborators to ensure that there were no other mutations which could account for a change 







Fig. 3.6: Mechanism of the PCR-based screen for the mupR SNP; the design of the primers creates two 
mismatches if the strain is mupirocin sensitive, but only one mismatch if the strain has the mupR SNP 
(A). This means that if the strain does not contain the mupR SNP there will be no amplification (B - 
sens. and 1). However, there is only one mismatch if the strain has the mupR SNP, therefore there is 
amplification (B - Res. and 2-4). This result show that the parent strain (SH1000) is sensitive to 
mupirocin and does not contain the mupR SNP, while the SH1000-mupR mutants (2-4) contain the 
mupR SNP.  
 
Does making SH1000 mupirocin resistant change its toxicity? 
These mupirocin resistant colonies were then grown for 18h without mupirocin, alongside the 
mupS parent strain (SH1000), and the supernatant was analysed for toxicity; it was found that 
mupR had a small but statistically significant lowering effect on the toxicity of the resistant 





Fig. 3.7: toxicity of mupS, mupR and agr-ve SH1000 strains. There is a reduction in toxicity seen in most 
mupR strains (MY40, SH1000:2 - :6) compared to its mupS parent strain (SH1000) (p=0.02 for MY40, 
one-way ANOVA) (n=9 for mupS and mupR samples, and n=4 for MY18). However, this reduction is not 
as great as seen in the agr-ve strain (MY18) – the agr system is a global quorum sensing system which 
regulates many phenotypes including toxicity. The box represents the lower and upper quartiles, with 
the line showing the median value. The whiskers show the lower and upper extremes, and the points 
outside the whiskers are the outliers.  
 
Does mupirocin resistance affect the growth of S. aureus? 
Many antibiotic resistance conferring mutations have effects on the fitness of the bacteria, 
and noting that ileS gene is an essential gene which is highly conserved across S. aureus, it is 
surprising that the mupR mutation in this gene is reported to have no effect on the fitness249. 
In the presence of mupirocin, these mupR strains indeed grow slower than in the absence of 
mupirocin, taking around 48h to grow. However, comparing the growth of SH1000 (mupS) and 
the mupR mutants in the absence of mupirocin shows no difference in growth rate (fig. 3.8). 
This is in accordance with previous research, which found that this mutation is “cost free”249. 
Also, the fact that the growth rate of these strains do not differ would suggest that agr activity 
between them would most likely be similar, thus the difference in toxicity seen in these strains 






Fig. 3.8: growth of mupR strains compared to its mupS parent shows no difference (n=3 for SH1000 
and MY18, n=6 for mutants). Both strains were grown as a pure single culture for 16h at 37°C, with 
OD600 readings taken every 5 mins. There is no difference between the growth of SH1000 (mupS) and 
its mupR mutants, therefore in pure culture the mupR SNP does not seem to affect fitness. The error 





Mupirocin is a clinically important antibiotic, but growing resistance could hamper its use as 
an MRSA-decolonising agent. Mupirocin resistance (mupR) is seen in two levels, low-level and 
high-level, and a SNP in ileS mediating low-level mupR was found to be associated with a 
change in toxicity in two distinct lineages of MRSA – ST239 and USA300. Due to the high false-
positive rate seen in bacterial GWASs, we sought to verify this association.  
 
Initially, we sought to verify that the mupR SNP and the mupA gene does indeed lead to mupR; 
screening USA300 isolates with the mupR SNP, we found that they exhibited the appropriate 
resistance phenotype. With ileS being an essential gene, it is impossible to obtain viable knock-
out mutants. However, as the SNP does lead to mupR, this could potentially be used as a 
selective pressure to obtain mupR mutants. Indeed, this process does work, and for the 
purposes of quickly detecting whether the correct mupR SNP was the cause of gaining mupR, 
we developed a PCR based assay. This approach could be applied to other antibiotic 
resistances resulting from SNPs, to develop a relatively fast screening method – this includes 
rifampicin resistance, where we did manage to get a similar assay working for one of the 
resistance SNPs.  
 
The genomes of the USA300 and ST239 isolates had been sequenced, therefore those carrying 
the mupR SNP were quickly identified. Using toxicity data collected by a colleague (Dr Maisem 
Laabei), we were able to look for differences in toxicity between mupS and mupR isolates; 
indeed, we saw that toxicity was different in mupR isolates. From genome sequencing, it is 
possible for us to identify isolates carrying previously known plasmids; this was done by using 
the mapped sequencing data for the USA300 isolates provided by the collaborators at the 
Sanger Institute. This meant that we were able to separate isolates into those with and 
without plasmids, including pUSA03 which has mupA. When analysing the toxicity data, we 
saw no difference in toxicity between isolates carrying any plasmid, therefore the difference 
in toxicity observed in the GWAS is isolated to low-level, chromosomal mupR.  
 
To study this further, we created six mupR mutants of the mupS laboratory strain SH1000 by 
the selection method above. The mutants were screened using the PCR-based method, and 
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were also sequenced to ensure that there were no other mutations. When the toxicity of these 
mutants were analysed, they showed decreased resistance compared to SH1000. This 
suggests not only that the association seen in the GWAS is true, but that this applies to more 
than the ST239/USA300 backgrounds. Interestingly, this SNP has been shown not to affect 
fitness of the strains carrying it; ileS being an essential gene, perhaps this is unexpected. In the 
absence of mupirocin, there is no difference in the growth rate of SH1000 and its mupR 
mutants, which is in line with the previous studies, however, in the presence of mupirocin, the 
mutants grow slower, needing up to 48h. In the presence of sub-inhibitory concentration of 
mupirocin (0.1µg/ml), one of the SH1000-mupR mutants (MY40) grows slower than SH1000, 
despite growing faster initially (fig. 3.9). This would suggest that exposing these strains to sub-
inhibitory mupirocin, where the strains have to induce the stringent response, reveals a 
possible fitness burden incurred by the V588F IleRS mutation.  
 
 
Fig. 3.9: growth of SH1000 (mupS) and MY40 (mupR) in the presence of sub-inhibitory mupirocin 
(0.1µg/ml) (n=3). While MY40 grows faster for ~23h, after ~37h SH1000 is growing faster than MY40, 





In conclusion; the G1762T SNP in ileS, leading to V588F mutation in the protein, was found to 
be associated with a change in toxicity when applying a Genome Wide Association Studies on 
ST239 and USA300 MRSA isolates. We first verified that the mupR SNP does indeed confer 
mupR, and used this to select for mutants containing the mupR SNP from mupS parents – 
SH1000 being the one used. We then screened SH1000-mupR mutants for toxicity, and found 
that it was significantly reduced (p=0.02). Previous studies had shown that the mupR SNP does 
not affect the fitness of strains harbouring it, and this was the case for the SH1000-mupR 
mutants in the absence of mupirocin. Looking at the toxicity of strains carrying mupA showed 


























- Elucidating the Mechanism Behind the Reduction 
in Toxicity Seen in Mupirocin Resistant 
Staphylococcus aureus Strains  
 
Introduction  
Antibiotic resistance is beneficial to the bacteria in the presence of the antibiotic, however 
this frequently comes at a fitness cost250. When bacteria acquire resistance to antibiotics, 
there are often compensatory mutations seen in these resistant bacteria which enables them 
to maintain a comparable level of fitness to antibiotic sensitive bacteria. Certain mutations 
are only observed in bacteria which are resistant to multiple antibiotics250. This would mean 
that antibiotic resistance becomes fitness cost-free, and thus more likely to be maintained in 
the population as it gives the bacteria the advantage of being antibiotic resistant without its 
fitness being affected. One antibiotic resistance mechanism considered to be fitness cost-free 
is a mutation leading to low-level resistance to mupirocin; this is a single nucleotide 
polymorphism (SNP) at position 1,762 in the isoleucyl-tRNA synthetase gene (ileS) of 
Staphylococcus aureus, where a G changes to a T (G1762T) (mupR SNP)249,251. This mupR SNP 
changes the amino acid at position 588 from valine to phenylalanine (V588F) in the product, 
IleRS, and this confers low-level resistance to mupirocin. IleRS charges tRNA with isoleucine 
(Ile), and mupirocin blocks this activity by binding to the active site of IleRS. Position 588 is 
situated in in the Rossman fold of IleRS, were the enzymatic activity of this protein occurs. 
Potentially, this V588F mutation could negatively affect the activity of the protein, thus we 
hypothesise that this mutation could lead to increased free Ile in the cytoplasm.  
 
Numerous attempts to inactivate the ileS gene (e.g. Nebraska Tn library170) have failed, 
suggesting that this is an essential gene. It is also highly conserved in S. aureus, so it is perhaps 
unexpected that the mupR SNP in ileS was found not to have an effect on the fitness of the 
strains harbouring it249; if this mutation does have an effect on fitness, then it is unlikely to be 
77 
 
maintained as it would be a disadvantage in the absence of mupirocin. Supporting the 
previous observations that the mupR SNP is not associated with a fitness cost, growing mupR 
strains as a single culture without mupirocin showed no difference in growth rate. But what 
happens when they are grown together with other strains? Making the mupR strain compete 
for nutrients and oxygen with another strain may reveal a fitness cost that is not seen when 
the mupR strain is not forced to compete. Toxin production is an energetically expensive 
process which is readily switched off under stressful conditions191, so is the reduction in 
toxicity that we have demonstrated in the previous chapter a mechanism by which these 
mupR strains are maintaining their fitness? - previous work in the lab showed that resistance 
to methicillin reduces virulence of MRSA, therefore this could potentially be the case for 
mupirocin resistance also.  
 
Previously, we verified the association seen in the Genome Wide Association Studies (GWAS) 
between the mupR SNP and toxicity in S. aureus, where it was found that the mupR SNP leads 
to reduced toxin production in the strains which harbour it. Ile is a hydrophobic amino acid, 
and as such is expected to be more prevalent in proteins which are present in or act in 
hydrophobic environments. Cytolytic toxins function by burrowing into the membrane of 
target cells199, and as the cell membrane is hydrophobic toxins could have a high Ile content. 
Also, membrane proteins may be high in Ile due to them being present in a hydrophobic 
environment. In order to narrow down the list of proteins high in Ile, a Monte Carlo simulation 
will be run252. These simulated Ile counts will then be compared to the actual Ile count, and a 
p-value assigned depending on how many simulated Ile counts are as “extreme” as the actual 
Ile count. The p-values will then be corrected using both Bonferroni and Benjamini-Hochberg 
correction for multiple comparisons as the simulation involves a million Ile counts for over 
2,500 genes.  
 
In this chapter, we endeavour to determine if the rate of tRNA charging is slower in mupR 
strains by seeing if there is more free Ile in the mupR cells. If this hypothesis is true, we then 
want to investigate if this affects proteins which are high in Ile; we will look at these proteins 
to see if any of these have a role in toxicity, and see if their translation is affected by being 
resistant to mupirocin. To see if the previous observation that methicillin resistance reduced 
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virulence of MRSA also applies to mupirocin resistance, we will also investigate if mupirocin 
resistance has an effect on the fitness of mupR strains.  
 
Results 
Mupirocin resistant cells contain more free Isoleucine compared to mupirocin sensitive cells. 
To test our hypothesis that mupR SNP in ileS decreases the rate of isoleucyl-tRNA production, 
we quantified free Ile in the cytoplasm of SH1000 (mupS) and MY40 (SH1000-mupR) cells by 
LC-MS using a variation of the protocol by Sowell et al.242. The strains were grown for 18h then 
pelleted and washed before being lysed. Debris was removed by centrifugation, and soluble 
proteins (>3kDa) removed using a spin concentrator. These prepared lysates were then put 
through LC-MS. We found a small but significant increase in free Ile in the mupR cells 
(5.5μg/ml) compared to the mupS cells (5.2μg/ml) (one-tailed p=0.03) (fig. 4.1). This suggests 
that there could be a reduction in the rate at which isoleucyl-tRNA is formed.  
 
Fig. 4.1: Quantifying free isoleucine in mupS (SH1000) and mupR (MY40) cells (n=16). The cells were 
lysed and the lysate was analysed by LC-MS alongside known concentrations of isoleucine to determine 
the amount of isoleucine present. There is more free isoleucine present in mupR cells (MY40) 
compared to mupS cells (SH1000) (p=0.03, one-tailed T-test. n=12). The box represents the lower and 
upper quartiles, with the line showing the median value. The whiskers show the lower and upper 
extremes, and the points outside the whiskers are the outliers. 
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Using a Monte Carlo simulation to determine which proteins are high in isoleucine 
Since there were no obvious proteins which were translated differently, we took a different 
approach and used a computational method to find out which proteins are significantly high 
in Ile. This was achieved by running a Monte Carlo simulation where each gene in two MRSA 
genomes (TW20 (ST239 reference strain253) and FPR3757 (USA300 reference strain248)) were 
assigned random Ile counts (fig. 4.3). This was achieved by first finding out the total number 
of amino acids in the whole genome. The number of genes present in the genome was also 
calculated, and this was subtracted from the total amino acids count generated above to 
create a new total; this is to account for the non-variable first amino acid in each polypeptide. 
Then, a random number was generated up to that new total. For example, if the total number 
of amino acids was A and the number of genes was B, then the maximum random number 
generated is D (D = A – B). A threshold was set to the number of total Ile in the genome (C), 
and if the random number generated was below the threshold, it was counted as an Ile. If the 
random number was above the threshold, it was counted as not Ile. This was repeated for 
each amino acid in the gene minus one, as the first amino acid is always a methionine, which 
generates a simulated Ile count. This process was repeated 1 million times for each gene, then 
repeated for all the genes in the whole genome. The number of these simulated Ile counts 
which were greater-than-or-equal to (≥, E) or less-than-or-equal-to (≤, F) than the actual Ile 
count of the gene were determined, then the smaller of these numbers (E or F) was divided 
by 1 million (the number of simulated Ile counts) to determine a p-value.   
 
 
 Fig. 4.3: a schematic describing the approach used for the Monte Carlo simulation of Ile count.  
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Due to the number of genes involved, it is necessary to use a method to correct for multiple 
comparisons. A p-value of 0.05 means that there is a 5% chance of a result occurring by 
chance, therefore if we are looking at 2,500 genes then there would be 125 genes which are 
significantly different in Ile only by chance. Corrections for multiple comparisons take this into 
account by lowering the threshold of significance. Here the stringent Bonferroni and the less 
stringent Benjamini-Hochberg corrections were used (Appendix A, (p107)); under the 
Bonferroni correction, there are 48 genes in ST239 (Appendix A, table 1 (p107)) which are 
significantly different in Ile, and 51 such genes in USA300 (Appendix A, table 2 (p119)). Both 
these include AgrC, which will be examined in the next section. However, these numbers 
increase to 887 genes in ST239 and 828 genes in USA300 which are significantly high in Ile 
when the Benjamini-Hochberg correction is used. The Benjamini-Hochberg correction 
includes the genes which are significant under the Bonferroni correction, so AgrC is also 
significant using the Benjamini-Hochberg correction. Genes which become significant under 
the Benjamin-Hochberg correction include AgrB, a part of the accessory gene regulator (agr) 
quorum sensing system, and one of the four α-Phenol Soluble Modulins (α-PMSs) in ST239, as 
well as 3 of 4 in USA300. PSMs are small peptide toxins, and the three significant α-PSMs have 
an Ile content of >25%. This is extremely high considering that the genome average is ~9%, 
but due to their small size these are only significant under the Benjamini-Hochberg correction. 
The fourth α-PSM (PSM-α3) has no Ile, and this is not significant under either correction 
method.  
 
Using an alternative method to identify proteins significantly high in isoleucine 
To back up the simulation carried out above, Dr Mario Recker created a regression model of 
the Ile counts in the ST239 and USA300 genomes (fig. 4.4). Here, the purple line represents 
the average Ile count, and the dark grey area represents the 95% prediction interval; 95% of 
the Ile counts are expected to fall within this area given the frequency of Ile in the genome. 
The Ile counts were transformed using a Box-Cox power transformation to limit variability in 
the data, then plotted onto the graph. AgrC, AgrB and the α-PMSs all fall outside the 95% 
prediction interval, so these are all significantly high in Ile – this further supports the findings 





Fig. 4.4: a regression model showing the distribution of Ile counts in the proteins from ST239 and 
USA300. When fitting the Ile counts onto a regression model, AgrC, AgrB and the α-PSMs all fall outside 
the 95% prediction interval (dark grey area), indicating that they have a significantly high Ile content. 
The Ile counts for all genes were transformed using a Box-Cox power transformation prior to plotting. 
The purple line represents the average Ile count, with the dark grey area representing the 95% 
prediction interval – this is where 95% of Ile counts are expected to be, given tis frequency. Data 
courtesy of Dr Mario Recker. 
 
AgrC, a protein high in isoleucine, is translated slower in a mupirocin resistant strain 
From the Monte Carlo simulation, we discovered that AgrB and AgrC were significantly high in 
Ile content (Benjamini-Hochberg corrected for AgrB, Bonferroni and Benjamini-Hochberg 
corrected for AgrC), which was verified in the regression model. The accessory gene regulator 
(agr) system is a global regulatory system in S. aureus which controls many genes in response 
to population density, and is an auto-amplification loop activated at high population 
density225. Two of the gene of this system, agrB and agrC, code for membrane proteins; AgrB, 
which processes and exports the signal peptide AIP, and the sensor histidine kinase AgrC. 




We next wanted to study the effect of mupR on AgrC translation and transcription, and to 
achieve this we created isogenic mupS and mupR strains which were not able to produce AIP 
but were able to respond to exogenous AIP; into agr knock-out mupS (MY18) and mupR 
(MY41) strains, a plasmid containing the agr P3 promoter, agrC(his) and agrA (pAgrC(his)A 
(from collaborators in Nottingham)) was transformed. These “agr replaced” strains ensure 
that the agr system is activated to the same extent and the addition of the hexa-his tag 
enabled visualisation of the AgrC protein (fig. 4.5). This removes the variability in general agr 
activity between strains which could occur naturally, to give a comparable result between the 
mupS and mupR strains.  
 
 
Fig. 4.5: construction of the “agr-replaced” strain to facilitate the analysis of agrC protein and mRNA. 
This become an agr knock-out strain with the ability to respond to exogenous AIP. The native agr 
system was replaced with a P3-lux and erythromycin resistance cassette, then a plasmid containing 
AgrC(his)A was transformed into the knock-out strain. This allows the strain to respond to synthetic 
AIP in the media, without having the ability to produce AIP. The his-tag on AgrC allows for visualisation 
of this protein by Western Blotting. 
 
Translation of AgrC was quantified by Western blotting; MY42 (mupS) and MY43 (mupR) were 
induced with synthetic exogenous AIP for 1-3h, and then were lysed. The proteins in the 
lysates were then separated on SDS-PAGE gels and then transferred onto nitrocellulose 
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membrane for the Western blot. At 1h post-induction, there was approximately 2x more 
AgrC(his) in MY42 compared to its MY43 using densiotometry (fig. 4.6 A). This was not seen at 
2h and 3h post-induction. So, it seems that mutating ileS slows the translation of AgrC early 
on, with the mupR strain producing the same amount of AgrC as the mupS strain later on.  
 
 
Fig. 4.6: Western blot analysis of AgrC(his) produced by mupS and mupR agr-replaced strains (n=3). 
Both mupS and mupR versions of the agr-replaced strain were grown overnight, then diluted 1:500 
into fresh media, then grown for 2h before adding AIP. 1h after this addition of AIP, there is less 
AgrC(his) in the mupR strain compared to the mupS strain, as shown by a reduced intensity in the band 
(A). However, this is not reflected in the transcription (B); the Ct threshold values from the qPCR run 
for agrC were converted into ratios by dividing it with the Ct value of a housekeeping gene, gyrB, which 
is constantly expressed. The values are average of three repeats, shown with the 95% confidence 
interval. 
 
As the translation of AgrC is affected in MY43, we next sought to see if this was due to 
differences in transcription. Transcription of agrC was tested by quantitative reverse-
transcription PCR (qRT-PCR); first, the primers were tested by a standard PCR and genomic S. 
aureus DNA to ensure that they were specific to agrC. Once verified, qRT-PCR was performed 
on cDNA samples – these samples were taken from MY42 and MY43 1h post-induction, as this 
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was where the difference in translation was seen. The qRT-PCR showed that there is no 
difference in the rate of agrC transcription (fig. 4.6 B), therefore the difference seen in the 
quantity of AgrC(his) is due to a reduced translation rather than transcription. Therefore, this 
suggests that mutating ileS to become mupR affects the rate of IleRS activity, which in turn 
affects AgrC(his) translation.  
 
Does the temporal slowing of AgrC translation affect downstream processes regulated by the 
agr system? 
As early AgrC translation is affected in mupR strains, we sought to determine if this had a 
knock-on effect on genes regulated by agr. Therefore, we looked at the amount of Protein A 
and α-toxin produced by SH1000 and MY40 by Western blotting; Protein A is down-regulated 
by the agr system, while α-toxin is up-regulated223. We also looked at the production of Phenol 
Soluble Modulins (PSMs), as three of the four α-PSMs were shown to be high in Ile and they 
also regulated by the agr system181. It was clearly visible from the SDS-PAGE that there is more 
α-toxin and PSMs produced by SH1000 compared to MY40, while more Protein A was 
produced by MY40 (fig. 4.7). This suggests the possibility of the agr system being affected by 












Fig. 4.7: analysis of proteins controlled by the agr system to see if the early reduction in translation of 
AgrC has an effect on these proteins; part A shows the gel/Western blot and part B shows the 
densiotometry results using imageJ as a measure of quantification (n=9 for PSMs, n=6 for α-toxin and 
Protein A). p-values from T-tests. Phenol Soluble Modulins (PSMs) are short peptide toxins, and along 
with α-toxin is upregulated by the agr system. Also, three of the four α-PSMs have an extremely high 
isoleucine content, however due to their short nature this is not significant using the Monte Carlo 
simulation. Both PSMs and α-toxin show reduced production in the mupR strain. Protein A is an 
immune evasion protein which binds to antibodies, and this is down-regulated by the agr system. 
There is a higher amount of Protein A produced by the mupR strain.  
 
Mupirocin resistance in an agr-ve strain affects its fitness 
The above data suggests that the reduction in toxicity seen in mupR strains could be through 
the delay in agr activity in the mupR strains. The initial delay in AgrC translation seemingly is 
sufficient to cause this slight delay in agr activity, however other mechanisms may also be 
reducing the toxicity of mupR strains. As mentioned before, toxin production is an 
energetically expensive process which is switched off readily if the growth conditions become 
sub-optimal. Also, a previous study in our lab showed that methicillin resistance reduced toxin 
production in MRSA, offsetting some of the associated fitness costs.  
 
Knowing that this mutation has been reported to have no effect on fitness despite being an 
essential gene, but having detected that they have lowered their toxin production, we sought 
to understand the fitness consequence of mupirocin resistance in greater detail. To achieve 
this we performed some relative fitness competition assays; by growing mupS and mupR 
together, they are forced to compete for nutrients and oxygen, thus effects on fitness not 
86 
 
seen in a pure culture may be exposed here. To investigate the role of toxin production in the 
maintenance of competitive fitness, we utilised four strains; mupS and mupR strains with an 
intact agr system (which can produce toxins) and mupS and mupR strains with the agr system 
knocked-out (which do not produce toxins). The four strains (SH1000 & MY40 (agr+ve), and 
MY18 & MY41 (agr-ve)) were grown overnight individually, and then competed against 
another strain by culturing together, as “SH1000 and MY40” (SH1000-pair) and “MY18 and 
MY41” (MY18-pair).  
 
The overnight cultures of the four strains were diluted, then equal volume of the dilute mupS 
and mupR strains were pipette into fresh media. One culture contained the SH1000 (Agr+ve)-
pair, while the other contained the MY18 (Agr-ve)-pair. These were grown for 24h, diluted 
then the plated onto fresh agar plates – one containing mupirocin and the other containing 
no antibiotic. This enabled us to obtain a colony forming unit/ml (CFU/ml) count for each 
strain. By subtracting the number of colonies on the mupirocin plates from the number of 
colonies from the no antibiotic plate, it is possible to obtain the count for the mupS strain. 
These CFU/ml values were converted into Malthusian parameters using the equation in the 
materials and methods to show the maximal exponential growth of each strain, and compared 
as the SH1000-pair and MY18-pair. The SH1000-pair showed no significant difference in fitness 
(p=0.6), but MY41 showed reduced fitness when grown together with MY18 (p=0.02) (table 
4.1). The data show that MY41 (the agr-ve mupR strain) has a significantly lower MP compared 
to its mupS counterpart, MY18, which shows that MY41 does not grow as fast as MY18. 
Therefore, the competitive fitness of MY41 is lower than that of MY18. The agr+ve mupR 
strain MY40 does not show this reduction in MP, thus does not show a reduction in 
competitive fitness. The difference between MY41 and MY40 is that MY40 produces toxins 
while MY41 does not, and this means that toxin production can be modulated in MY40 if 
necessary. Therefore, S. aureus is able to off-set the fitness cost associated with mupR 
mutation by reducing the amount of toxins it produces, effectively providing a cost-free 






Table 4.1: analysing the fitness of mupS and mupR strains by growing them in a co-culture (n=19 for 
agr+ve, n=18 for agr-ve). When SH1000 (mupS) and MY40 (mupR) have an intact agr system, and there 
is no difference in fitness between these strains (p=0.6). However, when the agr system is knocked-
out (MY18 (mupS) and MY41 (mupR)), fitness is reduced in the mupR strain (p=0.02, T-test). 
 
Discussion 
Here, we set out to determine the mechanism behind the change in toxicity seen in low-level 
mupirocin resistant (mupR) strains carrying the V588F mutation. The product of the ileS gene 
charges tRNA with isoleucine (Ile), and with the amino acid 588 predicted to be in the Rossman 
fold where this activity occurs, we hypothesised that mutation could slow the rate of tRNA 
charging. If this were the case, we would expect more free Ile in the cytoplasm of mupR strains 
compared to mupirocin sensitive (mupS) strains. LC-MS analysis showed an increased amount 
of free Ile in mupR cells, so this suggests that the rate at which isoleucyl-tRNA forms is slower 
in mupR cells. This would then possibly affect proteins with high Ile content.  
 
Due to decreased isoleucyl-tRNA in mupR cells, proteins high in Ile may be translated slower 
in mupR strains compared to the mupS strains. Therefore the next step we took was to 
establish which proteins are high in Ile; this was achieved by simulating Ile counts for each 
protein, and comparing this to the actual Ile count. Due to the high number of simulated 
counts generated for each gene, it was necessary to correct for multiple comparisons. Here, 
we used both the stringent Bonferroni method and the less stringent Benjamini-Hochberg 
method. This then gives a list of proteins which are significantly high in Ile, which is different 
to those which have a high percentage of Ile; if the gene yielded a short peptide, it is 
statistically more likely to simulate an Ile count which is extremely high compared to genes 
which produce long peptides. For example, three of the four αPSMs have an Ile count of >25%, 
which is very high compared to the genome average of 9%. These are short peptide toxins 
which form pores in the target cell membrane. Due to their very short peptide length the 
agr +ve agr -ve
mupS mupR mupS mupR 




chances of a simulated Ile count being that high is high, therefore this did not reach statistical 
significance under Bonferroni correction.  
 
One of the proteins which was highly statistically significant after Bonferroni correction, both 
from the ST239 and USA300 genomes, was AgrC. This is a component of the accessory gene 
regulator (agr) quorum sensing system. AgrC is a membrane bound histidine kinase which 
phosphorylates the response regulator (AgrA) when the signal (autoinducing peptide (AIP)) 
binds. In order to see if translation of AgrC was slower in mupR strains, we devised a system 
whereby the activation of the agr system was controlled. This ensures that the system is 
activated to the same degree, so differences in overall agr activity between strains will not 
affect the results. A hexa-his tag was added to the AgrC by collaborators to allow the detection 
of AgrC; rather than having an antibody or probe against AgrC, this enables us to use one 
against the his-tag. Western blots showed a fainter AgrC band from mupR lysates taken 1h 
after induction, but this was not maintained at later time points (2-3h). This shows that at the 
early stages, translation of AgrC is slower in mupR strains. However, qRT-PCR on cDNA from 
cells 1h post-induction showed no difference, therefore the decrease in AgrC protein is not 
due to a decrease in agrC transcription. As this was one of the proteins identified as being high 
in Ile, it would seem that the reduced isoleucyl-tRNA present in mupR cells is causing AgrC to 
be translated slower temporarily. This difference is made up later on, therefore there is a 
possibility that overall agr activity is not greatly affected. However, as the difference in toxicity 
between mupS and mupR strains is small, the early delay of AgrC translation in mupR strains 
may be sufficient to cause this difference.  
 
Protein A and α-toxin are both regulated by the agr system223, and as such if there was a 
difference in agr activity then there would be a difference in expression of these proteins. A 
group of toxins are the phenol soluble modulins (PSMs), and as mentioned above three of the 
four α-PSMs have a high Ile content. When Protein A, α-toxin and PSMs were examined by 
Western blots and SDS-PAGE, there was a difference seen between mupS and mupR; there 
was more Protein A in the mupR strain, and more α-toxin and PSMs in mupS strains (all 




When the strains are grown individually without mupirocin, there is no difference in growth 
rate between mupS and mupR strains, including strains which have the agr system knocked-
out; these strains cannot make toxins due to the lack of agr system. However, when we 
compete mupS and mupR strains in a co-culture, we start seeing a difference in fitness – the 
SH1000-pair, with an intact agr system, are equally fit, as shown by their similar Malthusian 
Parameter (MP), meaning they are able to grow to the same extent. The mupR strain of the 
MY18-pair, MY41, with the agr system knocked-out, shows reduced fitness compared to its 
mupS equivalent (MY18), as shown by its reduced MP, meaning MY41 does not grow as well 
as MY18 in a co-culture. When these strains are cultured together, the two are having to 
compete for nutrients and oxygen, therefore this is more likely to reveal reduction in fitness 
compared to growing the strains in a pure culture. This suggests that having the ability to 
produce toxins means that this can be reduced to alleviate any fitness costs associated with 
becoming mupR, but taking this ability away makes the mupR strain unable to retain fitness 
in a competition. This is an elegant example of how bacteria are able to adapt to stressful 
situations in order to survive and thrive.  
 
As we discovered in the previous chapter, the V588F IleRS mutation leading to low-level mupR 
causes a reduction in toxicity. Here, we found evidence to suggest that this mutation lowers 
the rate of IleRS activity, in that there is more free Ile found in mupR cells. One of the proteins 
which we found to be high in Ile, AgrC, is translated slower in mupR strains during the early 
phases of its translation. Toxin production is an energetically expensive process, and we found 
that losing this ability made the mupR strain less fit compared to its mupS counterpart, while 
this was not seen when the strain had the ability to produce toxins. This suggests that the 
combination of slower AgrC translation and the need to maintain fitness in the face of IleRS 
mutation leads to the reduction in toxicity seen in mupR strains.  
 
Future directions 
In this research, we saw a slight increase in the amount of free Ile present in mupR cells which 
would indicate that there is less isoleucyl-tRNA present in these cells. This could be 
investigated further, by quantifying the amount of isoleucyl-tRNA directly or by comparing the 
activity of the mupS (V588) and mupR (F588) IleRS. Here, we did not quantify the level of IleRS 
90 
 
present in the mupS and mupR cells, so this is something that could be investigated. If there 
is more IleRS present in mupR cells, then this may counteract any delay in its activity. 
 
This research also revealed a decrease in AgrC translation at the early stages of its induction. 
This protein was found to be significantly high in Ile, therefore is this delayed translation seen 
in all proteins high in Ile? Or is there a trade-off where essential proteins high in Ile are 
preferentially translated, so that there is no delay in the translation of these proteins? These 

































Lipases are enzymes which hydrolyse ester bonds in lipids, and in Staphylococcus aureus these 
enzymes are involved in lipid metabolism as well as virulence219. Part of the defence 
mechanisms used by humans is the production of fatty acids on the skin, and the most 
effective of these against staphylococci is cis-6-hexadecenoic acid, also called sapienic acid 
(C16:1 Δ6)220. It has been noted that individuals who are prone to atopic dermatitis produce 
reduced amounts of hexadecenoic acid, which is linked to increased S. aureus carriage in these 
individuals254. Also, lipases can hydrolyse these lipids into free fatty acids, which are also toxic 
to staphylococci. A study observed an increased presence of bactericidal fatty acids in 
staphylococcal abscesses, which seems to be a mechanism used by the host immune system 
to control and eliminate staphylococci255. The authors found that these fatty acids were long-
chain fatty acids released from glycerides, most likely by the action of staphylococcal lipases. 
Therefore, it seems paradoxical that staphylococci produce lipases, which would cause the 
formation of compounds which are toxic to staphylococci.  Another study showed that lipase 
from USA300 strains were capable of releasing growth-inhibitory free fatty acids and a study 
by White et al. showed that phospholipase C from USA300, which is specific for 
phosphatidylinositol, aided survival in blood256.  
 
A study by Hu et al. found that biofilm formation was decreased when a lipase gene was 
knocked-out, and that inoculation with the lipase mutant led to reduced peritoneal abscesses 
and lower bacterial loads in the organs of inoculated mice221. This supports findings from other 
studies which found S. aureus strains derived from deep infections produced more lipase 
compared to those isolated from superficial infections257. This indicates that lipase also has a 
role in invasion, and also in degradation of host tissue for nutrient acquisition. Studies 
investigating the link between staphylococcal lipase and immune responses have found that 
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while low concentration of lipase was chemotactic for granulocytes, higher concentrations 
seemed to immobilise granulocytes258. Also, the same study found that pre-incubation of 
granulocytes with staphylococcal lipase reduced its ability to kill bacteria by phagocytosis, 
mainly due to reduced phagocytic uptake.  
 
Lipase production is regulated by the accessory gene regulator quorum sensing system; at 
high cell density, the agr system is activated, and this up-regulates lipase production225. 
Mutants lacking the agr system shows reduced lipase production, and this could contribute to 
reduced virulence of these mutants in a mouse model. Also, sarA mutants showed a reduction 
in lipase production, suggesting that the sar regulatory system also plays a part in regulating 
lipase production259.  
 
Staphylococcal lipases are also used in biotechnology as catalysts; their reactions are highly 
specific, and they are not only able to hydrolyse a wide range of substrates but can also 
synthesise fatty acids219. Using enzymatic catalysis therefore is more favourable than using 
chemical reactions because of its specificity, which in turn reduces unwanted reactions and 
prevents toxic by-products from forming260. These properties then make downstream 
separation simpler and as less energy is required for these processes the use of lipase more 
cost-effective compared to chemical reactions. Lipases are used in many industries including 
food and pharmaceutical industries, and also in the production of biodiesel222.  
 
In this project, we wanted to identify novel regulators of staphylococcal lipase activity. To 
achieve this, we screened a sequenced collection of Methicillin-Resistant S. aureus (MRSA) 
isolates for variation in lipase activity, and then compared these results with the genome 
sequences in a Genome Wide Association Study (GWAS) to see what genomic polymorphisms 
were associated with the variation in lipase activity239. As seen in the previous chapters and 
from other research in our lab, GWAS have given us an insight into novel ways which virulence, 
such as toxin production, is regulated, therefore we sought to achieve the same with lipase 






Developing a high-throughput method for analysing lipase activity  
Assays to quantify lipase activity are commonly carried out in a liquid buffer system. A method 
developed by Gupta et al. used a Tris-based buffer with gum Arabic with the substrates para-
nitrophenol butyrate (pNPB, short chain) and para-nitrophenol palmitate (pNPP, long 
chain)261. The substrates are suspended in isopropanol, and are then mixed in a 1:9 ratio with 
the Tris-based buffer. The study by Gupta et al. found that the fatty acids released from the 
substrates by the lipase activity dissolved into the buffer with the addition of Triton-X100, 
which prevented the assay from becoming turbid. The assay by Gupta et al. was carried out 
as 1ml reactions using cuvettes and a spectrophotometer, but we reduced the total volume 
to 200μl so that the assay can be carried out in a 96-well microtitre plate. This makes it 
possible to assay multiple strains simultaneously, making the assay more high-throughput and 
facilitating the analysis of a whole strain collection.  
 
A standard curve (fig 5.1) was prepared by dissolving known concentrations of para-
nitrophenol (pNP), the yellow compound conjugated to the fatty acids in the substrate which 
is released by lipase activity. The absorbance was read in a plate reader every 5 mins for 1h, 
which gives a kinetic curve from which μM para-nitrophenol (pNP) released/min can be 
determined; this was achieved by finding out the peak amount of pNP release and dividing it 







Fig. 5.1: example standard curves used for the lipase assay (n=2). Known concentrations of para-
nitrophenol (pNP) was dissolved into the assay buffer, and their OD410 was read. This example is of the 
pNP dissolved into the para-nitrophenol butyrate (pNPB) assay buffer. The equation shown was 
generated by Excel from the data, and this was used to calculate the pNP concentration of the samples 
from their OD410 readings.  
 
Lipase is secreted, thus released into the supernatant therefore the cultures were grown for 
18h then pelleted to collect the supernatants. In the preliminary assays, an agr+ve strain 
(SH1000) and an agr-ve strain (MY18) were used, as the agr system is known to regulate lipase 
activity. These strains gave a consistent difference in lipase activity (fig. 5.2), therefore SH1000 





Fig. 5.2: lipase activity of an agr+ve strain, SH1000, and its agr-ve strain, MY18, shows that the activity 
of the agr system is involved in lipase production (n=3). As these strains consistently showed a 
difference in lipase activity, these were chosen as the control strains for subsequent lipase assays. 
pNPB (para-nitrophenol butyrate) is the short-chain substrate and pNPP (para-nitrophenol palmitate) 
is the long-chain substrate. The box represents the lower and upper quartiles, with the line showing 
the median value. The whiskers show the lower and upper extremes, and the points outside the 
whiskers are the outliers. 
 
Identifying novel genes associated with lipase activity in ST239 strains 
To identify genes which affect lipase production, a Genome Wide Association Study (GWAS) 
was carried out by Dr Mario Recker using 95 ST239 MRSA strains; the ST239 lineage of MRSA 
is healthcare-associated, and is a global clone with prevalence in Asia, South America and 
Eastern Europe253. The results showed that in general, these ST239 strains produce a low level 
of lipase but there were differences between individual isolates (fig. 5.3). It was also noticed 
that activity towards the short-chain substrate (pNPB) was greater than towards the long-
chain substrate (pNPP). Dr Recker then performed a GWAS using PLINK262 with this data and 
the genome sequence of these strains, and this approach identified various SNPs which were 








Fig. 5.3: a graph showing the lipase activity of ST239 strains, represented by the amount of para-nitrohenol (pNP) released per min (n=3). The blue bars show the 
release from a short chain substrate, para-nitrophenol butyrate, and the orange bars show the release from a long chain substrate (para-nitrophenol palmitate), 
with the 95% confidence interval shown as error bars. From the graph, it is visible that there is variation in lipase activity between the ST239 strains, with higher 
activity seen for the short chain substrate.
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Table 5.1: The genomic polymorphisms which showed the most significant association with lipase 
activity as identified by the GWAS. When comparing strains with and without the below SNPs, there 
was a statistical difference in lipase activity. In some cases, there were multiple SNPs in the same gene 
or intergenic location, and these are only listed once in the table; noted by “From...” and “x...” in the 
left two columns. These hits have a -Log10 p-value of >5, which is the equivalent to p<0.00001. Some 
of the hits are part of a prophage which had integrated into the genome (fig. 5.4), in the “geh” and 
“hlb” genes, a lipase or a phospholipase precursor gene.  
position 
in 





lytA – autolysin 
Part of a prophage in lipase 




Part of a prophage in 
phospholipase C precursor 
gene/hlb NE1786 
2942464 9.357797992 clfB Clumping factor B NE391 
From 
2147007 7.79207275 
SATW20_19900 (phage protein) 
x2 
Part of a prophage in 





2144787 7.270977981 SATW20_19830 (phage protein) 
Part of a prophage in 
phospholipase C precursor 
gene/hlb   
From 
390115 6.913652874 
SATW20_03490 (phage protein) 
x2 





152937 6.80695886 SATW20_01390   NE585 
301089 6.80695886 intergenic tarK/tarF 
tarK – putative CDP-glycerol: 
poly(glycerolphosphate) 
glycerophosphotransferase 
tarF –  putative teichoic acid 
biosynthesis protein   
967656 6.80695886 SATW20_09130   NE499 
972267 6.80695886 SATW20_09170     
1557020 6.80695886 ebh 
Very large surface anchored 
protein NE1 
1937314 6.80695886 SATW20_17780     
2174068 6.80695886 agrC 
Histidine kinase of the 
accessory gene regulator 
system NE873 
2377659 6.80695886 atpH 
Putative ATP synthase δ 
chain  NE1889 






2608746 6.80695886 SATW20_24680     
2997008 6.80695886 lip Lipase precursor NE338 
78396 6.80695886 mecA Penicillin binding protein 2’  NE1868 
961636 6.651881751 
intergenic 
SATW20_09020/SATW20_09030     
From 
2145704 6.41023554 SATW20_19860 x2     
From 
2138296 6.403156921 SATW20_19730 x4   NE1826 
2145901 6.403156921 SATW20_19870   NE1298 
From 
2147150 6.403156921 SATW20_19900 x3 
Part of a prophage in 






2151200 6.403156921 SATW20_19980 x5 
Part of a prophage in 
phospholipase C precursor 
gene/hlb   
From 
2152025 6.403156921 int x8 
int – integrase. 
Part of a prophage in 
phospholipase C precursor 
gene/hlb NE327 
2153030 6.403156921 intergenic int/SATW20_20010 
Part of a prophage in 
phospholipase C precursor 





x4     
2128192 6.218343607 SATW20_19530   NE181 
1121452 6.002470016 intergenic SATW20_10520/fmt 
fmt – autolysis and 
methicillin resistant-related 
protein   
From 
2145746 5.850814809 SATW20_19860 x2     
2138224 5.736809249 SATW20_19730     
From 








x3     
From 




411798 5.072590458 SATW20_03800 





412877 5.072294037 SATW20_03810 








Interestingly, some of the hits of the GWAS were from prophages which had integrated into 
either the geh gene or the hlb gene (fig. 5.4). The geh gene is a lipase precursor, and the hlb 
gene is a phospholipase C precursor. Potentially, the phages could have inserted into slightly 
different position along the geh and hlb genes in the isolates. In turn, this could mean that 
there is transcription of a fragment from the geh and hlb in these isolates, which may be 
functionally active. If this is the case, then it would be expected that lipase activity would be 
higher in these isolates, and these may have coincided with particular variations seen in the 
prophage DNA. These would then be identified in the GWAS as loci affecting lipase activity. 
Also, looking through the prophage genes within geh and hlb revealed that there are genes 
designated “geh” within the geh prophage and “hlb” within the hlb prophage. Potentially, 
these could play a role in lipase activity, and perhaps the polymorphisms in the prophage DNA 
could affect the rate at which these genes are transcribed, translated or affect any post-
translational modification.  
 
 
Fig. 5.4: a diagram showing how a prophage (blue box) disrupts an active gene (line). Without the 
insertion of the prophage, the gene is not disrupted, therefore expressed (A). However, the insertion 
of the prophage disrupts the gene, i.e. it splits the gene into two fragments (B). In the lipase GWAS 
hits, some polymorphisms were found in the prophages which had inserted into the geh and hlb genes. 
geh is a lipase precursor and hlb is a phospholipase C precursor.   
 
Confirming the GWAS result – knocking out the genes of possible interest 
As GWAS can produce false-positives, it is necessary to determine if these associations are in 
fact true. If the polymorphism had occurred in a gene, the gene can be inactivated (knocked-
out) if is a non-essential gene – this is only possible if the candidate genes are non-essential, 
as knocking-out essential genes makes the mutant unviable. This can then be compared to a 
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strain with the active gene to see if the inactivation has an effect on lipase activity. Methods 
for inactivating genes include using transposons, such as the one used to create the Nebraska 
Transposon (Tn) mutant library170. If, for example, a SNP in the agrC gene was associated with 
a change in lipase activity according to the GWAS, then a Tn mutant from the Nebraska Tn 
mutant library which has a Tn in the agrC gene will be screened. The Nebraska Tn mutant 
library is a collection of strains based on a USA300 MRSA strain, JE2, where all non-essential 
genes are knocked-out; the mutants will be referred to as “NE mutants” from here on.   
 
As this library is based on a USA300 strain, which is different to the ST239 MRSA strains we 
had analysed, it was necessary to use Basic Local Alignment Search Tool (BLAST) to find the 
GWAS candidate genes in the USA300 reference genome; BLAST searches for similar DNA or 
protein sequence, so here we use the DNA sequence of the ST239 gene of interest, and look 
for a match in the USA300 sequence. For example, murA2 was identified in the GWAS as being 
associated with lipase activity, then BLAST was used to identify the region in the USA300 
reference genome which matched murA2, which was murA. From there, we looked through 
the NE mutant library to see if murA had been knocked-out. We displayed the GWAS data to 
show the most significant associations at the top, then took the top 81 hits to find 14 NE Tn 
mutants and assayed these NE mutants alongside JE2 (table 5.2). Some hits were multiple 
SNPs in the same gene, while others were intergenic or did not have a corresponding NE 
mutant (i.e. in an essential gene), which reduced the 81 hits to 14 NE mutants. By comparing 
the lipase activity of JE2 and an NE mutant, it is possible to see if knocking-out the gene does 
affect lipase activity (table 5.2). We found eight such genes, however two were not 
investigated further as they were a lipase gene and agrC, which is a known regulator of lipase. 









Table 5.2: table showing the 14 NE mutants tested. P-values using Kruskal-Wallis test was calculated 
for the pNPB (long-chain) substrate, using JE2 for comparison. The Kruskal-Wallis test was used as the 
distribution of the data showed that a non-parametric test should be used. agrC is already a known 
regulator of lipase, therefore this and the lipase gene will not be investigated further. The bottom 6 
NE mutants showed no significant difference in lipase activity compared to JE2, therefore these will 
also not be investigated further.  
 
Using mutants in other backgrounds to verify the results seen in NE mutants 
To verify that the results seen in the NE mutants were specific to the transposon insertion 
rather than other mutations which may be present in the NE mutants, we used mutants in 
other genetic backgrounds of S. aureus. We had mutants available for mecA, as well as a 
mutant lacking the SCCmec locus which carries the mecA gene, and clfB in other backgrounds, 
so we characterised them using our lipase assay. BH1CC is a clinical HA-MRSA strain, and LAC 
is a USA300 CA-MRSA strain263,264. The assays revealed no difference between the wild-type 
and mutants for mecA (p=0.09) and clfB (p=0.25), so we can conclude that the difference in 
lipase activity seen in the NE mutants lacking these candidate genes were not due to the 
deletion of these genes (fig. 5.5).  
 
NE mutant gene (TW20) gene (USA300) p-value (Kurskal-Wallis)
NE873 agrC agrC 0.003948
NE338 lipase lipase 0.02497
NE1786 SATW20_19910 (phage antirepressor protein) SAUSA300_1966 0.01041
NE939 murA2 murA (2,239,704) 0.01631
NE1868 mecA mecA 0.01631
NE181 SATW20_19530 SAUSA300_1936 0.02497
NE1889 atpH atpH 0.03737
NE391 clfB clfB 0.04495
NE1298 SATW20_19870 SAUSA300_1964 0.05466
NE1826 SATW20_19730 SAUSA300_1953 0.07817
NE499 SATW20_09130 SAUSA300_0817 0.1093
NE585 SATW20_01390 SAUSA300_0130 0.1093
NE1 ebh SAUSA300_1327 0.1495




Fig. 5.5: using mutants of mecA/SCCmec (A) and clfB (B) in other backgrounds revealed no difference 
in lipase activity between the wild-type and mutants (n=6). Therefore, the difference in lipase activity 
between JE2 and the NE mutants with the above genes knocked-out does not seem to be due to the 
lack of clfB or mecA. The box represents the lower and upper quartiles, with the line showing the 
median value. The whiskers show the lower and upper extremes, and the points outside the whiskers 
are the outliers. 
 
Complementing the knocked-out genes in the NE mutants 
Another way to verify that the reduction in lipase activity seen in the above mutants was due 
to the knocked-out gene than other mutations is to replace these genes into the NE mutants 
lacking them by using a tetracycline inducible plasmid vector, pRMC2243, to see if the re-
introduction of the gene of interest restores the lipase activity. First, primers were designed 
to amplify a fragment more than the whole gene, and had aaa/ttt and a restriction site of 
choice added to the 5’ end. Two restriction sites were chosen to reduce the chances of self-
ligation. The vector was isolated from E. coli DH5α, and meanwhile, PCR was carried out using 
JE2 DNA and the above primers to amplify the candidate genes. High-fidelity taq polymerase, 
such as Phusion, is necessary for this PCR reaction to ensure no mutations occur. The PCR 
products will be the inserts which will be ligated into the vector. 
 
Once the PCR product was verified as being the correct size, the remaining PCR reaction was 
purified before being digested with two restriction enzymes, at the same time as the vector 
in a separate reaction. Once the insert and vector were digested, they were then mixed in 
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varying ratios and ligated. The re-ligated plasmid was transformed first into E. coli, then 
restriction deficient strain RN4220 before transforming into the relevant NE mutant. The 
transformants were plated out, and if any colonies grew on the plate they were re-grown in 
broth and the plasmid was extracted. The plasmid was then double digested again using the 
same two restriction enzymes to check if the insert is there; two bands will be present if there 
is, one around 6.5kb (pRMC2) and one where the insert should be. With the SAUSA300_1966 
and atpH, these ligations worked well and we were able to complement the relevant NE 
mutants. However, the murA gene could not be cloned into pRMC2; we tried using varying 
vector:insert ratios, and had controls to check transformation efficiency, and  using 
electroporation rather than chemical transformation.  
 
Does replacing SAUSA_1966 and atpH into their respective mutants restore lipase activity?  
With the two NE mutants that we managed to complement, we again looked at the lipase 
activity; we compared the complemented NE mutant, the NE mutant and JE2. pRMC2 includes 
a tetracycline inducible promoter, therefore anhydrotetracycline was added to the culture 
media to induce the expression of the cloned genes. At higher concentrations of 
anhydrotetracycline, sometimes the strains did not grow well – these were not analysed, as 
there would be less lipase present due to the lack of growth.  
 
Unfortunately, when we analysed these strains, there was no difference in lipase activity 
between the NE mutant and the complemented NE mutant (fig. 5.6). Varying concentrations 
of anhydrotetracycline was used, ranging from 50ng/ml to 400ng/ml, and several different 
stocks of anhydrotetracycline was also used to ensure that the lack of induction was not due 
to a particular batch of the inducer. In the absence of the inducer the SAUSA300_1966 
complemented NE1786 shows higher lipase activity compared to NE1786 (p=0.03) (fig. 5.6 A). 
Despite obtaining 6 repeats for each inducer concentration, there was no difference in lipase 
activity between the NE mutant and the complemented NE mutant. Perhaps 
anhydrotetracycline affects lipase production in some way, or there may have been an issue 





Fig. 5.6: lipase activity of the complemented NE mutants. The complemented NE mutants carry a copy 
of the knocked-out gene (SAUSA300_1966 (into NE1786, graph A) or atpH (into NE1889, graph B)) on 
a tetracycline inducible plasmid (n=6). The concentrations represent the amount of 
anhydrotetracycline added to the culture medium. Aside from the SAUSA300_1966 complemented 
NE1786 in the absence of anhydrotetracycline (0ng/ml, graph A), there is no difference in lipase activity 
between the NE mutant and the complemented strain (p=0.03, T-test). The box represents the lower 
and upper quartiles, with the line showing the median value. The whiskers show the lower and upper 
extremes, and the points outside the whiskers are the outliers. 
 
Discussion  
When analysing lipase activity of ST239 MRSA strains, it was noted that it is low compared to 
the USA300-based strains; however, there was variation between the strains. From this, a 
GWAS was carried out by Dr Recker and revealed genetic polymorphisms which were 
statistically associated with a change in lipase production. When we looked through the list of 
polymorphisms, there were some cases when they occurred in the same gene. Some of the 
hits were genes in a prophage which had inserted into the lipase precursor gene geh or the 
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phospholipase C precursor gene hlb. There is a possibility that in the isolates carrying the 
polymorphisms within the prophage genes identified by the GWAS, the prophages have 
inserted into a slightly different location within the geh and hlb genes. This in turn could give 
rise to the possibility that a functional fragment of Geh and Hlb could be expressed in these 
isolates, which would increase lipase activity. Re-sequencing of the ST239 isolates with the 
current improved technology could help identify if the prophages are in a subtly different 
position. Alternatively, sequencing which generate long read data (such as Pac Bio or MinION) 
could be used.  
 
Looking from the most significant, we identified candidate genes and then sought to verify 
these associations. Of the 14 NE mutants tested, eight were significantly lower in lipase 
activity compared to the parent strain, JE2. However, two of these were the lipase gene and 
agrC, part of the accessory gene regulator quorum sensing system, which is a global regulator 
of virulence. Therefore, it was unsurprising to find an agr gene among the hits, and given that 
a lipase gene was also among the list of candidate genes shows that the GWAS method used 
is reliable.   
 
SAUSA300_1966 is an unidentified gene which is listed as “phi77 ORF014-like protein, phage 
anti-repressor protein” in the GenBank entry. This was shown to be a putative phage-anti-
repressor which counteracts the bacteriophage Phi77248. This protein may also function as an 
anti-repressor for lipase, or could be interacting with an unknown repressor of lipase. This 
would mean that in the presence of the protein, lipase production is either enhanced by the 
protein itself or enhanced by the protein blocking the action of a lipase repressor.  
 
MurA is part of the cell wall synthesis pathway, and catalyses the first committed step of 
peptidoglycan biosynthesis; the formation of UDP-N-acetylglucosamine-enolpyruvate from 
UDP-N-acetylglucosamine and phosphoenolpyruvate (fig. 5.7)265. This protein is also the 
target of the antibiotic fosfomycin. In the cell wall biosynthesis pathway, a lipid carrier is used 
to shuttle precursors across the cell membrane, therefore the up-regulation of lipase by murA 
during the stationary phase of growth may be involved in reducing the amount of cell wall 
biosynthesis by degrading the lipid carrier. The reduction in the number of lipid carriers 
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available would lead to a reduction in overall cell-wall synthesis, thus slowing down the rate 
of cell division in the stationary phase. Cell wall lipids could be quantified using methods such 
as thin-layer chromatography of gas chromatography255, or by potentially labelling the lipid 
carriers so that breakdown would either emit or diminish a signal.  
 
 
Fig. 5.7: schematic showing the action of MurA, taken from Silver et al., Cold Spring Harb Perspect Med 
2017265. MurA catalysed the formation of UDP-N-acetylglucosamine-enolpyruvate from UDP-N-
acetylglucosamine and phosphoenolpyrivate via a tetrahedral intermediate. 
 
AtpH is the δ subunit of F1F0 ATP synthase, which is responsible for providing ATP for the 
cell266. Many chaperones which aid in protein folding has been characterised as ATPases, thus 
ATP hydrolysis is important for protein folding267. Mutations in the δ subunit of ATP synthase 
has been shown to reduce intracellular ATP concentrations in E. coli266, therefore it is possible 
that atpH is affecting lipase production by interfering with its folding process, due to reduced 
availability of intracellular ATP. There is a commercial assay kit available from Abcam which 
quantifies ATP concentrations, so a cell lysate of JE2 and NE1889 could be prepared to be 
analysed by the above kit. 
 
Attempts to clone the above genes were made, but these were unsuccessful. We managed to 
successfully ligate the genes into the tetracycline-inducible plasmid pRMC2, but when these 
were transformed into the corresponding NE mutants there was no difference in lipase activity 
between the transformed mutants and the NE mutant. A reason could be that the gene was 
not cloned in the correct reading frame, therefore the primers should be verified, and re-
designed if necessary. Interestingly, when SAUSA300_1966 was replaced into NE1786, in the 
absence of the inducer (anhydrotetracycline) there was greater lipase activity compared to 
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NE1786. Perhaps the promoter used in this plasmid is leaky, thus producing some gene 
product in the absence of the inducer, however if this were the case then it would be expected 
that the inducer would yield more of the product, thus restoring the lipase activity more. 
Potentially, anhydrotetracycline may inhibit lipase production, but there is no data to support 
this at this stage.  
 
In this chapter, we aimed to find novel regulators of lipase production by using a GWAS. It was 
noted in the GWAS that a lipase gene and a gene from a regulatory system known to affect 
lipase production, agrC, was among the candidate genes from the GWAS. We then sought to 
verify the other candidate genes by using mutants with these genes knocked-out; this is only 
possible if the candidate is a non-essential gene. By doing this, we were able to determine if 
the association identified by the GWAS was a false-positive or an actual association. These 
revealed six genes, including SAUSA300_1966, atpH and murA, as genes potentially involved 
in lipase production.  
 
Future directions 
Studies have revealed a potential link between lipase production and virulence in S. aureus, 
as well as link between lipase and host immunity. This would suggest that lipase does have a 
role in S. aureus pathogenicity, and studies like the one in this chapter aims to gain further 
understanding of how this is regulated and potentially lead to understanting how this affects 
the overall virulence of S. aureus.  
 
Completing the complementation of SAUSA300_1966, atpH and murA, as well as cloning 
SAUSA300_1936 is the next step for this research. The murA gene was not able to be ligated 
into pRMC2 despite varying most of the conditions needed for the process. The restriction 
enzyme site added onto the murA forward primer differed from the one added to 
SAUSA300_1966 and atpH primers (EcoRI), as the murA gene contains an EcoRI restriction site. 
The restriction site chosen for the murA forward primer was that for SacI and BanII, and as 
SacI was the available enzyme in the lab this was used for the cloning. Perhaps using BanII in 
the cloning rather than SacI would improve the outcome of the ligation, so this should be 
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carried out. If the ligation is still unsuccessful, then the primers should be re-designed, possibly 
with an alternative restriction enzyme site.  
 
SAUSA300_1966 and atpH were successfully ligated into the vector, but their expression was 
not able to complement the knock-out NE mutants. NE1786 carrying SAUSA300_1966 showed 
recovery of lipase activity, which was not seen when anhydrotetracycline was added. There is 
therefore a potential that anhydrotetracycline is interfering with lipase production. To see if 
this is the case, agr+ve strains could be used; these strains could be grown in the presence of 
anhydrotetracycline to see if this makes a difference to their lipase activity. NE1889 carrying 
atpH did not show a recovery of lipase activity like the NE1786 carrying SAUSA300_1966. The 
primers could be re-designed to ensure that the complemented strain has the gene in the 
correct reading frame, and thus is able to recover lipase activity. However this gene may not 
in fact be associated with lipase activity, so the difference seen between NE1889 and JE2 could 





















- can we use genome sequences to study bacterial 
virulence? 
 
Genome Wide Association Studies (GWAS) look for statistical associations between a 
phenotype and genotypic variations – typically, it is used to identify genetic mutations (Single 
Nucleotide Polymorphisms (SNPs) for example) which are associated with a disease239. An 
early GWAS in humans compared the genotypes of patients with Age-related Macular 
Degeneration (AMD) and a control population, and found that a SNP in the complement factor 
H gene was associated with AMD, leading to the link between AMD and autoimmunity.  
 
The improvements in genome sequencing technology has made it easier to obtain genome 
sequences for bacteria, and this has led to a rise in the number of genome sequences 
available239. The availability of genome sequences means that it is possible to do GWAS with 
bacteria, to further investigate how virulence is controlled for example. Some early bacterial 
GWAS using shotgun sequencing data to be published includes one by Sheppard et al., which 
looked at how Campylobacter species adapted to the host, and another by Farhat et al. 
investigated what mutations arose frequently in drug resistant Mycobacterium tuberculosis, 
thereby allowing the identification of genes which promote resistant to anti-tuberculosis 
drugs268,269.  
 
The distribution of these genetic polymorphisms is linked to success in GWAS239; in humans 
genetic recombination and chromosomal segregation means that mutations are usually linked 
to alleles in its vicinity, and the way alleles mix in different genetic backgrounds gives an insight 
into which of the mutation is causing the phenotypic change as opposed to being passively 
carried. In bacteria, however, genetic diversity occurs less frequently, by either horizontal 
gene transfer (movement of mobile genetic elements from one to another), recombination 
(replacement of DNA) or by recurrent mutation (mutation arising in separate lineages), and 
these lead to homoplasy; this is where similar genetic loci are found in separate phylogenetic 
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branches. This is something that needs to be taken into consideration when carrying out 
bacterial GWAS.  
 
Previous studies in our lab have used GWAS to try and identify novel ways in which virulence 
is regulated in Staphylococcus aureus, particularly Methicillin-Resistant S. aureus (MRSA). This 
includes a study using ST239 MRSA strains to identify new genetic loci which affect toxicity 
(toxin production) of this lineage, as well as a study which used strains from a single patient 
and a collection of USA300 strains from various origins191,246. The ST239 study and the GWAS 
carried out using the USA300 strains identified an epistatic association between a SNP in the 
ileS gene and other SNPs at other loci; this means that the presence of the ileS SNP does not 
lead to a change in toxicity, however differences are seen when the presence/absence of the 
secondary SNPs are taken into account. This particular SNP had been shown to cause 
resistance to the antibiotic mupirocin, but had not been associated with toxicity before. 
 
The first part of my research focused on uncovering the mechanism behind the association 
between the SNP in the ileS gene causing mupirocin resistance (mupR SNP)75 and toxin 
production – between the two MRSA lineages, this was the only SNP in common in this 
epistasis. This revealed a mechanism by which S. aureus balances antibiotic resistance and 
fitness by modulating virulence, in this case lowering the amount of toxins produced to retain 
fitness. Studies investigating this particular SNP showed that this was a fitness cost free 
resistance mechanism249, and in pure cultures there is no difference seen in the growth rate 
of isogenic mupirocin sensitive and resistant strains. However, when these strains are forced 
to compete, fitness is retained only in strains with a functional agr system; these agr negative 
strains are not able to produce much toxins. Antibiotic resistance is an increasing problem, 
and in cases like this mupirocin resistance SNP investigated in my research, the fact that 
bacteria are able to offset the fitness cost of this resistance mutation means that it is able to 
be stably maintained in a population; in fact, this mutation is the one most frequently seen in 
clinical S. aureus isolates75.  
 
The GWAS association seen between mupirocin resistance (mupR) and toxicity was shown to 
be an epistatis, as stated before. This means that other secondary SNPs are involved in 
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changing the toxicity of mupirocin resistant strains. This study did not go into details into these 
secondary SNPs and the role they play in this association; this is a question which still remains. 
Creating secondary SNP-mutants in isogenic mupirocin sensitive (mupS) and mupR strains will 
reveal which of these combinations actually lead to a change in toxicity. Perhaps this will help 
us to further understand how mupR is affecting toxicity. Interestingly, there was no overlap in 
these secondary SNPs, meaning that the list of secondary SNPs in USA300 and ST239 lineages 
are different. Does this mean that the GWAS association is lineage specific? – this can be 
addressed by analysing another sequenced strain collection.  
  
The second part of my research utilised GWAS to find novel genes affecting lipase activity in 
S. aureus. What was first required for this was to create a high throughput approach to analyse 
lipase activity, which was achieved by adapting an existing assay261 to be run using a 96 well 
plate in a plate reader. To validate the assay, an agr+ve strain and its isogenic agr-ve strain 
were used, as the agr system is known to regulate lipase activity225. GWAS revealed genes 
which were associated with a variation in lipase activity, and these were verified using the 
Nebraska Transposon (Tn) mutants170. To ensure that the results seen was not due to 
mutations elsewhere, we either used mutants in a different genetic background (where 
available) or attempted to complement the Tn mutant by introducing the knocked-out gene 
on an inducible plasmid.  
 
Although we were not able to see difference in lipase activity seen in mutants of clfB and mecA 
in other backgrounds, and were not successful in cloning the genes of interest, the GWAS 
approach was successful in identifying novel genes which seem to have an effect on lipase 
activity; further research is needed to fully characterise the function of SAUSA300_1966, 
murA, SAUSA300_1936 and atpH in modulating lipase activity. For example, when no inducer 
was added to the SAUSA300_1966 knock-out mutant carrying that gene on pRMC2, there was 
a significant increase in lipase activity compared to the knock-out mutant without the plasmid; 
is the inducer, anhydrotetracycline, affecting lipase activity?  
 
These studies demonstrate the potential for GWAS to identify new ways in which virulence of 
the opportunistic pathogen S. aureus is regulated. It is necessary to follow up any significant 
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hits from the GWAS with experimental work to back-up the finding, as we attempted to do 
here. Due to the rising problem of antibiotic resistance, it is vital that we understand more 
about the bacterial pathogens we are facing, and GWAS can be used as a tool by which 
functions of genes in virulence can be quickly identified. This would allow us to provide new 
targets for antibiotics which would target the production of virulence factors, and this could 
be expanded to other pathogens. GWAS may also aid the understanding of virulence in 
bacteria which have not been well studied, as well as perhaps aiding annotation of genomes 
through the understanding of the gene’s function. This would then increase our understanding 
of bacteria and facilitate the annotation of the genomes of other organisms. The reduction in 
cost and time, and the improvements in genome sequencing has seen an increase in the 
number of sequences available, and I believe there is much we can learn from this information 


























Table showing the genes in ST239 (TW20) which translate into proteins with a significantly 
altered isoleucine (Ile) content, according to the Mote Carlo simulation.  
 










SATW20_01700 cap8K Yes High SATW20_15510 mreB Yes High 
SATW20_02780 lytM Yes Low SATW20_17630 arsB2 Yes High 
SATW20_05240   Yes High SATW20_20070   Yes High 
SATW20_05720   Yes High SATW20_02080   Yes High 
SATW20_06310 sdrC Yes Low SATW20_26150   Yes High 
SATW20_06320 sdrD Yes Low SATW20_10750   Yes High 
SATW20_06330 sdrE Yes Low SATW20_08750   Yes High 
SATW20_06910   Yes High SATW20_14080   Yes High 
SATW20_07840   Yes High SATW20_16570   Yes High 
SATW20_08220 tarO Yes High SATW20_24490   Yes High 
SATW20_08620 clfA Yes Low SATW20_05370   Yes High 
SATW20_10490 atl Yes Low SATW20_17310   Yes Low 
SATW20_11230 isdB Yes Low SATW20_25000   Yes Low 
SATW20_13440   Yes Low SATW20_22340 sceD Yes Low 
SATW20_14350 ebh Yes Low SATW20_00810   Yes High 
SATW20_17210 harA Yes Low SATW20_01480 tet38 Yes High 
SATW20_17280   Yes Low SATW20_09430   Yes High 
SATW20_20210 agrC Yes High SATW20_01430   No High 
SATW20_21710   Yes Low SATW20_24720   No High 
SATW20_22950 fmtB Yes Low SATW20_13510 citB No Low 
SATW20_23100   Yes High SATW20_14780 ebpS No Low 
SATW20_24330   Yes High SATW20_01960   No High 
SATW20_27680 clfB Yes Low SATW20_28080 lip No Low 
SATW20_27920 sraP Yes Low SATW20_20190 agrB No High 
SATW20_00110   Yes High SATW20_14370   No High 
SATW20_09780   Yes High SATW20_08630   No Low 
SATW20_20150   Yes Low SATW20_23400 hysA No Low 
SATW20_26230 fnbA Yes Low SATW20_01260 sirB No High 
SATW20_26330   Yes High SATW20_09980 pepB No Low 
SATW20_02960   Yes High SATW20_06870   No High 
SATW20_08450   Yes Low SATW20_16620   No High 
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SATW20_15830   No High SATW20_14360   No High 
SATW20_11240 isdA No Low SATW20_16810   No High 
SATW20_05380   No High SATW20_15370   No High 
SATW20_22230   No High SATW20_26380   No High 
SATW20_10090   No High SATW20_11530   No High 
SATW20_08710   No High SATW20_27750 aur No Low 
SATW20_01840   No High SATW20_18530   No High 
SATW20_23040   No High SATW20_06700   No High 
SATW20_02310 coa No Low SATW20_04420   No High 
SATW20_26210 fnbB No Low SATW20_07230 fhuB No High 
SATW20_05960   No High SATW20_27650 phoB No Low 
SATW20_14490 pbp2 No Low SATW20_15050 malA No Low 
SATW20_07240 fhuD No High SATW20_23110   No High 
SATW20_22130   No High SATW20_09930 appC No High 
SATW20_01090   No High SATW20_28310   No High 
SATW20_01230 spa No Low SATW20_26480   No High 
SATW20_24590   No High SATW20_25950 opp-1A No Low 
SATW20_20140   No High SATW20_04340 ssb No Low 
SATW20_24860 tcaB No High SATW20_05220   No Low 
SATW20_25270 narG No Low SATW20_25580   No High 
SATW20_07070 mntB No High SATW20_19560   No Low 
SATW20_00130   No High SATW20_08080 sstA No High 
SATW20_10070   No High SATW20_23050   No High 
SATW20_04510   No Low SATW20_28050 icaD No High 
SATW20_05201 PSM-α4 No High SATW20_07940   No Low 
SATW20_13750 femB No Low SATW20_07490   No High 
SATW20_08300   No Low SATW20_00660 tet No High 
SATW20_11490   No High SATW20_06980   No High 
SATW20_10280   No High SATW20_10200   No High 
SATW20_02760   No High SATW20_04180   No High 
SATW20_04290   No High SATW20_24290   No High 
SATW20_25890   No High SATW20_10950   No High 
SATW20_27600   No High SATW20_22480 atpI No High 
SATW20_09920 appB No High SATW20_01450 sasD No Low 
SATW20_13590   No High SATW20_01790   No High 
SATW20_01880   No High SATW20_11360   No High 
SATW20_11900 lspA No High SATW20_18130   No High 
SATW20_06210   No Low SATW20_15990   No High 
SATW20_01680 cap8I No High SATW20_28180   No Low 
SATW20_26320   No High SATW20_24310   No High 
SATW20_00230 sasH No Low SATW20_10710 ykoC No High 
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SATW20_11840   No High SATW20_07800 saeS No High 
SATW20_04700   No Low SATW20_18140   No High 
SATW20_17440   No High SATW20_14680 menH No Low 
SATW20_00610 merB No Low SATW20_28220   No High 
SATW20_14150 arlS No High SATW20_24140   No High 
SATW20_16240 aspS No Low SATW20_26010   No High 
SATW20_26910   No High SATW20_00820   No High 
SATW20_24450   No High SATW20_13800   No High 
SATW20_05310   No High SATW20_19240   No High 
SATW20_26900 isaA No Low SATW20_26880 ssaA No Low 
SATW20_13250   No High SATW20_22180 kdpD No High 
SATW20_01510   No High SATW20_24820   No High 
SATW20_06120 rpoB No Low SATW20_25410 fmhA No Low 
SATW20_27500 cudB No Low SATW20_08470 gap1 No Low 
SATW20_13210   No High SATW20_26360   No High 
SATW20_13760   No High SATW20_25790   No High 
SATW20_13870   No High SATW20_15350   No High 
SATW20_02530 ispD1 No High SATW20_11000   No High 
SATW20_11750 pbpA No Low SATW20_25430   No High 
SATW20_09880   No Low SATW20_01420   No High 
SATW20_23150   No High SATW20_02880 essB No Low 
SATW20_13360 katA No Low SATW20_23860   No High 
SATW20_15750 dnaJ No Low SATW20_09230   No High 
SATW20_01520   No High SATW20_13550 grlB No Low 
SATW20_17720   No High SATW20_06670   No High 
SATW20_13810   No High SATW20_11760 mraY No High 
SATW20_27790   No High SATW20_21760   No Low 
SATW20_20090   No High SATW20_21770   No High 
SATW20_05900 nupC No High SATW20_12070   No Low 
SATW20_19350   No High SATW20_26430   No Low 
SATW20_04000   No High SATW20_08870   No High 
SATW20_27350   No Low SATW20_25820   No High 
SATW20_04080   No High SATW20_05400 gltA No Low 
SATW20_01250 sirC No High SATW20_22160 kdpB No High 
SATW20_06760   No High SATW20_24400   No Low 
SATW20_08110 sstD No Low SATW20_27820   No Low 
SATW20_00631   No High SATW20_24300   No Low 
SATW20_08360 lgt No High SATW20_18600   No High 
SATW20_19110   No High SATW20_03180   No High 
SATW20_26520   No High SATW20_11930 pyrP No High 
SATW20_03880 lytA No Low SATW20_18640   No High 
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SATW20_26870   No High SATW20_03030   No High 
SATW20_23370   No High SATW20_01550   No Low 
SATW20_14330   No High SATW20_16700 rpmI No Low 
SATW20_06940   No High SATW20_20180 hld No High 
SATW20_09760   No High SATW20_17880   No Low 
SATW20_15700   No High SATW20_02800   No High 
SATW20_07030   No High SATW20_21850   No Low 
SATW20_27710 arcD No High SATW20_12880   No High 
SATW20_25480 sbi No Low SATW20_25520   No High 
SATW20_14000 msa No High SATW20_16560 tag No Low 
SATW20_10470   No High SATW20_09490 mnhD No High 
SATW20_24480   No High SATW20_12690   No High 
SATW20_25510 hlgB No Low SATW20_02210   No High 
SATW20_11920 pyrR No High SATW20_19260   No High 
SATW20_07260   No Low SATW20_23950 fmhB No Low 
SATW20_09590 glpQ No Low SATW20_02260   No Low 
SATW20_27910   No High SATW20_16530   No High 
SATW20_11870 ileS No Low SATW20_08090 sstB No High 
SATW20_17480 leuS No Low SATW20_19320 hlb No Low 
SATW20_01920   No High SATW20_28390   No High 
SATW20_24110 modA No Low SATW20_23980   No High 
SATW20_08070 rir2 No Low SATW20_04200   No High 
SATW20_25810   No High SATW20_10990   No High 
SATW20_07020   No High SATW20_26240 gntP No High 
SATW20_08020   No High SATW20_07580 bacA No High 
SATW20_10190 htrA2 No Low SATW20_01220 lldP1 No High 
SATW20_21700   No Low SATW20_07370 vraG No High 
SATW20_02090   No High SATW20_09130   No High 
SATW20_23470   No High SATW20_02570 ispD2 No High 
SATW20_04940   No High SATW20_14850   No Low 
SATW20_15640 cdd No Low SATW20_13540   No High 
SATW20_26060   No Low SATW20_13830   No Low 
SATW20_25360   No Low SATW20_13710 trpF No High 
SATW20_14880   No Low SATW20_23300 lacD No Low 
SATW20_28350   No High SATW20_13020 glnA No Low 
SATW20_07100   No High SATW20_17700   No High 
SATW20_27290   No Low SATW20_09530   No Low 
SATW20_25080   No High SATW20_10260   No High 
SATW20_23540   No High SATW20_27560   No High 
SATW20_03240   No High SATW20_23090   No High 
SATW20_23420   No Low SATW20_24500   No High 
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SATW20_23880   No Low SATW20_07180 abcA No High 
SATW20_03970   No High SATW20_03040   No High 
SATW20_00710   No High SATW20_11080   No High 
SATW20_06740   No High SATW20_16820 phoR No High 
SATW20_20010   No Low SATW20_11860   No Low 
SATW20_14600   No High SATW20_13930 asd No Low 
SATW20_19810   No Low SATW20_15340   No High 
SATW20_13230   No High SATW20_24920   No High 
SATW20_03400   No Low SATW20_06520   No High 
SATW20_07410   No High SATW20_10970   No Low 
SATW20_10450 sspA No Low SATW20_09470 mnhF No High 
SATW20_07770   No High SATW20_16160   No Low 
SATW20_27180   No Low SATW20_07010   No High 
SATW20_05203   No High SATW20_06470   No High 
SATW20_26140   No High SATW20_15650   No High 
SATW20_15070   No Low SATW20_18210 hlgB No Low 
SATW20_05204   No High SATW20_13290   No High 
SATW20_23910   No High SATW20_07210   No High 
SATW20_26550   No High SATW20_03090   No High 
SATW20_04500   No High SATW20_04020 mepA No High 
SATW20_19410 sea No Low SATW20_13470   No High 
SATW20_11570   No High SATW20_23200 asp23 No Low 
SATW20_11610 otc No Low SATW20_07390   No High 
SATW20_21730   No Low SATW20_16960   No High 
SATW20_06790   No Low SATW20_10960   No High 
SATW20_25680   No High SATW20_18400   No High 
SATW20_13400   No Low SATW20_12910 glpP No High 
SATW20_10130   No High SATW20_07290   No High 
SATW20_14820   No High SATW20_24980 lldP2 No High 
SATW20_20260   No High SATW20_16860 cycA No High 
SATW20_23830 rplD No Low SATW20_01040   No High 
SATW20_24180   No High SATW20_24960   No High 
SATW20_14140 odhA No Low SATW20_13730 trpA No High 
SATW20_09730   No High SATW20_09750   No High 
SATW20_04400   No Low SATW20_07590   No High 
SATW20_19990 hlb No Low SATW20_25260 narH No Low 
SATW20_17360   No High SATW20_03110   No High 
SATW20_20280   No High SATW20_20020   No Low 
SATW20_28290 cna No Low SATW20_15490 sodA No Low 
SATW20_09630   No High SATW20_02020   No High 
SATW20_15280   No High SATW20_02150   No Low 
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SATW20_01440 sodM No Low SATW20_16380 obg No Low 
SATW20_18520   No High SATW20_15260   No High 
SATW20_01190   No High SATW20_15850   No Low 
SATW20_17740   No High SATW20_04550 pbuX No High 
SATW20_14960 fur No Low SATW20_07670   No High 
SATW20_16730 thrS No Low SATW20_04720   No Low 
SATW20_28370 vraE No High SATW20_18950 gatA No Low 
SATW20_28450   No High SATW20_27440   No High 
SATW20_21570   No Low SATW20_27780   No High 
SATW20_15060 malR No High SATW20_01360 sbnI No Low 
SATW20_01000   No High SATW20_24630 hutU No Low 
SATW20_24580   No High SATW20_25750 opuCC No Low 
SATW20_09250 lipA No Low SATW20_22840 czrB No High 
SATW20_21940 ilvB No Low SATW20_10870   No Low 
SATW20_24970 mqo1 No Low SATW20_13880   No Low 
SATW20_07520   No Low SATW20_00670   No Low 
SATW20_01170   No Low SATW20_12460   No Low 
SATW20_09520 mnhA No High SATW20_26650   No Low 
SATW20_13740 femA No Low SATW20_04860   No High 
SATW20_00190 yycG No High SATW20_01210   No High 
SATW20_21450   No Low SATW20_25740 opuCD No High 
SATW20_11120   No High SATW20_03010   No High 
SATW20_05910 ctsR No High SATW20_07620   No High 
SATW20_08660 nuc No Low SATW20_18710   No Low 
SATW20_13580   No High SATW20_12210 recG No Low 
SATW20_01770   No High SATW20_03770   No Low 
SATW20_23510 rpsI No Low SATW20_18900   No High 
SATW20_18940 gatB No Low SATW20_16420   No High 
SATW20_04440   No High SATW20_03810   No Low 
SATW20_07610 mgrA No Low SATW20_13840   No High 
SATW20_17050   No High SATW20_16750 dnaB No Low 
SATW20_21461   No High SATW20_18460   No High 
SATW20_20460   No High SATW20_10360   No High 
SATW20_17890   No Low SATW20_04490   No Low 
SATW20_11130   No Low SATW20_07650   No High 
SATW20_01270 sirA No Low SATW20_23840 rplC No Low 
SATW20_18620   No Low SATW20_22960   No Low 
SATW20_22850   No High SATW20_07000   No High 
SATW20_01300 sbnC No Low SATW20_11320 pheS No Low 
SATW20_00200 yycH No Low SATW20_27770   No Low 
SATW20_24760   No High SATW20_09480 mnhE No High 
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SATW20_28330   No High SATW20_28410   No High 
SATW20_08200   No High SATW20_09620   No Low 
SATW20_08500 pgm No Low SATW20_21400   No High 
SATW20_18930   No High SATW20_24160 fhuD No Low 
SATW20_05680 prs No High SATW20_02330 fadB No Low 
SATW20_05180   No High SATW20_00090 serS No Low 
SATW20_21670   No Low SATW20_09200   No High 
SATW20_06820 adhA No Low SATW20_09460 mnhG No High 
SATW20_01130   No High SATW20_10830   No High 
SATW20_21560   No Low SATW20_12310 ffh No Low 
SATW20_06170 fus No Low SATW20_15450   No High 
SATW20_06550   No High SATW20_09020   No Low 
SATW20_11280 isdF No High SATW20_25500 hlgC No Low 
SATW20_24890   No High SATW20_25470   No High 
SATW20_26890   No High SATW20_21340   No High 
SATW20_15480 pbpF No Low SATW20_08040   No High 
SATW20_00770   No High SATW20_06060 nusG No Low 
SATW20_05110   No Low SATW20_25900   No High 
SATW20_00870   No High SATW20_25600   No High 
SATW20_01180 norC No High SATW20_27550 nrdD No Low 
SATW20_14860   No Low SATW20_09120   No Low 
SATW20_28520 rpmH No Low SATW20_07700 norA No High 
SATW20_08520   No High SATW20_00100   No High 
SATW20_01370   No High SATW20_26260 gntR No Low 
SATW20_27810   No Low SATW20_10150 murE No Low 
SATW20_25630   No High SATW20_00600 merA No Low 
SATW20_21600   No Low SATW20_25180 narT No High 
SATW20_00860 tnpB No Low SATW20_23230 opuD2 No High 
SATW20_01540   No Low SATW20_07420   No High 
SATW20_27620   No High SATW20_03190   No High 
SATW20_13350   No High SATW20_13910   No Low 
SATW20_17230 acsA No Low SATW20_24950   No High 
SATW20_20500   No Low SATW20_12280   No Low 
SATW20_26190 sarU No High SATW20_20380   No Low 
SATW20_14530 asnS No Low SATW20_19340   No High 
SATW20_23870   No High SATW20_20360   No Low 
SATW20_06080 rplA No Low SATW20_09690   No High 
SATW20_12290   No Low SATW20_15220   No High 
SATW20_19510   No High SATW20_10100   No High 
SATW20_02290   No High SATW20_14180   No High 
SATW20_12930 glpK No Low SATW20_01070   No High 
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SATW20_18800   No High SATW20_17410   No Low 
SATW20_25940 opp-1B No High SATW20_05450   No Low 
SATW20_17120   No High SATW20_26530   No High 
SATW20_07990   No Low SATW20_12730   No Low 
SATW20_12180 rpmB No Low SATW20_00950   No Low 
SATW20_10840   No High SATW20_06690   No High 
SATW20_22770   No Low SATW20_16850 citZ No Low 
SATW20_11100 ctaA No High SATW20_21180   No Low 
SATW20_27740   No High SATW20_05150   No Low 
SATW20_02500   No Low SATW20_23070   No High 
SATW20_15560   No High SATW20_14090   No Low 
SATW20_25590   No High SATW20_17500   No Low 
SATW20_22250   No High SATW20_12980   No Low 
SATW20_00761   No High SATW20_18120   No Low 
SATW20_07830 saeP No Low SATW20_15030 zwf No Low 
SATW20_21590   No Low SATW20_02600   No Low 
SATW20_07400   No Low SATW20_20110   No High 
SATW20_00120   No Low SATW20_17460 sasC No Low 
SATW20_23650 rplO No Low SATW20_16390 rpmA No Low 
SATW20_09190   No High SATW20_02720   No High 
SATW20_15180   No Low SATW20_24690   No Low 
SATW20_25690   No High SATW20_22980   No High 
SATW20_24600   No Low SATW20_07200   No High 
SATW20_03630   No Low SATW20_25930 opp-1C No High 
SATW20_14290   No Low SATW20_05020   No Low 
SATW20_08010   No High SATW20_14260   No High 
SATW20_21290   No Low SATW20_20630   No Low 
SATW20_02340 fadD No Low SATW20_23020   No High 
SATW20_20120 groEL No Low SATW20_01670 cap8H No High 
SATW20_01560   No Low SATW20_22510 glyA No Low 
SATW20_18230   No High SATW20_12360   No High 
SATW20_00480   No Low SATW20_10420 menB No Low 
SATW20_06660   No High SATW20_25440   No Low 
SATW20_16030   No High SATW20_15710 rpsU No Low 
SATW20_15390   No High SATW20_26750   No High 
SATW20_24830   No High SATW20_13170   No High 
SATW20_23270 lacG No Low SATW20_15190   No Low 
SATW20_19040 scpA No Low SATW20_16760   No Low 
SATW20_09510 mnhB No High SATW20_07130 tagG No High 
SATW20_08370   No High SATW20_22720 luxS No Low 
SATW20_04210   No High SATW20_06160 rpsG No Low 
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SATW20_12440 topA No Low SATW20_00400 tnpB1 No Low 
SATW20_04850   No High SATW20_24540   No High 
SATW20_01140 plc No Low SATW20_16510 tnpB2 No Low 
SATW20_12940 glpD No Low SATW20_19120   No High 
SATW20_15310   No Low SATW20_00620   No Low 
SATW20_16360 ruvA No Low SATW20_27240   No Low 
SATW20_11220 rpmF No Low SATW20_23460   No High 
SATW20_02640 lrgA No High SATW20_02890 essC No High 
SATW20_24710   No High SATW20_28480 gidB No Low 
SATW20_17420   No Low SATW20_18630   No High 
SATW20_11430 sdhB No Low SATW20_23530   No Low 
SATW20_16540 folC No High SATW20_09960   No Low 
SATW20_13460   No High SATW20_03890   No High 
SATW20_09770   No High SATW20_16630 hemA No High 
SATW20_18510 glnQ No Low SATW20_20700 
aacA-
aphD No High 
SATW20_12920 glpF No High SATW20_13490 mscL No High 
SATW20_13570   No High SATW20_07270   No High 
SATW20_18450 citG No Low SATW20_10760   No Low 
SATW20_13220   No High SATW20_21550   No Low 
SATW20_24460   No High SATW20_12470 hslV No Low 
SATW20_03150   No High SATW20_02610 scdA No Low 
SATW20_03660   No Low SATW20_06750   No High 
SATW20_13100   No High SATW20_23670 rpsE No Low 
SATW20_10430 sspC No High SATW20_13380   No Low 
SATW20_11070   No Low SATW20_14580   No Low 
SATW20_11410 sdhC No High SATW20_24340   No Low 
SATW20_10440 sspB No Low SATW20_07440   No Low 
SATW20_22090   No Low SATW20_05470   No Low 
SATW20_19780   No Low SATW20_11420 sdhA No Low 
SATW20_25300 nasD No Low SATW20_27110 blaR1 No High 
SATW20_03430   No Low SATW20_25070   No High 
SATW20_14900 srrA No Low SATW20_02490   No High 
SATW20_04130   No High SATW20_24670   No High 
SATW20_19210   No High SATW20_18730   No Low 
SATW20_24570   No Low SATW20_05850 lysS No Low 
SATW20_27040   No High SATW20_26440   No Low 
SATW20_05390   No High SATW20_02040   No High 
SATW20_04030 mepB No Low SATW20_18350   No Low 
SATW20_27450 fda No Low SATW20_26680 mvaS No Low 
SATW20_09220   No Low SATW20_01630 capD No High 
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SATW20_02270   No Low SATW20_16130 alaS No Low 
SATW20_23900 glcU No High SATW20_05120   No Low 
SATW20_19300   No Low SATW20_00880   No High 
SATW20_17140   No High SATW20_03800   No Low 
SATW20_01870   No Low SATW20_03510   No Low 
SATW20_20240 scrB No Low SATW20_07910   No High 
SATW20_19290   No High SATW20_14510   No Low 
SATW20_17900   No Low SATW20_19840   No High 
SATW20_13340   No Low SATW20_08530 secG No High 
SATW20_20760 aphA No Low SATW20_11630   No High 
SATW20_08790   No Low SATW20_24090 modC No High 
SATW20_04810   No Low SATW20_03670   No Low 
SATW20_04140   No High SATW20_27070   No High 
SATW20_02850 esaA No Low SATW20_04970   No High 
SATW20_04430   No Low SATW20_19880   No High 
SATW20_07980   No High SATW20_19160   No Low 
SATW20_03840   No Low SATW20_11010   No Low 
SATW20_20670   No Low SATW20_22600   No Low 
SATW20_15380   No High SATW20_13480   No High 
SATW20_04300   No High SATW20_25140 gltT No High 
SATW20_09400   No Low SATW20_18170   No High 
SATW20_12080   No High SATW20_00050 gyrB No Low 
SATW20_04660   No Low SATW20_23930   No High 
SATW20_17390   No Low SATW20_06570 pta No Low 
SATW20_06730   No High SATW20_12770 pgsA No High 
SATW20_28260   No Low SATW20_28120 hisH No High 
SATW20_18980   No Low SATW20_13140   No High 
SATW20_22560 prfA No Low SATW20_21810   No Low 
SATW20_14830   No Low SATW20_13900 cvfB No Low 
SATW20_19380 sak No Low SATW20_06180 tuf No Low 
SATW20_06240   No Low SATW20_19820   No High 
SATW20_06490 thiD No Low SATW20_03390   No High 
SATW20_26620 cidA No High SATW20_08640   No Low 
SATW20_12060 priA No Low SATW20_08320   No High 
SATW20_23440   No Low SATW20_14840   No Low 
SATW20_01850   No Low SATW20_27950   No Low 
SATW20_19500   No Low SATW20_20870   No High 
SATW20_22700   No Low SATW20_15820   No High 
SATW20_24430   No High SATW20_28170 hisZ No Low 
SATW20_14250 msrA1 No Low SATW20_25670   No High 
SATW20_25250 narJ No Low SATW20_18990 lig No Low 
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SATW20_15110   No Low SATW20_15580 dnaG No Low 
SATW20_21580   No Low SATW20_23640 secY No High 
SATW20_04220 thl No Low SATW20_18340   No High 
SATW20_24100 modB No High SATW20_28300   No High 
SATW20_05540   No Low SATW20_07380   No High 
SATW20_08100 sstC No High SATW20_27340   No High 
SATW20_21100   No Low SATW20_17100 rpsD No Low 
SATW20_17090   No High SATW20_08060 rir1 No Low 
SATW20_02650 lrgB No High SATW20_06680   No High 
SATW20_18300   No High SATW20_27720 arcB No Low 
SATW20_27930   No Low SATW20_27360 panD No High 
SATW20_12850   No High SATW20_06620   No Low 
SATW20_10050   No High SATW20_15470 rpmG1 No Low 
SATW20_03100   No High SATW20_21010   No Low 
SATW20_18970 putP No High SATW20_15760 dnaK No Low 
SATW20_26690   No Low SATW20_14010 cspA No Low 
SATW20_11650   No High SATW20_05560   No Low 
SATW20_21620   No Low SATW20_04670   No Low 
SATW20_07170 pbp4 No Low SATW20_02630 lytR No High 
SATW20_23130   No High SATW20_01820   No High 
SATW20_20430   No Low SATW20_00580   No High 
SATW20_13860   No High SATW20_05950 radA No Low 
SATW20_26130   No High SATW20_26850   No Low 
SATW20_18470   No Low SATW20_21380   No High 
SATW20_23770 rplP No Low SATW20_21330   No Low 
SATW20_16040   No High SATW20_25390   No Low 
SATW20_00990   No High SATW20_18370   No Low 
SATW20_24530   No High SATW20_27470   No Low 
SATW20_19620   No Low SATW20_15360   No High 
SATW20_20350   No High SATW20_03830   No High 
SATW20_18220 hlgA No Low SATW20_19790   No Low 
SATW20_28110 hisA No High SATW20_16550 valS No Low 
SATW20_09350 dltD No Low SATW20_09840 oppB No High 
SATW20_23590 rpsK No Low SATW20_06230   No Low 
SATW20_22460 atpE No High SATW20_03420   No Low 
SATW20_14450   No Low SATW20_17680   No High 
SATW20_01410   No High SATW20_08380   No Low 
SATW20_17820   No Low SATW20_05330   No Low 
SATW20_01280 sbnA No High SATW20_21960 ilvC No Low 
SATW20_02810   No High SATW20_05420   No High 









SATW20_15300   No High 
SATW20_16190   No Low 
SATW20_09180   No Low 
SATW20_05800   No Low 
SATW20_15920 aroE No High 
SATW20_12510 tsf No Low 






























Table showing the genes in USA300 (FPR3757) which translate into proteins with a 
significantly altered isoleucine (Ile) content, according to the Mote Carlo simulation.  
 










SAUSA300_0161 cap5J Y High SAUSA300_1613   Y High 
SAUSA300_0162 cap5K Y High SAUSA300_1718 arsB Y High 
SAUSA300_0428   Y High SAUSA300_0754   Y Low 
SAUSA300_0546 sdrC Y Low SAUSA300_0881   Y High 
SAUSA300_0547 sdrD Y Low SAUSA300_0980   Y High 
SAUSA300_0548 sdrE Y Low SAUSA300_1979   Y High 
SAUSA300_0731   Y High SAUSA300_1985 sdrH Y Low 
SAUSA300_0772 clfA Y Low SAUSA300_2266   Y High 
SAUSA300_0955 atl Y Low SAUSA300_2434   Y High 
SAUSA300_1028   Y Low SAUSA300_2441 fnbA Y Low 
SAUSA300_1239 tkt Y Low SAUSA300_0442   Y High 
SAUSA300_1327   Y Low SAUSA300_1300 brnQ (3) Y High 
SAUSA300_1393   Y Low SAUSA300_1687   Y Low 
SAUSA300_1677   Y Low SAUSA300_0224 coa Y Low 
SAUSA300_1684   Y Low SAUSA300_2315   Y Low 
SAUSA300_1991 agrC Y High SAUSA300_0846   Y High 
SAUSA300_2109 fmtB Y Low SAUSA300_2051   Y Low 
SAUSA300_2134   Y High SAUSA300_1370 ebpS Y Low 
SAUSA300_2252   Y High SAUSA300_0773   N Low 
SAUSA300_2565 clfB Y Low SAUSA300_0116 sirB N High 
SAUSA300_2589   Y Low SAUSA300_0091   N High 
SAUSA300_0083   Y High SAUSA300_0291   N High 
SAUSA300_0134   Y High SAUSA300_1246 acnA N Low 
SAUSA300_0270 lytM Y Low SAUSA300_2287   N High 
SAUSA300_0276   Y High SAUSA300_1329   N High 
SAUSA300_2451   Y High SAUSA300_0902 pepF N Low 
SAUSA300_0011   Y High SAUSA300_2161 hysA N Low 
SAUSA300_0113   Y Low SAUSA300_1989 agrB N High 
SAUSA300_0482   Y High SAUSA300_2440 fnbB N Low 
SAUSA300_0603   Y High SAUSA300_1547   N High 
SAUSA300_0694   Y High SAUSA300_1618 hemX N High 
SAUSA300_0784   Y High SAUSA300_2603 lip N Low 














SAUSA300_0073   N Low SAUSA300_0895 
oppB 
(2) N High 
SAUSA300_0320   N Low SAUSA300_0176   N High 
SAUSA300_0599   N High SAUSA300_2561 phoB N Low 
SAUSA300_0110   N High SAUSA300_0634 fhuB N High 
SAUSA300_0201   N High SAUSA300_2624   N High 
SAUSA300_1029   N Low SAUSA300_0109   N High 
SAUSA300_2040   N High SAUSA300_0374   N High 
SAUSA300_1341 pbp2 N Low SAUSA300_2411 opp-1A N Low 
SAUSA300_0139   N High SAUSA300_1809   N High 
SAUSA300_0268   N High SAUSA300_0583   N High 
SAUSA300_2343   N Low SAUSA300_2135   N High 
SAUSA300_2110 fmtB (2) N Low SAUSA300_1456   N Low 
SAUSA300_0443   N High SAUSA300_0426   N Low 
SAUSA300_0913   N High SAUSA300_0143 phnE (2) N High 
SAUSA300_2030   N High SAUSA300_0367 ssb N Low 
SAUSA300_0188 brnQ N High SAUSA300_2628 rarD N High 
SAUSA300_0635 fhuG N High SAUSA300_2466   N High 
SAUSA300_0619   N High SAUSA300_0896 
oppC 
(2) N High 
SAUSA300_2274   N High SAUSA300_1254   N High 
SAUSA300_0013   N High SAUSA300_1938   N Low 
SAUSA300_2301 tcaB N High SAUSA300_0932   N High 
SAUSA300_0136   N Low SAUSA300_2374   N High 
SAUSA300_1984   N High SAUSA300_0660   N High 
SAUSA300_0911   N High SAUSA300_0610   N High 
SAUSA300_0512   N High SAUSA300_0703   N Low 
SAUSA300_1270 femB N Low SAUSA300_0718   N High 
SAUSA300_0383   N Low SAUSA300_0351   N High 
SAUSA300_1637   N High SAUSA300_2129   N High 
SAUSA300_0739   N Low SAUSA300_0924   N High 
SAUSA300_2405   N High SAUSA300_1041   N High 
SAUSA300_1054   N High SAUSA300_0025   N Low 
SAUSA300_0934   N High SAUSA300_1360 ubiE N Low 
SAUSA300_2556   N High SAUSA300_1501   N High 
SAUSA300_2450   N High SAUSA300_0180   N High 
SAUSA300_0536   N Low SAUSA300_1760 epiG N High 
SAUSA300_0362   N High SAUSA300_1000 potB N High 
SAUSA300_1089 lspA N High SAUSA300_2248   N High 
  PSMα-4 N High SAUSA300_0074 opp-3B N High 
SAUSA300_2572 aur N Low SAUSA300_1561   N High 
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SAUSA300_2456   N High SAUSA300_0744 lgt N High 
SAUSA300_1217   N High SAUSA300_2233   N High 
SAUSA300_1084   N High SAUSA300_1534   N High 
SAUSA300_0127   N High SAUSA300_1761 epiE N High 
SAUSA300_0977   N High SAUSA300_2503   N Low 
SAUSA300_2250 nhaC N High SAUSA300_0282   N Low 
SAUSA300_1586 aspS N Low SAUSA300_0756 gap N Low 
SAUSA300_2506 isaA N Low SAUSA300_2417   N High 
SAUSA300_1700   N High SAUSA300_2033 kdpB N High 
SAUSA300_1307 arlS N High SAUSA300_1250 parE N Low 
SAUSA300_0527 ropB N Low SAUSA300_1910   N High 
SAUSA300_2602 icaC N High SAUSA300_2454   N High 
SAUSA300_1075 pbpA N Low SAUSA300_2297   N High 
SAUSA300_2545 betA N Low SAUSA300_2576   N High 
SAUSA300_2262   N High SAUSA300_2206   N High 
SAUSA300_1221   N High SAUSA300_0445 gltB N Low 
SAUSA300_0436   N High SAUSA300_2358   N High 
SAUSA300_0142 phnE N High SAUSA300_1106   N Low 
SAUSA300_0891 oppA N Low SAUSA300_2461   N Low 
SAUSA300_1282 pstC N High SAUSA300_0171   N High 
SAUSA300_1271   N High SAUSA300_2579   N Low 
SAUSA300_1232   N Low SAUSA300_2395   N High 
SAUSA300_1328   N High SAUSA300_2258   N Low 
SAUSA300_1539 dnaJ N Low SAUSA300_0581   N High 
SAUSA300_1276 opp-2B N High SAUSA300_0827   N High 
SAUSA300_2531   N Low SAUSA300_0797   N High 
SAUSA300_0215   N High SAUSA300_2249 ssaA N Low 
SAUSA300_0721   N Low SAUSA300_1275   N High 
SAUSA300_0506 nupC N High SAUSA300_1005   N High 
SAUSA300_0341   N High SAUSA300_1076 mraY N High 
SAUSA300_1500   N High SAUSA300_2398   N High 
SAUSA300_2614   N Low SAUSA300_2174   N High 
SAUSA300_0588   N High SAUSA300_0313   N High 
SAUSA300_0333   N High SAUSA300_2364 sbi N Low 
SAUSA300_2470 sdaAB N High SAUSA300_0115 sirC N High 
SAUSA300_2139   N High SAUSA300_0245   N High 
SAUSA300_0690 saeS N High SAUSA300_0712   N High 
SAUSA300_2356 fmhA N Low SAUSA300_1847   N High 
SAUSA300_2507   N High SAUSA300_1397   N Low 
SAUSA300_1897   N High SAUSA300_1092 pyrP N High 
SAUSA300_0297   N High SAUSA300_2035 kdpD N High 
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SAUSA300_0606   N High SAUSA300_1612 tag N Low 
SAUSA300_0064 arcD N High SAUSA300_1918   N Low 
SAUSA300_1851   N High SAUSA300_2568 arcD (2) N High 
SAUSA300_1324   N High SAUSA300_2214   N Low 
SAUSA300_0637   N Low SAUSA300_0272   N High 
SAUSA300_0879   N High SAUSA300_0330 ulaA N High 
SAUSA300_1087 ileS N Low SAUSA300_1187   N High 
SAUSA300_0615   N High SAUSA300_1920 chs N Low 
SAUSA300_2367 hlgB N Low SAUSA300_2368   N High 
SAUSA300_0862 glpQ N Low SAUSA300_1168   N High 
SAUSA300_0220 pflB N Low SAUSA300_0687   N High 
SAUSA300_1091 pyrR N High SAUSA300_1461   N High 
SAUSA300_2230 modA N Low SAUSA300_0852 mnhD N High 
SAUSA300_1704 leuS N Low SAUSA300_1004   N High 
SAUSA300_1294   N High SAUSA300_1912   N High 
SAUSA300_1378   N Low SAUSA300_1609   N High 
SAUSA300_2618   N High SAUSA300_2217   N High 
SAUSA300_0953   N High SAUSA300_2637   N High 
SAUSA300_0133   N High SAUSA300_0353   N High 
SAUSA300_2265   N High SAUSA300_1278 pepF (2) N Low 
SAUSA300_2588 secY (2) N High SAUSA300_0719   N High 
SAUSA300_0717 nrdF N Low SAUSA300_1739   N Low 
SAUSA300_0614   N High SAUSA300_0184 argB N High 
SAUSA300_2351   N Low SAUSA300_1201 glnA N Low 
SAUSA300_1440   N Low SAUSA300_2152 lacD N Low 
SAUSA300_2397   N High SAUSA300_2442 gntP N High 
SAUSA300_2525   N Low SAUSA300_1266 trpF N High 
SAUSA300_1528 cdd N Low SAUSA300_0112 lctP N High 
SAUSA300_0146   N Low SAUSA300_0856   N Low 
SAUSA300_2163   N Low SAUSA300_0817   N High 
SAUSA300_0393   N High SAUSA300_0304   N High 
SAUSA300_0923 htrA N Low SAUSA300_1724   N High 
SAUSA300_0202   N High SAUSA300_2208 topB N Low 
SAUSA300_2168   N High SAUSA300_0249 ispD N High 
SAUSA300_1626 rpmI N Low SAUSA300_1249   N High 
SAUSA300_0648   N High SAUSA300_1974   N Low 
SAUSA300_0622   N High SAUSA300_1436   N Low 
SAUSA300_0050   N High SAUSA300_1483   N Low 
SAUSA300_0937   N High SAUSA300_0319   N High 
SAUSA300_2323 cobI N High SAUSA300_1352   N High 
SAUSA300_1988   N High SAUSA300_0951 sspA N Low 
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SAUSA300_1410   N Low SAUSA300_1013   N High 
SAUSA300_2211   N High SAUSA300_0120 sbnC N Low 
SAUSA300_0652   N High SAUSA300_1499 aroK N High 
SAUSA300_1219   N High SAUSA300_2133   N High 
SAUSA300_1458   N Low SAUSA300_0565   N High 
SAUSA300_2632   N High SAUSA300_0850 mnhF N High 
SAUSA300_1062 argF N Low SAUSA300_2307   N High 
SAUSA300_1236   N Low SAUSA300_2479 cidA N High 
SAUSA300_0105   N Low SAUSA300_1529 dgkA N High 
SAUSA300_2502   N High SAUSA300_0613   N High 
SAUSA300_0591   N Low SAUSA300_2142 asp23 N Low 
SAUSA300_1306 sucA N Low SAUSA300_1253 glcT N High 
SAUSA300_0062 arcB N Low SAUSA300_2312 mqo N Low 
SAUSA300_1578 mnmA N Low SAUSA300_1225   N High 
SAUSA300_1692   N High SAUSA300_0632   N High 
SAUSA300_0382   N High SAUSA300_1242 sbcD N High 
SAUSA300_0586   N High SAUSA300_0917   N High 
SAUSA300_2203 rplD N Low SAUSA300_2207   N High 
SAUSA300_0372   N Low SAUSA300_2342 narH N Low 
SAUSA300_2384   N High SAUSA300_0335   N High 
SAUSA300_1374   N High SAUSA300_1651   N High 
SAUSA300_0669   N High SAUSA300_1001 potC N High 
SAUSA300_0344   N Low SAUSA300_1796   N High 
SAUSA300_1287 asd N Low SAUSA300_0650   N High 
SAUSA300_0866   N High SAUSA300_1975   N Low 
SAUSA300_0081   N High SAUSA300_0135   N Low 
SAUSA300_1996 amt N High SAUSA300_0209   N Low 
SAUSA300_1086   N Low SAUSA300_1513   N Low 
  PSMα-1 N High SAUSA300_1629 thrS N Low 
SAUSA300_0876   N High SAUSA300_1642   N High 
SAUSA300_0942   N High SAUSA300_2313   N High 
SAUSA300_0290   N High SAUSA300_2311   N High 
SAUSA300_2552   N High SAUSA300_0670   N High 
SAUSA300_1401   N Low SAUSA300_1268 trpA N High 
  PSMα-2 N High SAUSA300_1638 phoR N High 
SAUSA300_1002 potD N Low SAUSA300_2007 ilvB N Low 
SAUSA300_1493   N High SAUSA300_1448   N Low 
SAUSA300_1998   N High SAUSA300_2171 rpsI N Low 
SAUSA300_2436   N Low SAUSA300_0107   N High 
SAUSA300_0630   N High SAUSA300_0878   N High 
SAUSA300_1768 lukD N Low SAUSA300_0829 lipA N Low 
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SAUSA300_0194   N High SAUSA300_0035   N Low 
SAUSA300_0306 brnQ (2) N High SAUSA300_1283 pstS N Low 
SAUSA300_0663   N Low SAUSA300_0531   N Low 
SAUSA300_1726   N High SAUSA300_2482   N Low 
SAUSA300_1808   N High SAUSA300_1120 recG N Low 
SAUSA300_0776 nuc N Low SAUSA300_1858   N Low 
SAUSA300_2642   N High SAUSA300_2575   N High 
SAUSA300_0568   N High SAUSA300_2099   N High 
SAUSA300_1549   N Low SAUSA300_0640   N High 
SAUSA300_1880 gatB N Low SAUSA300_1631   N Low 
SAUSA300_1457 malR N High SAUSA300_0381   N Low 
SAUSA300_2472   N High SAUSA300_2390 opuCd N High 
SAUSA300_0672   N Low SAUSA300_0111   N High 
SAUSA300_0507 ctsR N High SAUSA300_1015 ctaA N High 
SAUSA300_1017   N High SAUSA300_2204 rplC N Low 
SAUSA300_1190 glpP N High SAUSA300_0673   N High 
SAUSA300_1740   N Low SAUSA300_2111 glmM N Low 
SAUSA300_0128   N High SAUSA300_1037 pheS N Low 
SAUSA300_0855 mnhA N High SAUSA300_1877   N High 
SAUSA300_1849 mutY N Low SAUSA300_1279 phoU N High 
SAUSA300_0021   N High SAUSA300_1802   N High 
SAUSA300_1018   N Low SAUSA300_1604 mreD N High 
SAUSA300_0376   N High SAUSA300_0759 gpmI N Low 
SAUSA300_0117 sirA N Low SAUSA300_0222   N High 
SAUSA300_1600 obgE N Low SAUSA300_0532 fusA N Low 
SAUSA300_2273   N High SAUSA300_0676   N High 
SAUSA300_1881 gatA N Low SAUSA300_0594 adh N Low 
SAUSA300_1660   N High SAUSA300_0612   N High 
SAUSA300_2278 hutU N Low SAUSA300_0094   N High 
SAUSA300_1663   N High SAUSA300_0851 mnhE N High 
SAUSA300_2578   N Low SAUSA300_0408   N Low 
SAUSA300_2391 opuCc N Low SAUSA300_0868 spsB N Low 
SAUSA300_0126   N Low SAUSA300_0729   N High 
SAUSA300_2100   N High SAUSA300_0478 prs N High 
SAUSA300_2291 gltS N High SAUSA300_1033   N High 
SAUSA300_1491   N High SAUSA300_0098   N High 
SAUSA300_1145 xerC N Low SAUSA300_1379   N Low 
SAUSA300_0992   N Low SAUSA300_2648 rpmH N Low 
SAUSA300_0022   N Low SAUSA300_1679 acsA N Low 
SAUSA300_0387 pbuX N High SAUSA300_0145   N Low 
SAUSA300_2237   N High SAUSA300_2304   N High 
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SAUSA300_1128 ftsY N Low SAUSA300_0708 hisC N Low 
SAUSA300_1345 asnC N Low SAUSA300_2333 narK N High 
SAUSA300_0523 rplA N Low SAUSA300_2540   N Low 
SAUSA300_0761   N High SAUSA300_0314   N High 
SAUSA300_1192 glpK N Low SAUSA300_0872   N High 
SAUSA300_0263 rbsD N High SAUSA300_1474   N High 
SAUSA300_0865 pgi N Low SAUSA300_1117 rpmB N Low 
SAUSA300_0147   N Low SAUSA300_1310   N High 
SAUSA300_2379   N High SAUSA300_0242 gutB N Low 
SAUSA300_2235   N Low SAUSA300_2092 dps N Low 
SAUSA300_0009 serS N Low SAUSA300_0914   N High 
SAUSA300_2558 nsaS N High SAUSA300_0066 argR N High 
SAUSA300_1130 ffh N Low SAUSA300_2410   N High 
SAUSA300_2438 sarU N High SAUSA300_1668   N High 
SAUSA300_1231   N High SAUSA300_1867   N High 
SAUSA300_2366 hlgC N Low SAUSA300_1269 femA N Low 
SAUSA300_0521 nusG N Low SAUSA300_0693   N Low 
SAUSA300_0072   N Low SAUSA300_2428   N Low 
SAUSA300_2551 nrdD N Low SAUSA300_0336   N Low 
SAUSA300_1127 smc N Low SAUSA300_0651   N Low 
SAUSA300_0849 mnhG N High SAUSA300_2185 rplO N Low 
SAUSA300_0824   N High SAUSA300_0106   N High 
SAUSA300_0169   N High SAUSA300_2275   N Low 
SAUSA300_0988 trkA N High SAUSA300_1470   N Low 
SAUSA300_0919 murE N Low SAUSA300_2571 argR (3) N High 
SAUSA300_0816   N Low SAUSA300_0989   N High 
SAUSA300_1107   N High SAUSA300_0423   N High 
SAUSA300_2444 gntR N Low SAUSA300_1321   N Low 
SAUSA300_0079   N Low SAUSA300_1520   N High 
SAUSA300_0933   N High SAUSA300_2042   N High 
SAUSA300_0714   N High SAUSA300_1982 groEL N Low 
SAUSA300_1285   N Low SAUSA300_0823   N High 
SAUSA300_1509   N High SAUSA300_0227 fadD N Low 
SAUSA300_2363   N High SAUSA300_2346 nirB N Low 
SAUSA300_2406   N High SAUSA300_2375   N High 
SAUSA300_2376   N High SAUSA300_0653   N High 
SAUSA300_1512 pbp3 N Low SAUSA300_2149 lacG N Low 
SAUSA300_0680 norA N High SAUSA300_1697   N Low 
SAUSA300_1395   N Low SAUSA300_0792   N High 
SAUSA300_2520   N High SAUSA300_1890   N Low 
SAUSA300_2145   N High SAUSA300_2385   N High 
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SAUSA300_0420   N Low SAUSA300_0226   N Low 
SAUSA300_1702   N Low SAUSA300_1389   N Low 
SAUSA300_0711   N High SAUSA300_2088 luxS N Low 
SAUSA300_1172   N Low SAUSA300_0241   N High 
SAUSA300_1301   N Low SAUSA300_2113   N High 
SAUSA300_0451   N Low SAUSA300_0631   N High 
SAUSA300_1641 gltA N Low SAUSA300_1213   N High 
SAUSA300_0283   N High SAUSA300_1318   N High 
SAUSA300_0580   N High SAUSA300_1496   N Low 
SAUSA300_1454 zwf N Low SAUSA300_2634   N High 
SAUSA300_1770   N High SAUSA300_1598 ruvA N Low 
SAUSA300_0252   N Low SAUSA300_2490   N High 
SAUSA300_1706   N Low SAUSA300_0417   N Low 
SAUSA300_0854 mnhB N High SAUSA300_1135   N High 
SAUSA300_1503   N High SAUSA300_1698   N Low 
SAUSA300_1197   N Low SAUSA300_1048 sdhB N Low 
SAUSA300_1759   N Low SAUSA300_0625 tagG N High 
SAUSA300_2284   N Low SAUSA300_1027 rpmF N Low 
SAUSA300_0346   N High SAUSA300_0010   N High 
SAUSA300_1143 topA N Low SAUSA300_1807   N Low 
SAUSA300_0745   N High SAUSA300_1801 fumC N Low 
SAUSA300_2298   N High SAUSA300_1244 mscL N High 
SAUSA300_0354 ltrA N High SAUSA300_2286   N High 
SAUSA300_1601 rpmA N Low SAUSA300_0950 sspB N Low 
SAUSA300_1973   N Low SAUSA300_1442 srrA N Low 
SAUSA300_2067 glyA N Low SAUSA300_1957   N Low 
SAUSA300_0400   N Low SAUSA300_1012   N Low 
SAUSA300_2471   N High SAUSA300_1610 folC N High 
SAUSA300_2131   N High SAUSA300_2272   N Low 
SAUSA300_0948 menB N Low SAUSA300_1191 glpF N High 
SAUSA300_2359   N Low SAUSA300_0307   N Low 
SAUSA300_2504   N High SAUSA300_0880   N High 
SAUSA300_1423 polA N Low SAUSA300_2448   N High 
SAUSA300_0063   N High SAUSA300_0049   N High 
SAUSA300_2630 nixA N High SAUSA300_0826   N Low 
SAUSA300_1471 xseB N Low SAUSA300_1208   N High 
SAUSA300_2126   N High SAUSA300_0949 sspC N High 
SAUSA300_1535 rpsU N Low SAUSA300_1218   N High 
SAUSA300_1193 glpD N Low SAUSA300_1046 sdhC N High 
SAUSA300_1958   N Low SAUSA300_0310 pfoR N High 
SAUSA300_1632 nrdR N Low SAUSA300_1252   N High 
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SAUSA300_2412   N Low SAUSA300_1994 scrB N Low 
SAUSA300_0413   N Low SAUSA300_1916   N Low 
SAUSA300_2644 gidB N Low SAUSA300_0638   N High 
SAUSA300_2574   N Low SAUSA300_1960   N Low 
SAUSA300_0012   N Low SAUSA300_0279   N Low 
SAUSA300_1907   N High SAUSA300_1619 hemA N High 
SAUSA300_0899   N Low SAUSA300_1876   N Low 
SAUSA300_2173 truA N Low SAUSA300_0118   N High 
SAUSA300_2341 narJ N Low SAUSA300_1230   N Low 
SAUSA300_1489   N Low SAUSA300_0788   N Low 
SAUSA300_0814   N Low SAUSA300_1540 dnaK N Low 
SAUSA300_0981   N Low SAUSA300_0038 ccrA N High 
SAUSA300_0256   N High SAUSA300_0375   N Low 
SAUSA300_2310   N High SAUSA300_2322   N High 
SAUSA300_1047 sdhA N Low SAUSA300_1884   N Low 
SAUSA300_1565   N High SAUSA300_0843   N Low 
SAUSA300_0288   N Low SAUSA300_2622   N Low 
SAUSA300_0253 scdA N Low SAUSA300_1971   N High 
SAUSA300_1146 hslV N Low SAUSA300_2210 glcU N High 
SAUSA300_0655   N Low SAUSA300_2282   N High 
SAUSA300_0348   N High SAUSA300_1243 sbcC N High 
SAUSA300_0444 gltC N High SAUSA300_1376   N Low 
SAUSA300_2269   N High SAUSA300_1105 priA N Low 
SAUSA300_1898   N High SAUSA300_2072 prfA N Low 
SAUSA300_1396   N Low SAUSA300_0539 ilvE N Low 
SAUSA300_2187 rpsE N Low SAUSA300_1915   N High 
SAUSA300_2253 ssaA (2) N Low SAUSA300_0033   N High 
SAUSA300_1234 rpsN N Low SAUSA300_0562 thiD N Low 
SAUSA300_1750   N High SAUSA300_0347 tatC N High 
SAUSA300_0496 lysS N Low SAUSA300_1502   N High 
SAUSA300_1860 pepS N Low SAUSA300_1670 serA N High 
SAUSA300_0453   N Low SAUSA300_2165 budA N Low 
SAUSA300_1350   N Low SAUSA300_1733   N Low 
SAUSA300_2484   N Low SAUSA300_0363   N High 
SAUSA300_1850   N High SAUSA300_1317 
msrA 
(2) N Low 
SAUSA300_2167   N High SAUSA300_2086   N Low 
SAUSA300_1790 prsA N Low SAUSA300_1575 alaS N Low 
SAUSA300_1956   N Low SAUSA300_1421   N Low 
SAUSA300_2462 frp N Low SAUSA300_0707   N High 
SAUSA300_0221 pflA N Low SAUSA300_0177   N Low 
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SAUSA300_1408   N Low SAUSA300_1176 pgsA N High 
SAUSA300_0585   N High SAUSA300_2044 cls N High 
SAUSA300_0409   N Low SAUSA300_0463   N Low 
SAUSA300_2409   N High SAUSA300_0629 pbp4 N Low 
SAUSA300_1343 nth N Low SAUSA300_2485   N Low 
SAUSA300_1902   N Low SAUSA300_1769 lukE N Low 
SAUSA300_0005 gyrB N Low SAUSA300_0838 dltD N Low 
SAUSA300_2076   N Low SAUSA300_2197 rplP N Low 
SAUSA300_0054   N High SAUSA300_1943   N Low 
SAUSA300_0570 eutD N Low SAUSA300_1522 dnaG N Low 
SAUSA300_0099 plc N Low SAUSA300_2179 rpsK N Low 
SAUSA300_1006   N Low SAUSA300_1803   N Low 
SAUSA300_2261   N High SAUSA300_0378   N High 
SAUSA300_0179   N Low SAUSA300_0716   N Low 
SAUSA300_0084   N High SAUSA300_1546 holA N High 
SAUSA300_0762 secG N High SAUSA300_2229 modB N High 
SAUSA300_0533 tuf N Low SAUSA300_1337   N Low 
SAUSA300_1284   N Low SAUSA300_2383   N High 
SAUSA300_1354   N Low SAUSA300_0720   N High 
SAUSA300_2228 modC N High SAUSA300_1665   N High 
SAUSA300_1885 ligA N Low SAUSA300_0257   N High 
SAUSA300_1064   N High SAUSA300_1184   N High 
SAUSA300_0528 ropC N Low SAUSA300_1666 rpsD N Low 
SAUSA300_0305   N High SAUSA300_1934   N Low 
SAUSA300_0774 empbp N Low SAUSA300_1785   N High 
SAUSA300_2505   N High SAUSA300_0909   N High 
SAUSA300_1977   N High SAUSA300_2569 arcB (2) N Low 
SAUSA300_0355   N Low SAUSA300_1792   N Low 
SAUSA300_2613 hisZ N Low SAUSA300_2137   N High 
SAUSA300_0587   N High SAUSA300_2063 atpE N High 
SAUSA300_0396 set7 N High SAUSA300_2542   N Low 
SAUSA300_1764 epiD N High SAUSA300_0511 radA N Low 
SAUSA300_0811   N Low SAUSA300_2268   N High 
SAUSA300_1463   N Low SAUSA300_1065   N High 
SAUSA300_1766 epiB N High SAUSA300_1281 pstA N High 
SAUSA300_1210   N High SAUSA300_1611 valS N Low 
SAUSA300_1377   N Low SAUSA300_0575   N Low 
SAUSA300_2329 gltT N High SAUSA300_2500   N Low 
SAUSA300_2608 hisH N High SAUSA300_1295   N Low 







(2) N Low 
SAUSA300_2354   N Low 
SAUSA300_0465   N Low 
SAUSA300_0273   N High 
SAUSA300_0538   N Low 
SAUSA300_0746   N Low 
SAUSA300_1789   N High 
SAUSA300_0132   N High 
SAUSA300_0649   N High 
SAUSA300_2530   N High 
SAUSA300_0514 cysE N High 
SAUSA300_2184 secY N High 
SAUSA300_0438   N Low 
SAUSA300_2009 ilvC N Low 
SAUSA300_0822 sufB N Low 
SAUSA300_0174   N High 
SAUSA300_0490 hslO N Low 
SAUSA300_1150 tsf N Low 
SAUSA300_1403   N Low 
SAUSA300_2277 hutI N Low 
SAUSA300_0255   N High 
SAUSA300_0160 cap5I N High 
SAUSA300_2075 rho N Low 
SAUSA300_2487 feoB N High 
SAUSA300_1581   N Low 
SAUSA300_1312   N Low 
SAUSA300_2457   N Low 
SAUSA300_1058   N Low 
SAUSA300_1550   N Low 
SAUSA300_1525 glyS N Low 
SAUSA300_0887 oppB N High 
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